Herbicidal compounds

Abstract

Compounds of the formula (I) wherein the substituents are as defined in herein. The invention further relates to herbicidal compositions which comprise a compound of formula (I) and to the use of compounds of formula (I) for controlling weeds, in particular in crops of useful plants.

Description

[0001] 83100 FF1 Herbicidal Compounds The present invention relates to herbicidal substituted triazole carboxylate derivatives of formula(I), as well as to processes and intermediates used for the preparation of such derivatives. The invention further extends to herbicidal compositions comprising such derivatives, as well as to the use of suchcompounds and compositions in agriculture or horticulture for controlling undesirable plant growth: inparticular the use in controlling weeds, in crops of useful plants. Pyridyl triazole derivatives are known from US 4,474,599.The present invention is based on the finding carboxylate substituted triazole derivatives offormula (I), exhibit surprisingly good herbicidal activity.According to the present invention, there is provided the use of a compound of formula (I) or anagronomically acceptable salt or an N-oxide thereof, as a herbicide: wherein R1 is selected from the group consisting of hydrogen, C1-C10alkyl, C3-C6cycloalkyl, C3-C6cycloalkyl-C1-C3alkyl-, C1-C6haloalkyl, C1-C3alkoxy-C1-C3alkyl-, C2-C6alkenyl, C5-C6cycloalkenyl, C5-C6cycloalkenyl-C1-C3alkyl-, C2-C6haloalkenyl, C2-C6alkynyl, C2-C6haloalkynyl, C1-C6alkoxycarbonyl-C1-C3alkyl-, cyanoC1-C6alkyl, -N=(C1-C6alkyl)C1-C6alkyl, phenyl, benzyl, heterocyclyl, heterocyclylC1-C3alkyl-, and heteroaryl, wherein said phenyl, benzyl, heterocyclyl or heteroaryl are optionallysubstituted by 1, 2 or 3 R10substituents, which may be the same or different, and wherein saidheterocyclyl is a 3- to 6- membered ring, which may be partially saturated or saturated, comprising 1 or2 heteroatoms individually selected from N and O, and said heteroaryl is a 5- or 6- membered monocyclicaromatic ring, which comprises 1, 2, 3 or 4 heteroatoms individually selected from N, O and S;A is selected from the group consisting of carbocyclyl, wherein the carbocyclyl is a 5- to 10-membered mono- or fused bicyclic ring system, which may be aromatic and / or partially saturated orsaturated, and heterocyclyl, wherein the heterocyclyl is a 5- to 10- membered mono- or fused bicyclicring system, which may be aromatic and / or partially saturated or saturated, comprising 1, 2, 3 or 4heteroatoms individually selected from N, O and S, and wherein said carbocyclyl or heterocyclyl areoptionally substituted where feasible by 1, 2, 3, 4 or 5 R2 substituents, which may be the same ordifferent;83100 FF2each R2 is independently selected from the group consisting of oxo, hydroxy, halogen, cyano, nitro, C1-C6alkyl, C3-C6cycloalkyl, C1-C6haloalkyl, C1-C6haloalkylcarbonyl, C1-C6haloalkoxy, C1-C3haloalkoxy-C1-C3alkyl-, C1-C6haloalkoxycarbonyl, C1-C6alkoxy, C1-C3alkoxy-C1-C3alkyl-, C1-C3alkoxy-C1-C3alkoxy-,C2-C6alkenyl, C5-C6cycloalkenyl, C2-C6haloalkenyl, C2-C6alkynyl, C2-C6haloalkynyl, C1-C6hydroxyalkyl-,C1-C6alkoxycarbonyl-, C1-C6alkylcarbonyl-, C3-C6cycloalkylcarbonyl-, C3-C6cycloalkyloxycarbonyl-, C1-C6alkylcarbonyloxy-, -C(O)OH, C1-C6alkyl-S(O)m-, C1-C3alkyl-S(O)m-C1-C3alkyl-, C1-C6haloalkyl-S(O)m-,C3-C6cycloalkyl-S(O)m-, amino, C1-C6alkylamino, diC1-C6alkylamino, C1-C6alkylaminocarbonyl, diC1-C6alkylaminocarbonyl, C1-C6alkylcarbonylamino-, diC1-C6alkylcarbonylamino-, C1-C6alkylaminocarbonyl-C1-C3alkoxy-, diC1-C6alkylaminocarbonyl-C1-C3alkoxy-, -C(R14)=NOR11, =NOR11,phenyl, heterocyclyl, heteroaryl and heteroarylC1-C3alkyl-, wherein said phenyl, heterocyclyl, heteroarylor heteroarylC1-C3alkyl- are optionally substituted by 1, 2 or 3 R12 substituents, which may be the sameor different, and wherein said heterocyclyl is a 3- to 6- membered ring, which may be partially saturatedor saturated, comprising 1 or 2 heteroatoms individually selected from N and O, and said heteroaryl isa 5- or 6- membered monocyclic aromatic ring, which comprises 1, 2, 3 or 4 heteroatoms individuallyselected from N, O and S;m is an integer of 0, 1, or 2; R3 and R4 are each independently selected from the group consisting of hydrogen, halogen, andC1-C6alkyl; or R3 and R4 together with the carbon atom to which they are attached form a ring selected fromthe group consisting of C3-C6cycloalkyl, C5-C6cycloalkenyl and heterocyclyl, wherein said heterocyclylis a 3- to 6- membered ring, which may be partially saturated or saturated, comprising 1 or 2 heteroatomsindividually selected from N and O; and X1is C-R5or N; X2is C-R6or N; X3is C-R7or N; each R5, R6 and R7 are independently selected from the group consisting of hydrogen, cyano,halogen, hydroxy, nitro, C1-C6alkyl, C3-C6cycloalkyl, C2-C6alkenyl, C5-C6cycloalkenyl, C2-C6alkynyl, C1-C6haloalkyl, C1-C6haloalkoxy, C1-C6alkoxy, C1-C3alkoxyC1-C3alkyl-, hydroxyC1-C6alkyl-, C1-C3alkoxyC1-C3alkoxy-, C1-C6alkyl-S(O)m-, amino, C1-C6alkylamino, diC1-C6alkylamino, phenyl, heterocyclyl, andheteroaryl, wherein said phenyl, heterocyclyl or heteroaryl are optionally substituted by 1, 2 or 3 R13substituents, which may be the same or different, and wherein said heterocyclyl is a 3- to 6- memberedring, which may be partially saturated or saturated, comprising 1 or 2 heteroatoms individually selectedfrom N and O, and said heteroaryl is a 5- or 6- membered monocyclic aromatic ring, which comprises1, 2, 3 or 4 heteroatoms individually selected from N, O and S;R8and R9are each independently selected from the group consisting of hydrogen, halogen and C1-C2alkyl;each R10 is independently selected from the group consisting of halogen, cyano, hydroxy, C1-C4alkyl,C1-C4alkoxy, C1-C4haloalkyl, C1-C4haloalkoxy, amino, C1-C4alkylamino and diC1-C4alkylamino;R11 is selected from the group consisting of hydrogen and C1-C6alkyl;83100 FF3each R12 is independently selected from the group consisting of halogen, cyano, hydroxy, C1-C4alkyl,C1-C4alkoxy, C1-C4haloalkyl, C1-C4haloalkoxy, amino, C1-C4alkylamino and diC1-C4alkylamino;each R13 is independently selected from the group consisting of halogen, cyano, hydroxy, C1-C4alkyl, C1-C4alkoxy, C1-C4haloalkyl, C1-C4haloalkoxy, amino, C1-C4alkylamino and diC1-C4alkylamino;and R14 is selected from the group consisting of hydrogen and C1-C6alkyl; with the proviso that one ortwo of X1, X2 and X3 are N.According to a second aspect of the invention, there is provided a compound of formula (I) or anagronomically acceptable salt or an N-oxide thereof, as defined above, with the proviso that thecompound of formula (I) is not selected from the group consisting of 5-(2-pyridyl)-1-(4- pyridylmethyl)triazole-4-carboxylic acid, 5-(1-methylpyrazol-4-yl)-1-(3-pyridylmethyl)triazole-4-carboxylic acid, 5-(2-pyridyl)-1-(3-pyridylmethyl)triazole-4-carboxylic acid, 5-(3-methylimidazol-4-yl)-1-(4-pyridylmethyl)triazole-4-carboxylic acid, 1-[(5-bromo-3-pyridyl)methyl]-5-(2-thienyl)triazole-4-carboxylic acid, 5-(1-methylpyrazol-4-yl)-1-(4-pyridylmethyl)triazole-4-carboxylic acid, 1-[(5-methyl-3-pyridyl)methyl]-5-(2-thienyl)triazole-4-carboxylic acid, 5-(1-methylimidazol-2-yl)-1-(3-pyridylmethyl)triazole-4-carboxylic acid, 5-(3-pyridyl)-1-(4-pyridylmethyl)triazole-4-carboxylic acid, 5-(3-methylimidazol-4-yl)-1-(3-pyridylmethyl)triazole-4-carboxylic acid, 1-(3-pyridylmethyl)-5-(2-thienyl)triazole-4-carboxylic acid, 5-(4-piperidyl)-1-(3-pyridylmethyl)triazole-4-carboxylic acid, 1-(4-pyridylmethyl)-5-(2-thienyl)triazole-4-carboxylic acid, 5-(3-pyridyl)-1-(3-pyridylmethyl)triazole-4-carboxylic acid, methyl 1-(4-pyridylmethyl)-5-pyrrolidin-2-yl-triazole-4-carboxylate, 5-(4-pyridyl)-1-(3-pyridylmethyl)triazole-4-carboxylic acid, 1-[(5-fluoro-3-pyridyl)methyl]-5-(2-thienyl)triazole-4-carboxylicacid, 5-(1-methylimidazol-2-yl)-1-(4-pyridylmethyl)triazole-4-carboxylic acid, 5-(4-pyridyl)-1-(4-pyridylmethyl)triazole-4-carboxylic acid, methyl 1-(3-pyridylmethyl)-5-pyrrolidin-2-yl-triazole-4-carboxylate, 5-phenyl-1-(3-pyridylmethyl)triazole-4-carboxylic acid, 1-[(3-chloro-4-pyridyl)methyl]-5-(2-thienyl)triazole-4-carboxylic acid, 5-(4-piperidyl)-1-(4-pyridylmethyl)triazole-4-carboxylic acid and 5-phenyl-1-(4-pyridylmethyl)triazole-4-carboxylic acid. According to a third aspect of the invention, there is provided an agrochemical compositioncomprising a herbicidally effective amount of a compound of formula (I) and an agrochemically-acceptable diluent or carrier. Such an agricultural composition may further comprise at least one additional active ingredient. According to a fourth aspect of the invention, there is provided a method of controlling orpreventing undesirable plant growth, wherein a herbicidally effective amount of a compound of formula (I), or a composition comprising this compound as active ingredient, is applied to the plants, to parts thereof or the locus thereof. According to a fifth aspect of the invention, there is provided an intermediate compound of formula (II),83100 FF4 wherein Y is selected from the group consisting of bromo, chloro, iodo, methylsulfonyloxy,trifluoromethylsulfonyloxy and p-tolylsulfonyloxy and X1, X2, X3, R1, R3, R4, R8 and R9 are as definedherein. As used herein, the term "halogen" or “halo” refers to fluorine (fluoro), chlorine (chloro), bromine (bromo) or iodine (iodo), preferably fluorine, chlorine or bromine. As used herein, cyano means a -CN group. As used herein, hydroxy means an -OH group. As used herein, nitro means an –NO2 group. As used herein, oxo means an =O group (eg, as in a carbonyl (C=O) group).As used herein, the term "C1-C6alkyl" refers to a straight or branched hydrocarbon chain radicalconsisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to sixcarbon atoms, and which is attached to the rest of the molecule by a single bond. C1-C4alkyl and C1-C2alkyl are to be construed accordingly. Examples of C1-C6alkyl include, but are not limited to, methyl(Me), ethyl (Et), n-propyl, 1-methylethyl (iso-propyl), n-butyl, and 1-dimethylethyl (t-butyl).A “C1-C2alkylene” group refers to the corresponding definition of C1-C2alkyl, except that such radical is attached to the rest of the molecule by two single bonds. Examples of C1-C2alkylene, are -CH2- and -CH2CH2-. As used herein, the term "C1-C6alkoxy" refers to a radical of the formula -ORa where Ra is a C1-C6alkyl radical as generally defined above. C1-C4alkoxy is to be construed accordingly. Examples of C1-4alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, iso-propoxy and t-butoxy. As used herein, the term "C1-C6haloalkyl" refers to a C1-C6alkyl radical as generally defined abovesubstituted by one or more of the same or different halogen atoms. C1-C4haloalkyl is to be construedaccordingly. Examples of C1-C6haloalkyl include, but are not limited to chloromethyl, fluoromethyl,fluoroethyl, difluoromethyl, trifluoromethyl and 2,2,2-trifluoroethyl. As used herein, the term "C2-C6alkenyl" refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one double bond that can beof either the (E)- or (Z)-configuration, having from two to six carbon atoms, which is attached to the restof the molecule by a single bond. C2-C4alkenyl is to be construed accordingly. Examples of C2-C6alkenylinclude, but are not limited to, prop-1-enyl, allyl (prop-2-enyl) and but-1-enyl. As used herein, the term “C2-C6haloalkenyl” refers to a C2-C6alkenyl radical as generally defined above substituted by one or more of the same or different halogen atoms. Examples of C2-C6haloalkenyl83100 FF5 include, but are not limited to chloroethylene, fluoroethylene, 1,1-difluoroethylene, 1,1-dichloroethylene and 1,1,2-trichloroethylene. As used herein, the term "C2-C6alkynyl" refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one triple bond, having fromtwo to six carbon atoms, and which is attached to the rest of the molecule by a single bond. C2-C4alkynylis to be construed accordingly. Examples of C2-C6alkynyl include, but are not limited to, prop-1-ynyl,propargyl (prop-2-ynyl) and but-1-ynyl. As used herein, the term “C2-C6haloalkynyl” refers to a C2-C6alkynyl radical as generally defined above substituted by one or more of the same or different halogen atoms. As used herein, the term "C1-C6haloalkoxy" refers to a C1-C6alkoxy group as defined abovesubstituted by one or more of the same or different halogen atoms. C1-C4haloalkoxy is to be construedaccordingly. Examples of C1-C6haloalkoxy include, but are not limited to, fluoromethoxy,difluoromethoxy, fluoroethoxy, trifluoromethoxy and trifluoroethoxy. As used herein, the term "C1-C3haloalkoxyC1-C3alkyl-" refers to a radical of the formula Rb-O-Ra-where Rb is a C1-C3haloalkyl radical as generally defined above, and Ra is a C1-C3alkylene radical asgenerally defined above. As used herein, the term "C1-C3alkoxyC1-C3alkyl-" refers to a radical of the formula Rb-O-Ra-where Rb is a C1-C3alkyl radical as generally defined above, and Ra is a C1-C3alkylene radical asgenerally defined above. As used herein, the term " C1-C3alkoxyC1-C3alkoxy-" refers to a radical of the formula Rb-O-Ra-O-where Rb is a C1-C3alkyl radical as generally defined above, and Ra is a C1-C3alkylene radical asgenerally defined above. As used herein, the term “hydroxyC1-C6alkyl” refers to a C1-C6alkyl radical as generally defined above substituted by one or more hydroxy groups. As used herein, the term "C1-C6alkoxycarbonyl" refers to a radical of the formula -C(O)ORa whereRa is a C1-C6alkyl radical as generally defined above. As used herein, the term "C3-C6cycloalkyl" refers to a stable, monocyclic ring radical which issaturated or partially unsaturated and contains 3 to 6 carbon atoms. C3-C4cycloalkyl is to be construedaccordingly. Examples of C3-C6cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. As used herein, the term “C1-C6alkylamino” refers to a radical of the formula RaNH- wherein Rais a C1-C6alkyl radical as generally defined aboveAs used herein, the term “diC1-C6alkylamino” refers to a radical of the formulaRa(Rb)N- wherein Ra and Rb are the same or different C1-C6alkyl radicals as generally defined above.As used herein, the term “C1-C6alkylaminocarbonyl” refers to a radical of the formula RaNHC(O)-wherein Ra is a C1-C6alkyl radical as generally defined above.As used herein, the term “diC1-C6alkylaminocarbonyl” refers to a radical of theformula Ra(Rb)NC(O)- wherein Ra and Rb are the same or different C1-C6alkyl radicals as generallydefined above. As used herein, except where explicitly stated otherwise, the term "heteroaryl" refers to a 5- or 6-membered monocyclic aromatic ring which comprises 1, 2, 3 or 4 heteroatoms individually selected from83100 FF6nitrogen, oxygen and sulfur. The heteroaryl radical may be bonded to the rest of the molecule via acarbon atom or heteroatom. Examples of heteroaryl include, furyl, pyrrolyl, imidazolyl, thienyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, pyrazinyl, pyridazinyl, pyrimidyl or pyridyl. As used herein, except where explicitly stated otherwise, the term "heterocyclyl" or "heterocyclic"refers to a stable 3- to 6-membered non-aromatic monocyclic ring radical which comprises 1, 2, or 3heteroatoms individually selected from nitrogen, oxygen and sulfur. The heterocyclyl radical may bebonded to the rest of the molecule via a carbon atom or heteroatom. Examples of heterocyclyl include,but are not limited to, pyrrolinyl, pyrrolidyl, tetrahydrofuryl, tetrahydrothienyl, tetrahydrothiopyranyl, piperidyl, piperazinyl, tetrahydropyranyl, dihydroisoxazolyl, dioxolanyl, morpholinyl or δ-lactamyl. As used herein, the term "heterocyclylC1-C3alkyl-" refers to a heterocyclyl ring as defined aboveattached to the rest of the molecule by a C1-C3alkylene radical as generally defined above.The presence of one or more possible asymmetric carbon atoms in a compound of formula (I)means that the compounds may occur in chiral isomeric forms, i.e., enantiomeric or diastereomericforms. Also, atropisomers may occur as a result of restricted rotation about a single bond. Formula (I) isintended to include all those possible isomeric forms and mixtures thereof. The present inventionincludes all those possible isomeric forms and mixtures thereof for a compound of formula (I). Likewise,formula (I) is intended to include all possible tautomers (including lactam-lactim tautomerism and keto-enol tautomerism) where present. The present invention includes all possible tautomeric forms for acompound of formula (I). Similarly, where there are di-substituted alkenes and / or substituted oximes,these may be present in E or Z form or as mixtures of both in any proportion. The present inventionincludes all these possible isomeric forms and mixtures thereof for a compound of formula (I).In each case, the compounds of formula (I) according to the invention are in free form, in oxidizedform as an N-oxide, in covalently hydrated form, or in salt form, e.g., an agronomically usable or agrochemically acceptable salt form. N-oxides are oxidized forms of tertiary amines or oxidized forms of nitrogen containing heteroaromatic compounds. They are described for instance in the book “Heterocyclic N-oxides” by A. Albini and S. Pietra, CRC Press, Boca Raton 1991. The following lists provide definitions, including preferred definitions, for substituents m, A, X1, X2,X3, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12and R13with reference to the compounds of formula(I) of the present invention. For any one of these substituents, any of the definitions given below may becombined with any definition of any other substituent given below or elsewhere in this document. R1 is selected from the group consisting of hydrogen, C1-C10alkyl, C3-C6cycloalkyl, C3-C6cycloalkyl-C1-C3alkyl-, C1-C6haloalkyl, C1-C3alkoxy-C1-C3alkyl-, C2-C6alkenyl, C5-C6cycloalkenyl, C5-C6cycloalkenyl-C1-C3alkyl-, C2-C6haloalkenyl, C2-C6alkynyl, C2-C6haloalkynyl, C1-C6alkoxycarbonyl-C1-C3alkyl-, cyanoC1-C6alkyl, -N=(C1-C6alkyl)C1-C6alkyl, phenyl, benzyl, heterocyclyl, heterocyclylC1-C3alkyl-, and heteroaryl, wherein said phenyl, benzyl, heterocyclyl or heteroaryl are optionallysubstituted by 1, 2 or 3 R10substituents, which may be the same or different, and wherein saidheterocyclyl is a 3- to 6- membered ring, which may be partially saturated or saturated, comprising 1 or83100 FF72 heteroatoms individually selected from N and O, and said heteroaryl is a 5- or 6- membered monocyclicaromatic ring, which comprises 1, 2, 3 or 4 heteroatoms individually selected from N, O and S.Preferably, R1 is selected from the group consisting of hydrogen, C1-C10alkyl, C3-C6cycloalkyl, C3-C6cycloalkyl-C1-C3alkyl-, C1-C6haloalkyl, C1-C3alkoxy-C1-C3alkyl-, C2-C6alkenyl, C5-C6cycloalkenyl, C5-C6cycloalkenyl-C1-C3alkyl-, C2-C6haloalkenyl, C2-C6alkynyl, C2-C6haloalkynyl, C1-C6alkoxycarbonyl-C1-C3alkyl-, cyanoC1-C6alkyl, phenyl, benzyl, tetrahydrofuranyl, tetrahydrofuranylmethyl, pyridyl andpyrazolyl, wherein said phenyl, benzyl, tetrahydrofuranyl, tetrahydrofuranylmethyl, pyridyl or pyrazolylare optionally substituted by 1, 2 or 3 R10 substituents, which may be the same or different. Morepreferably, R1 is selected from the group consisting of hydrogen, C1-C10alkyl, C3-C6cycloalkyl, C3-C6cycloalkyl-C1-C3alkyl-, C1-C6haloalkyl, C1-C3alkoxy-C1-C3alkyl-, C2-C6alkenyl, C2-C6alkynyl, C1-C6alkoxycarbonyl-C1-C3alkyl-, cyanoC1-C6alkyl, phenyl, benzyl, tetrahydrofuranyl,tetrahydrofuranylmethyl, pyridyl and pyrazolyl, wherein said phenyl, benzyl, tetrahydrofuranyl,tetrahydrofuranylmethyl, pyridyl or pyrazolyl are optionally substituted by 1, 2 or 3 R10 substituents,which may be the same or different. Even more preferably, R1 is selected from the group consisting ofhydrogen, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, n-pentyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 2-methylbutyl, iso-pentyl, 2,2-dimethylbutyl, 1-ethylhexyl, 1-methylhexyl, cyclopropyl,cyclopentyl, cyclopentylmethyl, 2,2-difluoroethyl, 3-methoxypropyl, 2-methoxyethyl, 2-methylallyl, 3-methylbut-2-enyl, allyl, prop-2-ynyl, 2-methoxy-2-oxo-ethyl, cyanomethyl, 2,4,6-trimethylphenyl, 4-fluorophenyl, benzyl, tetrahydrofuranylmethyl, 2-pyridyl and 2-methylpyrazol-3-yl. Yet even morepreferably, R1 is selected from the group consisting of hydrogen, methyl and ethyl. Most preferably, R1is hydrogen.A is selected from the group consisting of carbocyclyl, wherein the carbocyclyl is a 5- to 10-membered mono- or fused bicyclic ring system, which may be aromatic and / or partially saturated orsaturated, and heterocyclyl, wherein the heterocyclyl is a 5- to 10- membered mono- or fused bicyclicring system, which may be aromatic and / or partially saturated or saturated, comprising 1, 2, 3 or 4heteroatoms individually selected from N, O and S, and wherein said carbocyclyl or heterocyclyl areoptionally substituted where feasible by 1, 2, 3, 4 or 5 R2 substituents, which may be the same ordifferent. Preferably, A is selected from the group consisting of C5-C6cycloalkyl, C5-C6cycloalkenyl,napthalenyl, tetralinyl, phenyl, heterocyclyl, heteroaryl and the group A-I, wherein said C5-C6cycloalkyl,C5-C6cycloalkenyl, napthalenyl, phenyl, heterocyclyl, or heteroaryl are optionally substituted by 1, 2, 3,4 or 5 R2 substituents, which may be the same or different, and wherein said heterocyclyl is a 5- to 6-membered ring, which may be partially saturated or saturated, comprising 1 or 2 heteroatomsindividually selected from N and O, and said heteroaryl is a 5- or 6- membered monocyclic aromaticring, which comprises 1, 2, 3 or 4 heteroatoms individually selected from N, O and S, and wherein thegroup A-I is a fused bicyclic structure of general formula;83100 FF8 in which: (i) ring A1 and ring A2 each have 5 or 6 members;(ii) A-I includes at least one heteroatom selected from N, O and S, with the remainderbeing carbon atoms; (iii) at least one of ring A1 and ring A2 is aromatic, or A-I as a whole is aromatic;(iv) A-I can be attached to the remainder of the compound of formula (I) at any availableposition provided it is a carbon atom; (v) one of the carbon atoms is optionally a carbonyl;(vi) one of the carbon atoms is optionally an oxime of formula =NOR11, wherein R11 is asdefined in claim 1; (vii) A-I is optionally substituted in any available position in either or both of ring A1 or ringA2 by p substituents R2, which may be the same or different; and(viii) p is an integer of from 0 to 5.More preferably, A is selected from the group consisting of C5-C6cycloalkenyl, tetralinyl, phenyl,heteroaryl and the group A-I, wherein said phenyl or heteroaryl are optionally substituted by 1, 2, 3, 4 or5 R2 substituents, which may be the same or different, and wherein said heteroaryl is a 5-or 6-memberedmonocyclic aromatic ring which comprises 1, 2, 3 or 4 heteroatoms individually selected from N, O andS, and wherein the group A-I is a fused bicyclic structure of general formula; in which: (i) ring A1 and ring A2 each have 5 or 6 members;(ii) A-I includes at least one heteroatom selected from N, O and S, with the remainderbeing carbon atoms; (iii) at least one of ring A1 and ring A2 is aromatic, or A-I as a whole is aromatic;(iv) A-I can be attached to the remainder of the compound of formula (I) at any availableposition provided it is a carbon atom;83100 FF9 (v) one of the carbon atoms is optionally a carbonyl;(vi) one of the carbon atoms is optionally an oxime of formula =NOR11, wherein R11 is asdefined in claim 1; (vii) A-I is optionally substituted in any available position in either or both of ring A1 or ringA2 by p substituents R2, which may be the same or different; and(viii) p is an integer of from 0 to 5.Even more preferably, A is selected from the group consisting of cyclohexenyl, tetralinyl,phenyl, benzoxazolyl, 2,3-dihydro-1,4-benzodioxinyl, 2,3-dihydrobenzofuranyl, 1,3-benzodioxolyl,2,1,3-benzothiadiazolyl, 1,3-benzothiazolyl, quinolyl and pyridyl, wherein said cyclohexenyl, tetralinyl,phenyl, benzoxazolyl, 2,3-dihydro-1,4-benzodioxinyl, 2,3-dihydrobenzofuranyl, 1,3-benzodioxolyl,2,1,3-benzothiadiazolyl, 1,3-benzothiazolyl, quinolyl or pyridyl are optionally substituted by 1, 2, 3, 4 or5 R2 substituents, which may be the same or different.Yet even more preferably, A is selected from the group consisting of formula A-II to A-XVII below,

[0002] 83100 FF10 wherein the jagged line defines the point of attachment to the remaining part of a compound of formula (I); each R2aand R2bare independently selected from hydrogen or C1-C6alkyl; R2cis hydrogen or C1-C6alkyl;p is an integer of from 0 to 5 (preferably, from 0 to 3);R2is as defined herein; and R11is as defined herein.83100 FF11 Yet even more preferably still, A is selected from the group consisting of formula A-IIa to A-XXVa below, 83100 FF12 wherein the jagged line defines the point of attachment to the remaining part of a compound of formula (I). each R2 is independently selected from the group consisting of oxo, hydroxy, halogen, cyano,nitro, C1-C6alkyl, C3-C6cycloalkyl, C1-C6haloalkyl, C1-C6haloalkylcarbonyl, C1-C6haloalkoxy, C1-C3haloalkoxy-C1-C3alkyl-, C1-C6haloalkoxycarbonyl, C1-C6alkoxy, C1-C3alkoxy-C1-C3alkyl-, C1-C3alkoxy-C1-C3alkoxy-, C2-C6alkenyl, C5-C6cycloalkenyl, C2-C6haloalkenyl, C2-C6alkynyl, C2-C6haloalkynyl, C1-C6hydroxyalkyl-, C1-C6alkoxycarbonyl-, C1-C6alkylcarbonyl-, C3-C6cycloalkylcarbonyl-, C3-C6cycloalkyloxycarbonyl-, C1-C6alkylcarbonyloxy-, -C(O)OH, C1-C6alkyl-S(O)m-, C1-C3alkyl-S(O)m-C1-C3alkyl-, C1-C6haloalkyl-S(O)m-, C3-C6cycloalkyl-S(O)m-, amino, C1-C6alkylamino, diC1-C6alkylamino,C1-C6alkylaminocarbonyl, diC1-C6alkylaminocarbonyl, C1-C6alkylcarbonylamino-, diC1- C6alkylcarbonylamino-, C1-C6alkylaminocarbonyl-C1-C3alkoxy-, diC1-C6alkylaminocarbonyl-C1-C3alkoxy-, -C(R14)=NOR11, =NOR11, phenyl, heterocyclyl, heteroaryl and heteroarylC1-C3alkyl-, whereinsaid phenyl, heterocyclyl, heteroaryl or heteroarylC1-C3alkyl- are optionally substituted by 1, 2 or 3 R12substituents, which may be the same or different, and wherein said heterocyclyl is a 3- to 6- memberedring, which may be partially saturated or saturated, comprising 1 or 2 heteroatoms individually selectedfrom N and O, and said heteroaryl is a 5- or 6- membered monocyclic aromatic ring, which comprises1, 2, 3 or 4 heteroatoms individually selected from N, O and S. Preferably, each R2 is independentlyselected from the group consisting of oxo, hydroxy, halogen, C1-C6alkyl, C3-C6cycloalkyl, C1-C6haloalkyl,C1-C6haloalkoxy, C1-C3haloalkoxy-C1-C3alkyl-, C1-C6alkoxy, C1-C3alkoxy-C1-C3alkyl-, C1-C3alkoxy-C1-C3alkoxy-, C1-C6alkylaminocarbonyl-C1-C3alkoxy-, -C(R14)=NOR11, =NOR11,isoxazolyl andimidazolylmethyl. More preferably, each R2 is independently selected from the group consisting of oxo,hydroxy, chloro, fluoro, C1-C6alkyl, C1-C6alkoxy, C1-C3alkoxy-C1-C3alkyl-, C1-C3alkoxy-C1-C3alkoxy-,=NOR11and isoxazolyl. Even more preferably, each R2is independently selected from the groupconsisting of oxo, hydroxy, chloro, fluoro, methyl, n-propyl, methoxy, ethoxy, isopropoxy,methoxymethyl, methoxyethoxy, methoxyimino and isoxazol-3-yl.m is an integer of 0, 1, or 2. In one embodiment m is 0. In another embodiment m is 1. In another embodiment m is 2. R3 and R4 are each independently selected from the group consisting of hydrogen, halogen, andC1-C6alkyl. Preferably, R3 and R4 are each independently selected from the group consisting of hydrogenand C1-C6alkyl. More preferably, R3 and R4 are each independently selected from the group consistingof hydrogen, methyl and ethyl. Most preferably, R3 and R4 are hydrogen.Alternatively R3 and R4 together with the carbon atom to which they are attached form a ringselected from the group consisting of C3-C6cycloalkyl, C5-C6cycloalkenyl and heterocyclyl, wherein saidheterocyclyl is a 3- to 6- membered ring, which may be partially saturated or saturated, comprising 1 or83100 FF132 heteroatoms individually selected from N and O. Preferably, R3 and R4 together with the carbon atomto which they are attached form a C3-C6cycloalkyl ring. More preferably, R3 and R4 together with thecarbon atom to which they are attached form a cyclopropyl ring.X1 is C-R5 or N; and X2 is C-R6 or N; and X3 is C-R7 or N, with the proviso that one or two of X1,X2 and X3 are N.In one embodiment X1 is C-R5 or N, X2 is C-R6 and X3 is C-R7 or N (with the proviso that one ortwo of X1 and X3 are N).In another embodiment X1 is C-R5, X2 is N and X3 is C-R7.In another embodiment X1is N, X2is C-R6and X3is N. In another embodiment X1 is N, X2 is C-R6 and X3 is C-R7.In another embodiment X1is C-R5, X2is C-R6and X3is N. each R5, R6 and R7 are independently selected from the group consisting of hydrogen, cyano,halogen, hydroxy, nitro, C1-C6alkyl, C3-C6cycloalkyl, C2-C6alkenyl, C5-C6cycloalkenyl, C2-C6alkynyl, C1-C6haloalkyl, C1-C6haloalkoxy, C1-C6alkoxy, C1-C3alkoxyC1-C3alkyl-, hydroxyC1-C6alkyl-, C1-C3alkoxyC1-C3alkoxy-, C1-C6alkyl-S(O)m-, amino, C1-C6alkylamino, diC1-C6alkylamino, phenyl, heterocyclyl, andheteroaryl, wherein said phenyl, heterocyclyl or heteroaryl are optionally substituted by 1, 2 or 3 R13substituents, which may be the same or different, and wherein said heterocyclyl is a 3- to 6- memberedring, which may be partially saturated or saturated, comprising 1 or 2 heteroatoms individually selectedfrom N and O, and said heteroaryl is a 5- or 6- membered monocyclic aromatic ring, which comprises1, 2, 3 or 4 heteroatoms individually selected from N, O and S. Preferably, each R5, R6 and R7 areindependently selected from the group consisting of hydrogen, halogen, hydroxy, C1-C6alkyl, C3-C6cycloalkyl, C1-C6haloalkyl, C1-C6haloalkoxy, C1-C6alkoxy, C1-C3alkoxyC1-C3alkoxy-, C1-C6alkylamino,diC1-C6alkylamino, a 3- to 6- membered heterocyclyl, which may be partially saturated or saturated,comprising 1 or 2 heteroatoms individually selected from N and O, and a 5- or 6- membered heteroaryl,which comprises 1, 2, 3 or 4 heteroatoms individually selected from N, O and S, and wherein saidheterocyclyl or heteroaryl are optionally substituted by 1, 2 or 3 R13 substituents, which may be thesame or different. More preferably, each R5, R6and R7are independently selected from the groupconsisting of hydrogen, chloro, fluoro, hydroxy, methyl, ethyl, cyclopropyl, trifluoromethyl,difluoromethoxy, methoxy, methoxyethoxy, methylamino, dimethylamino, N-morpholinyl and pyrazolyl.R8and R9are each independently selected from the group consisting of hydrogen, halogen andC1-C2alkyl. Preferably, R8 and R9 are each independently selected from the group consisting ofhydrogen, chloro, fluoro and methyl. Most preferably, R8 and R9 are hydrogen.each R10 is independently selected from the group consisting of halogen, cyano, hydroxy, C1-C4alkyl, C1-C4alkoxy, C1-C4haloalkyl, C1-C4haloalkoxy, amino, C1-C4alkylamino and diC1-C4alkylamino.Preferably, each R10 is independently selected from the group consisting of halogen, C1-C4alkyl, C1-C4alkoxy, C1-C4haloalkyl and C1-C4haloalkoxy. More preferably, each R10 is independently selected fromthe group consisting of halogen and C1-C4alkyl.R11 is selected from the group consisting of hydrogen and C1-C6alkyl. Preferably, R11 is selectedfrom the group consisting of hydrogen, methyl and ethyl. Most preferably, R11 is methyl.each R12 is independently selected from the group consisting of halogen, cyano, hydroxy, C1-C4alkyl, C1-C4alkoxy, C1-C4haloalkyl, C1-C4haloalkoxy, amino, C1-C4alkylamino and diC1-C4alkylamino.83100 FF14Preferably, each R12 is independently selected from the group consisting of halogen, C1-C4alkyl, C1-C4alkoxy, C1-C4haloalkyl and C1-C4haloalkoxy. More preferably, each R12 is independently selected fromthe group consisting of halogen and C1-C4alkyl.each R13 is independently selected from the group consisting of halogen, cyano, hydroxy, C1-C4alkyl, C1-C4alkoxy, C1-C4haloalkyl, C1-C4haloalkoxy, amino, C1-C4alkylamino and diC1-C4alkylamino.Preferably, each R13 is independently selected from the group consisting of halogen, C1-C4alkyl, C1-C4alkoxy, C1-C4haloalkyl and C1-C4haloalkoxy. More preferably, each R13 is independently selected fromthe group consisting of halogen and C1-C4alkyl.R14 is selected from the group consisting of hydrogen and C1-C6alkyl. Preferably, R14 is selectedfrom the group consisting of hydrogen, methyl and ethyl. Most preferably, R14is methyl. Preferably, the compound according to formula (I) is selected from a compound A001 to A140listed in Table A (below).In a set of preferred embodiments, in a compound according to formula (I) of the invention, R1 is selected from the group consisting of hydrogen, methyl and ethyl;A is selected from the group consisting of C5-C6cycloalkenyl, phenyl, heteroaryl and the groupA-I, wherein said phenyl or heteroaryl are optionally substituted by 1, 2, 3, 4 or 5 R2 substituents,which may be the same or different, and wherein said heteroaryl is a 5-or 6-membered monocyclicaromatic ring which comprises 1, 2, 3 or 4 heteroatoms individually selected from N, O andS, and wherein the group A-I is a fused bicyclic structure of general formula; in which: (i) ring A1 and ring A2 each have 5 or 6 members;(ii) A-I includes at least one heteroatom selected from N, O and S, with the remainderbeing carbon atoms; (iii) at least one of ring A1 and ring A2 is aromatic, or A-I as a whole is aromatic;(iv) A-I can be attached to the remainder of the compound of formula (I) at any availableposition provided it is a carbon atom; (iv) one of the carbon atoms is optionally a carbonyl;(v) one of the carbon atoms is optionally an oxime of formula =NOR11, wherein R11 is asdefined in claim 1; (vii) A-I is optionally substituted in any available position in either or both of ring A1 or ringA2 by p substituents R2, which may be the same or different; and83100 FF15 (viii) p is an integer of from 0 to 5;each R2is independently selected from the group consisting of oxo, hydroxy, halogen, C1-C6alkyl, C3-C6cycloalkyl, C1-C6haloalkyl, C1-C6haloalkoxy, C1-C3haloalkoxy-C1-C3alkyl-, C1-C6alkoxy,C1-C3alkoxy-C1-C3alkyl-, C1-C3alkoxy-C1-C3alkoxy-, =NOR11and isoxazolyl; R3 and R4 are hydrogen;X1is C-R5or N; X2is C-R6or N; X3is C-R7or N; each R5, R6 and R7 are independently selected from the group consisting of hydrogen, halogen,hydroxy, C1-C6alkyl, C3-C6cycloalkyl, C1-C6haloalkyl, C1-C6haloalkoxy, C1-C6alkoxy, C1-C3alkoxyC1-C3alkoxy-, C1-C6alkylamino, diC1-C6alkylamino, a 3- to 6- membered heterocyclyl, which may be partiallysaturated or saturated, comprising 1 or 2 heteroatoms individually selected from N and O, and a 5- or6- membered heteroaryl, which comprises 1, 2, 3 or 4 heteroatoms individually selected from N, O andS, and wherein said heterocyclyl or heteroaryl are optionally substituted by 1, 2 or 3 R13 substituents,which may be the same or different; R8 and R9 are hydrogen;R11 is selected from the group consisting of hydrogen and C1-C6alkyl;each R13 is independently selected from the group consisting of halogen and C1-C4alkyl;with the proviso that one or two of X1, X2 and X3 are N and that the compound of formula (I) is notselected from the group consisting of 5-(2-pyridyl)-1-(4-pyridylmethyl)triazole-4-carboxylic acid, 5-(1-methylpyrazol-4-yl)-1-(3-pyridylmethyl)triazole-4-carboxylic acid, 5-(2-pyridyl)-1-(3-pyridylmethyl)triazole-4-carboxylic acid, 5-(3-methylimidazol-4-yl)-1-(4-pyridylmethyl)triazole-4-carboxylic acid, 1-[(5-bromo-3-pyridyl)methyl]-5-(2-thienyl)triazole-4-carboxylic acid, 5-(1-methylpyrazol-4-yl)-1-(4-pyridylmethyl)triazole-4-carboxylic acid, 1-[(5-methyl-3-pyridyl)methyl]-5-(2-thienyl)triazole-4-carboxylic acid, 5-(1-methylimidazol-2-yl)-1-(3-pyridylmethyl)triazole-4-carboxylicacid, 5-(3-pyridyl)-1-(4-pyridylmethyl)triazole-4-carboxylic acid, 5-(3-methylimidazol-4-yl)-1-(3-pyridylmethyl)triazole-4-carboxylic acid, 1-(3-pyridylmethyl)-5-(2-thienyl)triazole-4-carboxylic acid, 5-(4-piperidyl)-1-(3-pyridylmethyl)triazole-4-carboxylic acid, 1-(4-pyridylmethyl)-5-(2-thienyl)triazole-4-carboxylic acid, 5-(3-pyridyl)-1-(3-pyridylmethyl)triazole-4-carboxylic acid, methyl 1-(4-pyridylmethyl)-5-pyrrolidin-2-yl-triazole-4-carboxylate, 5-(4-pyridyl)-1-(3-pyridylmethyl)triazole-4-carboxylic acid, 1-[(5-fluoro-3-pyridyl)methyl]-5-(2-thienyl)triazole-4-carboxylic acid, 5-(1-methylimidazol-2-yl)-1-(4-pyridylmethyl)triazole-4-carboxylic acid, 5-(4-pyridyl)-1-(4-pyridylmethyl)triazole-4-carboxylic acid,methyl 1-(3-pyridylmethyl)-5-pyrrolidin-2-yl-triazole-4-carboxylate, 5-phenyl-1-(3-pyridylmethyl)triazole-4-carboxylic acid, 1-[(3-chloro-4-pyridyl)methyl]-5-(2-thienyl)triazole-4-carboxylic acid, 5-(4-piperidyl)-1-(4-pyridylmethyl)triazole-4-carboxylic acid and 5-phenyl-1-(4-pyridylmethyl)triazole-4-carboxylic acid.In another embodiment of the invention, there is provided an intermediate compound of formula (II),83100 FF16 wherein Y is selected from the group consisting of bromo, chloro, iodo, methylsulfonyloxy,trifluoromethylsulfonyloxy and p-tolylsulfonyloxy (preferably, Y is selected from the group consisting ofbromo, chloro and iodo, more preferably, Y is selected from the group consisting of bromo and chloro,most preferably Y is chloro); R1 is selected from the group consisting of hydrogen, C1-C10alkyl, C3-C6cycloalkyl, C3-C6cycloalkyl-C1-C3alkyl-, C1-C6haloalkyl, C1-C3alkoxy-C1-C3alkyl-, C2-C6alkenyl, C5-C6cycloalkenyl, C5-C6cycloalkenyl-C1-C3alkyl-, C2-C6haloalkenyl, C2-C6alkynyl, C2-C6haloalkynyl, C1-C6alkoxycarbonyl-C1-C3alkyl-, cyanoC1-C6alkyl, -N=(C1-C6alkyl)C1-C6alkyl, phenyl, benzyl, heterocyclyl, heterocyclylC1-C3alkyl-, and heteroaryl, wherein said phenyl, benzyl, heterocyclyl or heteroaryl are optionallysubstituted by 1, 2 or 3 R10substituents, which may be the same or different, and wherein saidheterocyclyl is a 3- to 6- membered ring, which may be partially saturated or saturated, comprising 1 or2 heteroatoms individually selected from N and O, and said heteroaryl is a 5- or 6- membered monocyclicaromatic ring, which comprises 1, 2, 3 or 4 heteroatoms individually selected from N, O and S;R3 and R4 are each independently selected from the group consisting of hydrogen, halogen, andC1-C6alkyl; or R3 and R4 together with the carbon atom to which they are attached form a ring selected fromthe group consisting of C3-C6cycloalkyl, C5-C6cycloalkenyl and heterocyclyl, wherein said heterocyclylis a 3- to 6- membered ring, which may be partially saturated or saturated, comprising 1 or 2 heteroatomsindividually selected from N and O; and X1is C-R5or N; X2is C-R6or N; X3is C-R7or N; each R5, R6 and R7 are independently selected from the group consisting of hydrogen, cyano,halogen, hydroxy, nitro, C1-C6alkyl, C3-C6cycloalkyl, C2-C6alkenyl, C5-C6cycloalkenyl, C2-C6alkynyl, C1-C6haloalkyl, C1-C6haloalkoxy, C1-C6alkoxy, C1-C3alkoxyC1-C3alkyl-, hydroxyC1-C6alkyl-, C1-C3alkoxyC1-C3alkoxy-, C1-C6alkyl-S(O)m-, amino, C1-C6alkylamino, diC1-C6alkylamino, phenyl, heterocyclyl, andheteroaryl, wherein said phenyl, heterocyclyl or heteroaryl are optionally substituted by 1, 2 or 3 R13substituents, which may be the same or different, and wherein said heterocyclyl is a 3- to 6- memberedring, which may be partially saturated or saturated, comprising 1 or 2 heteroatoms individually selected83100 FF17from N and O, and said heteroaryl is a 5- or 6- membered monocyclic aromatic ring, which comprises1, 2, 3 or 4 heteroatoms individually selected from N, O and S;m is an integer of 0, 1, or 2; R8and R9are each independently selected from the group consisting of hydrogen, halogen and C1-C2alkyl; each R10 is independently selected from the group consisting of halogen, cyano, hydroxy, C1-C4alkyl, C1-C4alkoxy, C1-C4haloalkyl, C1-C4haloalkoxy, amino, C1-C4alkylamino and diC1-C4alkylamino;each R13 is independently selected from the group consisting of halogen, cyano, hydroxy, C1-C4alkyl, C1-C4alkoxy, C1-C4haloalkyl, C1-C4haloalkoxy, amino, C1-C4alkylamino and diC1-C4alkylamino;with the proviso that one or two of X1, X2 and X3 are N.In a preferred embodiment, there is provided an intermediate compound of formula (II), wherein Y is selected from the group consisting of bromo, chloro, iodo, methylsulfonyloxy,trifluoromethylsulfonyloxy and p-tolylsulfonyloxy (preferably, Y is selected from the group consisting ofbromo, chloro and iodo, more preferably, Y is selected from the group consisting of bromo and chloro,most preferably Y is chloro); R1 is selected from the group consisting of hydrogen, C1-C10alkyl, C3-C6cycloalkyl, C3-C6cycloalkyl-C1-C3alkyl-, C1-C6haloalkyl, C1-C3alkoxy-C1-C3alkyl-, C2-C6alkenyl, C2-C6alkynyl, C1-C6alkoxycarbonyl-C1-C3alkyl-, cyanoC1-C6alkyl, phenyl, benzyl, tetrahydrofuranyl,tetrahydrofuranylmethyl, pyridyl and pyrazolyl, wherein said phenyl, benzyl, tetrahydrofuranyl,tetrahydrofuranylmethyl, pyridyl or pyrazolyl are optionally substituted by 1, 2 or 3 R10 substituents,which may be the same or different; R3 and R4 are each independently selected from the group consisting of hydrogen, methyl andethyl; and X1is C-R5or N; X2is C-R6or N; X3is C-R7or N; each R5, R6 and R7 are independently selected from the group consisting of hydrogen, halogen,hydroxy, C1-C6alkyl, C3-C6cycloalkyl, C1-C6haloalkyl, C1-C6haloalkoxy, C1-C6alkoxy, C1-C3alkoxyC1-C3alkoxy-, C1-C6alkylamino, diC1-C6alkylamino, a 3- to 6- membered heterocyclyl, which may be partiallysaturated or saturated, comprising 1 or 2 heteroatoms individually selected from N and O, and a 5- or6- membered heteroaryl, which comprises 1, 2, 3 or 4 heteroatoms individually selected from N, O and83100 FF18S, and wherein said heterocyclyl or heteroaryl are optionally substituted by 1, 2 or 3 R13 substituents,which may be the same or different; R8and R9are each independently selected from the group consisting of hydrogen, chloro, fluoro and methyl; each R10 is independently selected from the group consisting of halogen and C1-C4alkyl;each R13 is independently selected from the group consisting of halogen and C1-C4alkyl;with the proviso that one or two of X1, X2 and X3 are N.In a more preferred embodiment, there is provided an intermediate compound of formula (II), wherein Y is selected from the group consisting of bromo, chloro, iodo, methylsulfonyloxy,trifluoromethylsulfonyloxy and p-tolylsulfonyloxy (preferably, Y is selected from the group consisting ofbromo, chloro and iodo, more preferably, Y is selected from the group consisting of bromo and chloro,most preferably Y is chloro); R1 is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, iso-propyl, n-butyl,iso-butyl, n-pentyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 2-methylbutyl, iso-pentyl, 2,2-dimethylbutyl,1-ethylhexyl, 1-methylhexyl, cyclopropyl, cyclopentyl, cyclopentylmethyl, 2,2-difluoroethyl, 3-methoxypropyl, 2-methoxyethyl, 2-methylallyl, 3-methylbut-2-enyl, allyl, prop-2-ynyl, 2-methoxy-2-oxo-ethyl, cyanomethyl, 2,4,6-trimethylphenyl, 4-fluorophenyl, benzyl, tetrahydrofuranylmethyl, 2-pyridyl and2-methylpyrazol-3-yl; R3 and R4 are each independently selected from the group consisting of hydrogen, methyl andethyl; and X1is C-R5or N; X2is C-R6or N; X3is C-R7or N; each R5, R6 and R7 are independently selected from the group consisting of hydrogen, chloro,fluoro, hydroxy, methyl, cyclopropyl, trifluoromethyl, difluoromethoxy, methoxy, methoxyethoxy,methylamino, dimethylamino, N-morpholinyl and pyrazolyl; R8 and R9 are hydrogen;with the proviso that one or two of X1, X2 and X3 are N.83100 FF19 The skilled person would appreciate that where for example A is selected from the fused bicyclicgroup consisting of A-X, A-XI and A-XII, the substituent(s) R2 could be on either or both ringsystems, so for example the group A-X could equally be represented as, . It should be understood that compounds of formula (I) may exist / be manufactured in ‘procidal form’, wherein they comprise a group ‘G’. Such compounds are referred to herein as compounds of formula (I-I). G is a group which may be removed in a plant by any appropriate mechanism including, but notlimited to, metabolism and chemical degradation to give a compound of formula (Ia) containing acarboxylic acid which may also exist in a plant as the carboxylate anion (Ia-I), for example see thescheme below: Whilst such G groups may be considered as ‘procidal’, and thus yield active herbicidal compounds once removed, compounds comprising such groups may also exhibit herbicidal activity in their own right. The compounds in Tables 1 and 2 below illustrate the compounds of the invention. The skilledperson would understand that the compounds of formula (I) may exist as an agronomically acceptablesalt or N-oxide as described herein before.Table 1This table discloses 17 specific compounds of formula (I).83100 FF20Compound Structure Name5-(4-methoxyphenyl)-1-[(2- morpholinopyrimidin-5- P001 yl)methyl]triazole-4-carboxylic acid 5-(4-methoxyphenyl)-1-[(2- pyrazol-1-ylpyrimidin-5- P002 yl)methyl]triazole-4-carboxylic acid 5-(1,3-benzodioxol-5-yl)-1-[(5- chloro-3- P003 pyridyl)methyl]triazole-4- carboxylic acid

[0003] 83100 FF21Compound Structure Name1-[[6-(dimethylamino)-3- pyridyl]methyl]-5-(4- P004 methoxyphenyl)triazole-4- carboxylic acid O O N 5-(1,3-benzodioxol-5-yl)-1-[[2- N (dimethylamino)pyrimidin-5- P005 N N yl]methyl]triazole-4-carboxylic O N acid N H O 1-[(2-methoxy-4- pyridyl)methyl]-5-(1- P006 oxotetralin-6-yl)triazole-4- carboxylic acid83100 FF22Compound Structure Name5-[(1E)-1- methoxyiminotetralin-6-yl]-1- P007 [(2-methoxy-4- pyridyl)methyl]triazole-4- carboxylic acid 5-(2-fluoro-4-methoxy- phenyl)-1-[(5-methoxy-3- P008 pyridyl)methyl]triazole-4- carboxylic acid 5-(2-fluoro-4-methoxy- phenyl)-1-[(2-methoxy-4- P009 pyridyl)methyl]triazole-4- carboxylic acid83100 FF23Compound Structure Name5-(2-fluoro-4-methoxy- phenyl)-1-[(6-methyl-3- P010 pyridyl)methyl]triazole-4- carboxylic acid 1-[(6-chloro-3-pyridyl)methyl]- 5-(2,2-dimethyl-1,3- P011 benzodioxol-5-yl)triazole-4- carboxylic acid 5-(2,2-dimethyl-1,3- benzodioxol-5-yl)-1-[(6- P012 methoxy-3- pyridyl)methyl]triazole-4- carboxylic acid83100 FF24Compound Structure Name5-(1,3-benzodioxol-5-yl)-1-[(2- methoxy-4- P013 pyridyl)methyl]triazole-4- carboxylic acid O N N 5-(1,3-benzodioxol-5-yl)-1-[(2- methoxypyrimidin-5- P014NNyl)methyl]triazole-4-carboxylic N acid O OH O O 5-(1,3-benzodioxol-5-yl)-1-[(6- methyl-3- P015 pyridyl)methyl]triazole-4- carboxylic acid83100 FF25 Compound Structure Name5-(4-methoxyphenyl)-1-[[2- (methylamino)pyrimidin-5- P016 yl]methyl]triazole-4-carboxylic acid 1-[(2-chloro-4-pyridyl)methyl]- P017 5-(4-methoxyphenyl)triazole- 4-carboxylic acid Table 2This table discloses 30 specific compounds of formula (I).Compound Structure NameO O O isopropyl 5-(4-methoxyphenyl)- N N 1-[(6-methoxy-3- Q001 N pyridyl)methyl]triazole-4- carboxylate N O83100 FF26Compound Structure NameO O O isobutyl 5-(4-methoxyphenyl)- N N 1-[(6-methoxy-3- Q002 N pyridyl)methyl]triazole-4- carboxylate N O 1,1-dimethylpropyl 5-(4- methoxyphenyl)-1-[(6-methoxy- Q003 3-pyridyl)methyl]triazole-4- carboxylate O O O 2,2-dimethylpropyl 5-(4- N N methoxyphenyl)-1-[(6-methoxy- Q004 N 3-pyridyl)methyl]triazole-4- carboxylate N O83100 FF27Compound Structure NameO O O 2-methylbutyl 5-(4- N N methoxyphenyl)-1-[(6-methoxy- Q005 N 3-pyridyl)methyl]triazole-4- carboxylate N O isopentyl 5-(4-methoxyphenyl)- 1-[(6-methoxy-3- Q006 pyridyl)methyl]triazole-4- carboxylate 2,2-dimethylbutyl 5-(4- methoxyphenyl)-1-[(6-methoxy- Q007 3-pyridyl)methyl]triazole-4- carboxylate

[0004] 83100 FF28Compound Structure NameO O O cyclopropyl 5-(4- N N methoxyphenyl)-1-[(6-methoxy- Q008 N 3-pyridyl)methyl]triazole-4- carboxylate N O cyclopentylmethyl 5-(4- methoxyphenyl)-1-[(6-methoxy- Q009 3-pyridyl)methyl]triazole-4- carboxylate cyclopentyl 5-(4- methoxyphenyl)-1-[(6-methoxy- Q010 3-pyridyl)methyl]triazole-4- carboxylate83100 FF29Compound Structure Name2,2-difluoroethyl 5-(4- methoxyphenyl)-1-[(6-methoxy- Q011 3-pyridyl)methyl]triazole-4- carboxylate tetrahydrofuran-2-ylmethyl 5- (4-methoxyphenyl)-1-[(6- Q012 methoxy-3- pyridyl)methyl]triazole-4- carboxylate 1-ethylhexyl 5-(4- methoxyphenyl)-1-[(6-methoxy- Q013 3-pyridyl)methyl]triazole-4- carboxylate

[0005] 83100 FF30Compound Structure Name1-methylhexyl 5-(4- methoxyphenyl)-1-[(6-methoxy- Q014 3-pyridyl)methyl]triazole-4- carboxylate O O O (2,4,6-trimethylphenyl) 5-(4- methoxyphenyl)-1-[(6-methoxy- Q015 N N N 3-pyridyl)methyl]triazole-4- carboxylate N O benzyl 5-(4-methoxyphenyl)-1- [(6-methoxy-3- Q016 pyridyl)methyl]triazole-4- carboxylate83100 FF31Compound Structure Name3-methoxypropyl 5-(4- methoxyphenyl)-1-[(6-methoxy- Q017 3-pyridyl)methyl]triazole-4- carboxylate 2-methoxyethyl 5-(4- methoxyphenyl)-1-[(6-methoxy- Q018 3-pyridyl)methyl]triazole-4- carboxylate 2-methylallyl 5-(4- methoxyphenyl)-1-[(6-methoxy- Q019 3-pyridyl)methyl]triazole-4- carboxylate83100 FF32Compound Structure Nameprop-2-ynyl 5-(4- methoxyphenyl)-1-[(6-methoxy- Q020 3-pyridyl)methyl]triazole-4- carboxylate 3-methylbut-2-enyl 5-(4- methoxyphenyl)-1-[(6-methoxy- Q021 3-pyridyl)methyl]triazole-4- carboxylate allyl 5-(4-methoxyphenyl)-1-[(6- methoxy-3- Q022 pyridyl)methyl]triazole-4- carboxylate83100 FF33Compound Structure Name(2-methoxy-2-oxo-ethyl) 5-(4- methoxyphenyl)-1-[(6-methoxy- Q023 3-pyridyl)methyl]triazole-4- carboxylate (4-fluorophenyl)methyl 5-(4- methoxyphenyl)-1-[(6-methoxy- Q024 3-pyridyl)methyl]triazole-4- carboxylate cyanomethyl 5-(4- methoxyphenyl)-1-[(6-methoxy- Q025 3-pyridyl)methyl]triazole-4- carboxylate

[0006] 83100 FF34Compound Structure Namepropyl 5-(4-methoxyphenyl)-1- [(6-methoxy-3- Q026 pyridyl)methyl]triazole-4- carboxylate butyl 5-(4-methoxyphenyl)-1- [(6-methoxy-3- Q027 pyridyl)methyl]triazole-4- carboxylate pentyl 5-(4-methoxyphenyl)-1- [(6-methoxy-3- Q028 pyridyl)methyl]triazole-4- carboxylate83100 FF35 Compound Structure NameO N O O 2-pyridyl 5-(4-methoxyphenyl)- NN1-[(6-methoxy-3- Q029 N pyridyl)methyl]triazole-4- carboxylate N O (2-methylpyrazol-3-yl) 5-(4- methoxyphenyl)-1-[(6-methoxy- Q030 3-pyridyl)methyl]triazole-4- carboxylate Compounds of the present invention can be made as shown in the following schemes 1 to 7, inwhich, the substituents m, A, X1, X2, X3, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and R13are asdefined hereinbefore for a compound of formula (I) unless explicitly stated otherwise.A compound of formula (Ia) (a compound of formula (I) where R1 = H) may be prepared from acompound of formula (Ib) (a compound of formula (I) where R1 ≠ hydrogen) according to reactionscheme 1 via a hydrolysis reaction using a suitable reagent and in a suitable solvent. Suitable reagents may include LiOH or NaOH. Suitable solvents may include THF, Me-THF, MeOH or EtOH and combinations with water. Reaction Scheme 183100 FF36 Acompound of formula (I) (including (Ia and Ib) may be prepared from a compound of formula (A)(where Y1represents a suitable halogen such as I, Br, Cl, or pseudo halogen, for example triflate,mesylate and tosylate) via a cross-coupling reaction with a compound of formula B (where Y2 representsa suitable cross-coupling partner such as an organoboronic acid, organoboronic ester ororganotrifluoroborate) in the presence of a suitable catalyst / ligand combination, a suitable base and in a suitable solvent, according to reaction scheme 2. Suitable catalyst / ligand combinations may include XPhos Pd G3, XPhos Pd G4, ddpf Pd G3 or Pd(PPh3)4. Suitable bases may include K3PO4, NaHCO3 orCs2CO3. Suitable solvents may include Me-THF / water. Compounds of formula (B) are eithercommercially available or may be prepared by methods known in the literature.Reaction Scheme 2 Acompound of formula (A) may be prepared according to reaction scheme 3 via a cycloadditionreaction of a compound of formula (C) with a compound of formula (D) in the presence of a suitablecatalyst and in a suitable solvent. Suitable catalysts may include, but are not limited to Cu(OAc)2 or CuBrand suitable solvents may include but are not limited to Me-THF or THF, see for example Synlett (2005)3059. Reaction Scheme 383100 FF37 Acompound of formula (C) may be prepared according to reaction scheme 4 from a compoundof formula (E) (where Y3 represents a suitable leaving group such as a halogen, for example iodo, bromoand chloro, or pseudo halogen, for example triflate, mesylate and tosylate) via a displacement reactionwith a suitable azide source in a suitable solvent. Suitable azide sources may include, but are not limitedto, NaN3 and suitable solvents may include, but are not limited to, acetone / water, DMF or DMSO, seefor example Angewandte Chemie – International Edition (2013) 3485 or Bioorganic and MedicinalChemistry (2016) 5861. Compounds of formula (E) are commercially available or may be prepared bymethods known in the literature. Reaction Scheme 4 formula (E)formula (C)In an alternative approach, compounds of formula (C) may be prepared according to reactionscheme 5 from compounds of formula (F) via reaction with diphenyl phosphoryl azide (DPPA) in thepresence of a suitable base and in a suitable solvent. Suitable bases may include, but are not limitedto, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), whilst suitable solvents may include, but are not limitedto, THF or CH3CN, see for example Journal of the American Chemical Society (2013) 11680.Compounds of formula (F) are commercially available or may be prepared by methods known in theliterature. Reaction Scheme 583100 FF38 formula (F)formula (C)A compound of formula (D) may be prepared according to reaction scheme 6 from a compoundof formula (G) via reaction with a suitable halogenating reagent and in the presence of a suitable catalystand in a suitable solvent. Suitable halogenating reagents may include, but are not limited to, N-Iodosuccinimide (NIS), N-Bromosuccinimide (NBS) or N-Chlorosuccinimide (NCS). Suitable catalystsmay include, but are not limited to, AgNO3 and suitable solvents may include, but are not limited to,acetone, see for example Organic Syntheses (1997) 212. Compounds of formula (G) are commerciallyavailable or may be prepared by methods known in the literature. Reaction Scheme 6 In an alternative approach, a compound of formula (Ib) may be prepared according to reactionscheme 7 from a compound of formula (C) via a cyclisation reaction with a compound of formula (H) inthe presence of a suitable base and in a suitable solvent. Suitable bases may include, but are not limitedto, DBU or K2CO3 and suitable solvents may include, but are not limited to, CH3CN, DMF or DMSO, seefor example WO21086874. Compounds of formula (H) are commercially available or may be preparedby methods known in the literature. Reaction Scheme 783100 FF39 In an alternative approach, a compound of formula (Ib) may be prepared according to reaction scheme8, from a from a compound of formula (J) and a compound of formula (K) (where Y3 represents a suitablehalogen such as I or Br) in the presence of a suitable catalyst / additive system and a suitable base and in a suitable solvent. Suitable catalysts may include CataCXium A Pd G3. Suitable additives may include pivalic acid. Suitable bases may include K2CO3. Suitable solvents may include o-xylene. Compounds ofFormula (K) are commercially available or may be prepared by methods known in the literature.Reaction Scheme 8 Formula (J) Formula (Ib)A compound of formula (J) may be prepared from a compound (C) via a cycloaddition reaction (reactionscheme 9) with a compound of formula (G) in the presence of a suitable catalyst and a suitable reducingagent and in a suitable solvent. Suitable catalysts may include CuSO4. Suitable reducing agents may include sodium ascorbate. Suitable solvents may includetBuOH / water mixtures.83100 FF40 Reaction Scheme 9 The present invention still further provides a method of controlling weeds at a locus said method comprising application to the locus of a weed controlling amount of a composition comprising acompound of formula (I). Moreover, the present invention may further provide a method of selectivelycontrolling weeds at a locus comprising useful (crop) plants and weeds, wherein the method comprises application to the locus of a weed controlling amount of a composition according to the present invention. ‘Controlling’ means killing, reducing or retarding growth or preventing or reducing germination. It is noted that the compounds of the present invention show a much improved selectivity compared to know, structurally similar compounds. Generally the plants to be controlled are unwanted plants (weeds). ‘Locus’ means the area in which the plants are growing or will grow. The application may be applied to the locus pre-emergence and / or postemergence of the crop plant. Some crop plants may be inherentlytolerant to herbicidal effects of compounds of formula (I). Within the scope of present invention, targetcrops and / or useful plants to be protected typically comprise perennial and annual crops, such as berry plants for example blackberries, blueberries, cranberries, raspberries and strawberries; cereals for example barley, maize (corn), millet, oats, rice, rye, sorghum triticale and wheat; fibre plants for example cotton, flax, hemp, jute and sisal; field crops for example sugar and fodder beet, coffee, hops, mustard, oilseed rape (canola), poppy, sugar cane, sunflower, tea and tobacco; fruit trees for example apple, apricot, avocado, banana, cherry, citrus, nectarine, peach, pear and plum; grasses for example Bermuda grass, bluegrass, bentgrass, centipede grass, fescue, ryegrass, St. Augustine grass and Zoysia grass; herbs such as basil, borage, chives, coriander, lavender, lovage, mint, oregano, parsley, rosemary, sage and thyme; legumes for example beans, lentils, peas and soya beans; nuts for example almond, cashew, ground nut, hazelnut, peanut, pecan, pistachio and walnut; palms for example oil palm; ornamentals for example flowers, shrubs and trees; other trees, for example cacao, coconut, olive and rubber; vegetables for example asparagus, aubergine, broccoli, cabbage, carrot, cucumber, garlic, lettuce, marrow, melon, okra, onion, pepper, potato, pumpkin, rhubarb, spinach and tomato; and vinesfor example grapes. Preferred crop plants include maize, wheat, barley and rice.The rates of application of compounds of formula (I) may vary within wide limits and depend onthe nature of the soil, the method of application (pre- or post-emergence; seed dressing; application tothe seed furrow; no tillage application etc.), the crop plant, the weed(s) to be controlled, the prevailing climatic conditions, and other factors governed by the method of application, the time of application and83100 FF41the target crop. The compounds of formula (I) according to the invention are generally applied at a rateof from 10 to 2500 g / ha, especially from 25 to 1000 g / ha, more especially from 25 to 250 g / ha. The application is generally made by spraying the composition, typically by tractor mounted sprayer for large areas, but other methods such as dusting (for powders), drip or drench can also be used. The term "useful plants" is to be understood as also including useful plants that have beenrendered tolerant to herbicides like bromoxynil or classes of herbicides such as, for example, 4-Hydroxyphenylpyruvate dioxygenase (HPPD) inhibitors, ALS inhibitors, for example primisulfuron,prosulfuron and trifloxysulfuron, 5-enol-pyrovyl-shikimate-3-phosphate-synthase (EPSPS) inhibitors,glutamine synthetase (GS) inhibitors or protoporphyrinogen-oxidase (PPO) inhibitors as a result of conventional methods of breeding or genetic engineering. An example of a crop that has been rendered tolerant to imidazolinones, e.g. imazamox, by conventional methods of breeding (mutagenesis) is Clearfield® summer rape (Canola). Examples of crops that have been rendered tolerant to herbicidesor classes of herbicides by genetic engineering methods include glyphosate- and glufosinate-resistantmaize varieties commercially available under the trade names RoundupReady®, Herculex I^ andLibertyLink®. The term "useful plants" is to be understood as also including useful plants which have been so transformed by the use of recombinant DNA techniques that they are capable of synthesising one or more selectively acting toxins, such as are known, for example, from toxin-producing bacteria, especially those of the genus Bacillus. Examples of such plants are: YieldGard^ (maize variety that expresses a CryIA(b) toxin);YieldGard Rootworm^ (maize variety that expresses a CryIIIB(b1) toxin); YieldGard Plus^ (maizevariety that expresses a CryIA(b) and a CryIIIB(b1) toxin); Starlink^ (maize variety that expresses aCry9(c) toxin); Herculex I^ (maize variety that expresses a CryIF(a2) toxin and the enzymephosphinothricine N-acetyltransferase (PAT) to achieve tolerance to the herbicide glufosinateammonium); NuCOTN 33B^ (cotton variety that expresses a CryIA(c) toxin); Bollgard I^ (cotton varietythat expresses a CryIA(c) toxin); Bollgard II® (cotton variety that expresses a CryIA(c) and a CryIIA(b)toxin); VIPCOT^ (cotton variety that expresses a VIP toxin); NewLeaf^ (potato variety that expressesa CryIIIA toxin); NatureGard^ Agrisure® GT Advantage (GA21 glyphosate-tolerant trait), Agrisure® CBAdvantage (Bt11 corn borer (CB) trait), Agrisure® RW (corn rootworm trait) and Protecta^. The compounds of Formula (I) (or compositions comprising such) can be used to controlunwanted plants (collectively, ‘weeds’). The weeds to be controlled may be both monocotyledonousspecies, for example Aegilops Agrostis, Alopecurus, Avena, Beckmannia, Brachiaria, Bromus,Cenchrus, Cyperus, Digitaria, Echinochloa, Eleocharis, Eleusine, Lolium, Monochoria, Murdannia, Rottboellia, Sagittaria, Scirpus, Setaria and Sorghum, and dicotyledonous species, for example Abutilon, Amaranthus, Ambrosia, Capsella, Chenopodium, Chrysanthemum, Conyza, Descurania, Eclipta, Euphorbia Galium, Ipomoea, Nasturtium, Sida, Sinapis, Solanum, Stellaria, Veronica, Viola and Xanthium. Compounds of formula (I) may be used in unmodified form or, preferably, together with theadjuvants conventionally employed in the art of formulation to provide herbicidal compositions. The83100 FF42 invention therefore further provides a herbicidal composition, comprising at least one compound formula (I) and an agriculturally acceptable carrier and optionally an adjuvant. An agricultural acceptable carrier is for example a carrier that is suitable for agricultural use. Agricultural carriers are well known in the art. To this end compounds of formula (I) may be conveniently formulated in known manner toemulsifiable concentrates, coatable pastes, directly sprayable or dilutable solutions or suspensions, dilute emulsions, wettable powders, soluble powders, dusts, granulates, and also encapsulations e.g. in polymeric substances. As with the type of the compositions, the methods of application, such as spraying, atomising, dusting, scattering, coating or pouring, are chosen in accordance with the intended objectives and the prevailing circumstances. The compositions may also contain further adjuvants such as stabilizers, antifoams, viscosity regulators, binders or tackifiers as well as fertilizers, micronutrient donors or other formulations for obtaining special effects. Suitable carriers and adjuvants, e.g. for agricultural use, can be solid or liquid and are substances useful in formulation technology, e.g. natural or regenerated mineral substances, solvents, dispersants, wetting agents, tackifiers, thickeners, binders or fertilizers. Such carriers are for example described in WO 97 / 33890. Suspension concentrates are aqueous formulations in which finely divided solid particles of the active compound are suspended. Such formulations include anti-settling agents and dispersing agents and may further include a wetting agent to enhance activity as well an anti-foam and a crystal growth inhibitor. In use, these concentrates are diluted in water and normally applied as a spray to the area to be treated. The amount of active ingredient may range from 0.5% to 95% of the concentrate. Wettable powders are in the form of finely divided particles which disperse readily in water or other liquid carriers. The particles contain the active ingredient retained in a solid matrix. Typical solid matrices include fuller’s earth, kaolin clays, silicas and other readily wet organic or inorganic solids. Wettable powders normally contain from 5% to 95% of the active ingredient plus a small amount of wetting, dispersing or emulsifying agent. Emulsifiable concentrates are homogeneous liquid compositions dispersible in water or other liquid and may consist entirely of the active compound with a liquid or solid emulsifying agent, or may also contain a liquid carrier, such as xylene, heavy aromatic naphthas, isophorone and other non-volatile organic solvents. In use, these concentrates are dispersed in water or other liquid and normally applied as a spray to the area to be treated. The amount of active ingredient may range from 0.5% to 95% ofthe concentrate.Granular formulations include both extrudates and relatively coarse particles and are usually applied without dilution to the area in which treatment is required. Typical carriers for granular Formulations include sand, fuller’s earth, attapulgite clay, bentonite clays, montmorillonite clay, vermiculite, perlite, calcium carbonate, brick, pumice, pyrophyllite, kaolin, dolomite, plaster, wood flour, ground corn cobs, ground peanut hulls, sugars, sodium chloride, sodium sulphate, sodium silicate, sodium borate, magnesia, mica, iron oxide, zinc oxide, titanium oxide, antimony oxide, cryolite, gypsum, diatomaceous earth, calcium sulphate and other organic or inorganic materials which absorb or which can be coated with the active compound. Granular Formulations normally contain 5% to 25% of active ingredients which may include surface-active agents such as heavy aromatic naphthas, kerosene and other petroleum fractions, or vegetable oils; and / or stickers such as dextrins, glue or synthetic resins.83100 FF43 Dusts are free-flowing admixtures of the active ingredient with finely divided solids such as talc, clays, flours and other organic and inorganic solids which act as dispersants and carriers. Microcapsules are typically droplets or granules of the active ingredient enclosed in an inert porous shell which allows escape of the enclosed material to the surroundings at controlled rates. Encapsulated droplets are typically 1 to 50 microns in diameter. The enclosed liquid typically constitutes 50 to 95% of the weight of the capsule and may include solvent in addition to the active compound. Encapsulated granules are generally porous granules with porous membranes sealing the granule poreopenings, retaining the active species in liquid form inside the granule pores. Granules typically rangefrom 1 millimetre to 1 centimetre and preferably 1 to 2 millimetres in diameter. Granules are formed byextrusion, agglomeration or prilling, or are naturally occurring. Examples of such materials arevermiculite, sintered clay, kaolin, attapulgite clay, sawdust and granular carbon. Shell or membrane materials include natural and synthetic rubbers, cellulosic materials, styrene-butadiene copolymers, polyacrylonitriles, polyacrylates, polyesters, polyamides, polyureas, polyurethanes and starch xanthates. Other useful formulations for agrochemical applications include simple solutions of the active ingredient in a solvent in which it is completely soluble at the desired concentration, such as acetone, alkylated naphthalenes, xylene and other organic solvents. Pressurised sprayers, wherein the active ingredient is dispersed in finely-divided form as a result of vaporisation of a low boiling dispersant solvent carrier, may also be used. Suitable agricultural adjuvants and carriers that are useful in formulating the compositions of the invention in the formulation types described above are well known to those skilled in the art. Liquid carriers that can be employed include, for example, water, toluene, xylene, petroleum naphtha, crop oil, acetone, methyl ethyl ketone, cyclohexanone, acetic anhydride, acetonitrile, acetophenone, amyl acetate, 2-butanone, chlorobenzene, cyclohexane, cyclohexanol, alkyl acetates, diacetonalcohol, 1,2-dichloropropane, diethanolamine, p-diethylbenzene, diethylene glycol, diethylene glycol abietate, diethylene glycol butyl ether, diethylene glycol ethyl ether, diethylene glycol methyl ether, N,N-dimethyl formamide, dimethyl sulfoxide, 1,4-dioxane, dipropylene glycol, dipropylene glycol methyl ether, dipropylene glycol dibenzoate, diproxitol, alkyl pyrrolidinone, ethyl acetate, 2-ethyl hexanol,ethylene carbonate, 1,1,1-trichloroethane, 2-heptanone, alpha pinene, d-limonene, ethylene glycol,ethylene glycol butyl ether, ethylene glycol methyl ether, gamma-butyrolactone, glycerol, glycerol diacetate, glycerol monoacetate, glycerol triacetate, hexadecane, hexylene glycol, isoamyl acetate, isobornyl acetate, isooctane, isophorone, isopropyl benzene, isopropyl myristate, lactic acid, laurylamine, mesityl oxide, methoxy-propanol, methyl isoamyl ketone, methyl isobutyl ketone, methyl laurate, methyl octanoate, methyl oleate, methylene chloride, m-xylene, n-hexane, n-octylamine, octadecanoic acid, octyl amine acetate, oleic acid, oleylamine, o-xylene, phenol, polyethylene glycol (PEG400), propionic acid, propylene glycol, propylene glycol monomethyl ether, p-xylene, toluene, triethyl phosphate, triethylene glycol, xylene sulfonic acid, paraffin, mineral oil, trichloroethylene, perchloroethylene, ethyl acetate, amyl acetate, butyl acetate, methanol, ethanol, isopropanol, and higher molecular weight alcohols such as amyl alcohol, tetrahydrofurfuryl alcohol, hexanol, octanol, etc., ethylene glycol, propylene glycol, glycerine and N-methyl-2-pyrrolidinone. Water is generally the carrier of choice for the dilution of concentrates.83100 FF44 Suitable solid carriers include, for example, talc, titanium dioxide, pyrophyllite clay, silica, attapulgite clay, kieselguhr, chalk, diatomaxeous earth, lime, calcium carbonate, bentonite clay, fuller’s earth, cotton seed hulls, wheat flour, soybean flour, pumice, wood flour, walnut shell flour and lignin. A broad range of surface-active agents are advantageously employed in both said liquid and solid compositions, especially those designed to be diluted with carrier before application. These agents, when used, normally comprise from 0.1% to 15% by weight of the formulation. They can be anionic, cationic, non-ionic or polymeric in character and can be employed as emulsifying agents, wetting agents, suspending agents or for other purposes. Typical surface active agents include salts of alkyl sulfates, such as diethanolammonium lauryl sulphate; alkylarylsulfonate salts, such as calcium dodecylbenzenesulfonate; alkylphenol-alkylene oxide addition products, such as nonylphenol-C.sub.18 ethoxylate; alcohol-alkylene oxide addition products, such as tridecyl alcohol-C.sub. 16 ethoxylate; soaps, such as sodium stearate; alkylnaphthalenesulfonate salts, such as sodium dibutylnaphthalenesulfonate; dialkyl esters of sulfosuccinate salts, such as sodium di(2-ethylhexyl)sulfosuccinate; sorbitol esters, such as sorbitol oleate; quaternary amines, such as lauryltrimethylammonium chloride; polyethylene glycol esters of fatty acids, such as polyethylene glycol stearate; block copolymers of ethylene oxide and propylene oxide; and salts of mono and dialkyl phosphate esters. Other adjuvants commonly utilized in agricultural compositions include crystallisation inhibitors, viscosity modifiers, suspending agents, spray droplet modifiers, pigments, antioxidants, foaming agents, anti-foaming agents, light-blocking agents, compatibilizing agents, antifoam agents, sequestering agents, neutralising agents and buffers, corrosion inhibitors, dyes, odorants, spreading agents, penetration aids, micronutrients, emollients, lubricants and sticking agents. The compounds of formula (I) are normally used in the form of agrochemical compositions andcan be applied to the crop area or plant to be treated, simultaneously or in succession with further compounds. These further compounds can be e.g. fertilizers or micronutrient donors or other preparations, which influence the growth of plants. They can also be selective herbicides or non- selective herbicides as well as insecticides, fungicides, bactericides, nematicides, molluscicides ormixtures of several of these preparations, if desired together with further carriers, surfactants orapplication promoting adjuvants customarily employed in the art of formulation. The herbicidal compounds of present invention can also be used in mixture with one or more additional herbicides and / or plant growth regulators. Specific examples of such mixtures include(wherein “I” represents a compound of formula (I)): I + acetochlor, I + acifluorfen (including acifluorfen-sodium), I + aclonifen, I + ametryn, I + amicarbazone, I + aminopyralid, I + aminotriazole, I + atrazine, I + beflubutamid-M, I + benquitrione, I + bensulfuron (including bensulfuron-methyl), I + bentazone, I + bicyclopyrone, I + bilanafos, I + bipyrazone, I + bispyribac-sodium, I + bixlozone, I + bromacil, I + bromoxynil, I + butachlor, I + butafenacil, I + carfentrazone (including carfentrazone-ethyl), I + cloransulam (including cloransulam-methyl), I + chlorimuron (including chlorimuron-ethyl), I + chlorotoluron, I + chlorsulfuron, I + cinmethylin, I + clacyfos, I + clethodim, I + clodinafop (including clodinafop-propargyl), I + clomazone, I + clopyralid, I + cyclopyranil, I + cyclopyrimorate, I +cyclosulfamuron, I + cyhalofop (including cyhalofop-butyl), I + 2,4-D (including the choline salt and 2-ethylhexyl ester thereof), I + 2,4-DB, I + desmedipham, I + dicamba (including the aluminium,83100 FF45 aminopropyl, bis-aminopropylmethyl, choline, dichloroprop, diglycolamine, dimethylamine,dimethylammonium, potassium and sodium salts thereof), I + diclosulam, I + diflufenican, I +diflufenzopyr, I + dimethachlor, I + dimethenamid-P, I + dioxopyritrione, I + diquat dibromide, I + diuron, I + epyrifenacil, I + ethalfluralin, I + ethofumesate, I + fenoxaprop (including fenoxaprop-P-ethyl), I + fenoxasulfone, I + fenpyrazone, I + fenquinotrione, I + fentrazamide, I + flazasulfuron, I + florasulam, I + florpyrauxifen (including florpyrauxifen-benzyl), I + fluazifop (including fluazifop-P-butyl), I + flucarbazone (including flucarbazone-sodium), I + flufenacet, I + flumetsulam, I + flumioxazin, I + fluometuron, I + flupyrsulfuron (including flupyrsulfuron-methyl-sodium), I + fluroxypyr (including fluroxypyr-meptyl), I + fomesafen, I + foramsulfuron, I + glufosinate (including L-glufosinate and the ammonium salts of both), I + glyphosate (including the diammonium, isopropylammonium and potassium salts thereof), I + halauxifen (including halauxifen-methyl), I + haloxyfop (including haloxyfop- methyl), I + hexazinone, I + hydantocidin, I + imazamox (including R-imazamox), I + imazapic, I + imazapyr, I + imazethapyr, I + indaziflam, I + iodosulfuron (including iodosulfuron-methyl-sodium), I + iofensulfuron (including iofensulfuron-sodium), I + ioxynil, I + isoproturon, I + isoxaflutole, I + lancotrione, I + MCPA, I + MCPB, I + mecoprop-P, I + mesosulfuron (including mesosulfuron-methyl), I + mesotrione, I + metamitron, I + metazachlor, I + methiozolin, I + metolachlor, I + metosulam, I + metribuzin, I + metsulfuron, I + napropamide, I + nicosulfuron, I + norflurazon, I + oxadiazon, I + oxasulfuron, I + oxyfluorfen, I + paraquat dichloride, I + pendimethalin, I + penoxsulam, I + phenmedipham, I + picloram, I + pinoxaden, I + pretilachlor, I + primisulfuron-methyl, I + prometryne, I + propanil, I + propaquizafop, I + propyrisulfuron, I + propyzamide, I + prosulfocarb, I + prosulfuron, I + pyraclonil, I + pyraflufen (including pyraflufen-ethyl), I + pyrasulfotole, I + pyridate, I + pyriftalid, I + pyrimisulfan, I + pyroxasulfone, I + pyroxsulam, I + quinclorac, I + quinmerac, I + quizalofop (including quizalofop-P-ethyl and quizalofop- P-tefuryl), I + rimisoxafen, I + rimsulfuron, I + saflufenacil, I + sethoxydim, I + simazine, I + S-metalochlor, I + sulfentrazone, I + sulfosulfuron, I + tebuthiuron, I + tefuryltrione, I + tembotrione, I + terbuthylazine, I + terbutryn, I + tetflupyrolimet, I + thiencarbazone, I + thifensulfuron, I + tiafenacil, I + tolpyralate, I + topramezone, I + tralkoxydim, I + triafamone, I + triallate, I + triasulfuron, I + tribenuron (including tribenuron-methyl), I + triclopyr, I + trifloxysulfuron (including trifloxysulfuron-sodium), I + trifludimoxazin, I + trifluralin, I + triflusulfuron, I + tripyrasulfone, I + 3-(2-chloro-4-fluoro-5-(3-methyl-2,6-dioxo-4- trifluoromethyl-3,6-dihydropyrimidin-1(2H)-yl)phenyl)-5-methyl-4,5-dihydroisoxazole-5-carboxylic acidethyl ester, I + 4-hydroxy-1-methoxy-5-methyl-3-[4-(trifluoromethyl)-2-pyridyl]imidazolidin-2-one, I + 4-hydroxy-1,5-dimethyl-3-[4-(trifluoromethyl)-2-pyridyl]imidazolidin-2-one, I + 5-ethoxy-4-hydroxy-1- methyl-3-[4-(trifluoromethyl)-2-pyridyl]imidazolidin-2-one, I + 4-hydroxy-1-methyl-3-[4-(trifluoromethyl)- 2-pyridyl]imidazolidin-2-one, I + 4-hydroxy-1,5-dimethyl-3-[1-methyl-5-(trifluoromethyl)pyrazol-3- yl]imidazolidin-2-one, I + (4R)1-(5-tert-butylisoxazol-3-yl)-4-ethoxy-5-hydroxy-3-methyl-imidazolidin-2- one, I + 4-amino-3-chloro-5-fluoro-6-(7-fluoro-1H-indol-6-yl)pyridine-2-carboxylic acid (including agrochemically acceptable esters thereof, for example, methyl 4-amino-3-chloro-5-fluoro-6-(7-fluoro- 1H-indol-6-yl)pyridine-2-carboxylate, prop-2-ynyl 4-amino-3-chloro-5-fluoro-6-(7-fluoro-1H-indol-6- yl)pyridine-2-carboxylate and cyanomethyl 4-amino-3-chloro-5-fluoro-6-(7-fluoro-1H-indol-6-yl)pyridine- 2-carboxylate), I + 3-ethylsulfanyl-N-(1,3,4-oxadiazol-2-yl)-5-(trifluoromethyl)-[1,2,4]triazolo[4,3- a]pyridine-8-carboxamide, I + 3-(isopropylsulfanylmethyl)-N-(5-methyl-1,3,4-oxadiazol-2-yl)-5- (trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-8-carboxamide, I + 3-(isopropylsulfonylmethyl)-N-(5-83100 FF46 methyl-1,3,4-oxadiazol-2-yl)-5-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-8-carboxamide, I + 3- (ethylsulfonylmethyl)-N-(5-methyl-1,3,4-oxadiazol-2-yl)-5-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine- 8-carboxamide, I + ethyl-2-[[3-[[3-chloro-5-fluoro-6-[3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1- yl]-2-pyridyl]oxy]acetate,6-chloro-4-(2,7-dimethyl-1-naphthyl)-5-hydroxy-2-methyl-pyridazin-3-one, I + tetrahydrofuran-2-ylmethyl (2R)-2-[(4-amino-3,5-dichloro-6-fluoro-2-pyridyl)oxy]propanoate, I + tetrahydrofuran-2-ylmethyl (2R)-2-[(4-amino-3,5-dichloro-6-fluoro-2-pyridyl)oxy]propanoate, I + tetrahydrofuran-2-ylmethyl 2-[(4-amino-3,5-dichloro-6-fluoro-2-pyridyl)oxy]propanoate, 2-[(4-amino-3,5- dichloro-6-fluoro-2-pyridyl)oxy]propanoic acid, I + 2-fluoro-N-(5-methyl-1,3,4-oxadiazol-2-yl)-3-[(R)- propylsulfinyl]-4-(trifluoromethyl)benzamide, I + 2-fluoro-N-(5-methyl-1,3,4-oxadiazol-2-yl)-3- propylsulfinyl-4-(trifluoromethyl)benzamide, I + (2-fluorophenyl)methyl 6-amino-5-chloro-2-(4-chloro-2- fluoro-3-methoxy-phenyl)pyrimidine-4-carboxylate and I + 6-amino-5-chloro-2-(4-chloro-2-fluoro-3- methoxy-phenyl)pyrimidine-4-carboxylic acid. The mixing partners of the compound of formula (I) may also be in the form of esters or salts, asmentioned e.g. in The Pesticide Manual, Sixteenth Edition, British Crop Protection Council, 2012. The compound of formula (I) can also be used in mixtures with other agrochemicals such asfungicides, nematicides or insecticides, examples of which are given in The Pesticide Manual. The mixing ratio of the compound of formula (I) to the mixing partner is preferably from 1: 100 to1000:1. The mixtures can advantageously be used in the above-mentioned formulations (in which case"active ingredient" relates to the respective mixture of compound of formula (I) with the mixing partner).The compounds or mixtures of the present invention can also be used in combination with one or more herbicide safeners. Examples of such safeners include benoxacor, cloquintocet (including cloquintocet-mexyl), cyprosulfamide, dichlormid, fenchlorazole (including fenchlorazole-ethyl), fenclorim, fluxofenim, furilazole, isoxadifen (including isoxadifen-ethyl), mefenpyr (including mefenpyr- diethyl), metcamifen and oxabetrinil. Particularly preferred are mixtures of a compound of formula (I) with cyprosulfamide, isoxadifen-ethyl, cloquintocet-mexyl and / or metcamifen. The safeners of the compound of formula (I) may also be in the form of esters or salts, asmentioned e.g. in The Pesticide Manual, 16thEdition (BCPC), 2012. The reference to cloquintocet-mexyl also applies to a lithium, sodium, potassium, calcium, magnesium, aluminium, iron, ammonium,quaternary ammonium, sulfonium or phosphonium salt thereof as disclosed in WO 02 / 34048.Preferably the mixing ratio of compound of formula (I) to safener is from 100:1 to 1:10, especiallyfrom 20:1 to 1:1. EXAMPLES The Examples which follow serve to illustrate the invention. Throughout this description, temperatures are given in degrees Celsius (°C) and “mp.” means melting point. LC / MS means Liquid Chromatography Mass Spectrometry. Formulation Examples83100 FF47 Wettable powders a) b) c)Active ingredient [compound of Formula (I)] 25 % 50 % 75 %sodium lignosulfonate 5 % 5 % -sodium lauryl sulfate 3 % - 5 %sodium diisobutylnaphthalenesulfonate - 6 % 10 %phenol polyethylene glycol ether - 2 % -(7-8 mol of ethylene oxide) highly dispersed silicic acid 5 % 10 % 10 % Kaolin 62 % 27 % -The active ingredient is thoroughly mixed with the adjuvants and the mixture is thoroughly ground in a suitable mill, affording wettable powders that can be diluted with water to give suspensions of the desired concentration. Powders for dry seed treatment a) b) c)Active ingredient [compound of Formula (I)] 25 % 50 % 75 %light mineral oil 5 % 5 % 5 %highly dispersed silicic acid 5 % 5 % -Kaolin 65 % 40 % -Talcum - - 20 %The active ingredient is thoroughly mixed with the adjuvants and the mixture is thoroughly ground in a suitable mill, affording powders that can be used directly for seed treatment. Emulsifiable concentrate active ingredient [compound of Formula (I)] 10 %octylphenol polyethylene glycol ether 3 %(4-5 mol of ethylene oxide) calcium dodecylbenzenesulfonate 3 %castor oil polyglycol ether (35 mol of ethylene oxide) 4 %Cyclohexanone 30 %xylene mixture 50 % Emulsions of any required dilution, which can be used in plant protection, can be obtained from this concentrate by dilution with water.83100 FF48 Dusts a) b) c)Active ingredient [compound of Formula (I)] 5 % 6 % 4 %Talcum 95 % - -Kaolin - 94 % -mineral filler - - 96 %Ready-for-use dusts are obtained by mixing the active ingredient with the carrier and grinding the mixture in a suitable mill. Such powders can also be used for dry dressings for seed. Extruder granules Active ingredient [compound of Formula (I)] 15 %sodium lignosulfonate 2 %Carboxymethylcellulose 1 %Kaolin 82 %The active ingredient is mixed and ground with the adjuvants, and the mixture is moistened with water. The mixture is extruded and then dried in a stream of air. Coated granules Active ingredient [compound of Formula (I)] 8 %polyethylene glycol (mol. wt.200) 3 % Kaolin 89 % The finely ground active ingredient is uniformly applied, in a mixer, to the kaolin moistened with polyethylene glycol. Non-dusty coated granules are obtained in this manner. Suspension concentrate Active ingredient [compound of Formula (I)] 40 %propylene glycol 10 %nonylphenol polyethylene glycol ether (15 mol of ethylene oxide) 6 %Sodium lignosulfonate 10 %Carboxymethylcellulose 1 %Silicone oil (in the form of a 75 % emulsion in water) 1 %Water 32 %The finely ground active ingredient is intimately mixed with the adjuvants, giving a suspension concentrate from which suspensions of any desired dilution can be obtained by dilution with water. Using such dilutions, living plants as well as plant propagation material can be treated and protected against infestation by microorganisms, by spraying, pouring or immersion. Flowable concentrate for seed treatment83100 FF49 Active ingredient [compound of Formula (I)] 40 %propylene glycol 5 %copolymer butanol PO / EO 2 %tristyrenephenole with 10-20 moles EO 2 %1,2-benzisothiazolin-3-one (in the form of a 20% solution in water) 0.5 %monoazo-pigment calcium salt 5 %Silicone oil (in the form of a 75 % emulsion in water) 0.2 %Water 45.3 %The finely ground active ingredient is intimately mixed with the adjuvants, giving a suspension concentrate from which suspensions of any desired dilution can be obtained by dilution with water. Using such dilutions, living plants as well as plant propagation material can be treated and protected against infestation by microorganisms, by spraying, pouring or immersion. Slow-Release Capsule Suspension 28 parts of a combination of the compound of Formula (I) are mixed with 2 parts of an aromaticsolvent and 7 parts of toluene diisocyanate / polymethylene-polyphenylisocyanate-mixture (8:1). This mixture is emulsified in a mixture of 1.2 parts of polyvinylalcohol, 0.05 parts of a defoamer and 51.6 parts of water until the desired particle size is achieved. To this emulsion a mixture of 2.8 parts 1,6- diaminohexane in 5.3 parts of water is added. The mixture is agitated until the polymerization reaction is completed. The obtained capsule suspension is stabilized by adding 0.25 parts of a thickener and 3 parts of a dispersing agent. The capsule suspension Formulation contains 28% of the active ingredients. The medium capsule diameter is 8-15 microns. The resulting formulation is applied to seeds as an aqueous suspension in an apparatus suitable for that purpose. List of Abbreviations: B2pin2 = bis(pinacolato)diboronbr = broad°C = degrees CelsiusDCM = dichloromethaned = doubletdd = double doubletdt = double tripletDBU = 1,8-diazabicyclo[5.4.0]undec-7-eneDIBAL-H = diisobutyl aluminium hydrideDMSO = dimethylsulfoxideDMF = N, N-dimethylformamideEtOAc = ethyl acetateh = hour(s)83100 FF50HPLC = high-performance liquid chromatographym = multipletM = molarMe-THF = 2-methyl tetrahydrofuranmin = minutesMHz = mega hertzmL = millilitremp = melting pointNMR = nuclear magnetic resonanceppm = parts per millionq = quartetquin = quintetrt = room temperatures = singlett = tripletTHF = tetrahydrofuranLC / MS = Liquid Chromatography Mass SpectrometryPreparation Examples Using the synthetic techniques described both above and below, compounds of formula (I) maybe prepared accordingly.Example 1: Preparation of of ethyl 1-[(6-chloro-3-pyridyl)methyl]-5-(4-methoxyphenyl)triazole-4-carboxylate (A001)1.1 5-(azidomethyl)-2-chloro-pyridine To a stirred solution of NaN3 (401mg, 6.17 mmol) in DMF (15 mL) at RT was added 2-chloro-5- (chloromethyl)pyridine (1.0g, 6.17 mmol). The reaction was stirred at RT for 2 hours, then diluted with water (150 mL) and extracted with EtOAc (2 x 75 mL). The combined organic extracts were washed with brine (50 mL), dried over Na2SO4 and evaporated to dryness under reduced pressure to give 5-(azidomethyl)-2-chloro-pyridine (1.00g, 96%) as a yellow oil.1H NMR (400 MHz, DMSO-d6) δ 8.43 (d, 1H), 7.89 (dd, 1H), 7.56 (d, 1H), 4.56 (s, 2H).83100 FF511.2 ethyl 1-[(6-chloro-3-pyridyl)methyl]-5-(4-methoxyphenyl)triazole-4-carboxylate (A001) A001 To a stirred solution of 5-(azidomethyl)-2-chloro-pyridine (1.12g, 6.64 mmol) in DMF (25 mL) atRT was added ethyl 3-(4-methoxyphenyl)-3-oxo-propanoate (1.48 g, 6.64 mmol) and K2CO3 (2.75 g,19.9 mmol). The reaction was stirred at 90°C for 3 hours, allowed to cool to RT then diluted with water (200 mL) and extracted with EtOAc (2 x 100 mL). The combined organic extracts were washed with brine (100 mL), dried over Na2SO4 and evaporated to dryness under reduced pressure to give ethyl 1-[(6-chloro-3-pyridyl)methyl]-5-(4-methoxyphenyl)triazole-4-carboxylate (1.21g, 49%) as an off-whitesolid. 1H NMR (400 MHz, DMSO-d6) δ 8.05 (d, 1H), 7.50-7.43 (m, 2H), 7.35 (d, 2H), 7.05 (d, 2H),5.48 (s, 2H), 4.15 (q, 2H), 3.82 (s, 3H), 1.13 (t, 3H) Example 2 : 1-[(6-chloro-3-pyridyl)methyl]-5-(4-methoxyphenyl)triazole-4-carboxylic acid (A003) A003 To a stirred solution of ethyl 1-[(6-chloro-3-pyridyl)methyl]-5-(4-methoxyphenyl)triazole-4- carboxylate (800mg, 2.15 mmol) in THF (15 mL) at RT was added a solution of LiOH (51mg, 2.15 mmol)in water (15 mL). The reaction was stirred at RT for 3 hours then evaporated to dryness under reducedpressure. To the crude residue was added 2M HCl (5 mL) and the resultant solid filtered, washed with83100 FF52 pentane and air dried to give 1-[(6-chloro-3-pyridyl)methyl]-5-(4-methoxyphenyl)triazole-4-carboxylicacid (510mg, 69%) as an off-white solid.1H NMR (400 MHz, DMSO-d6) δ 12.89 (s, 1H), 8.04 (d, 1H), 7.49-7.43 (m, 2H), 7.33 (d, 2H), 7.03 (d, 2H), 5.54 (s, 2H), 3.81 (s, 3H) Example 3: Preparation of ethyl 5-(4-methoxyphenyl)-1-[(6-methoxy-3-pyridyl)methyl]triazole-4- carboxylate (A010)3.1 ethyl 5-bromo-1-[(6-methoxy-3-pyridyl)methyl]triazole-4-carboxylate To a solution of 5-(azidomethyl)-2-methoxy-pyridine (prepared using an analogous method to1.1 above, 620 mg, 3.78 mmol) in DMF (3 mL) at RT under an N2 atmosphere was added Me-THF (9 mL), ethyl 3-bromoprop-2-ynoate (735 mg, 4.15 mmol), Cu(I)Br (108 mg, 0.75mmol) and Cu(OAc)2 (165 mg, 0.91 mmol). The reaction mixture was then stirred at 50 °C for 72 hours, allowed to cool to RT and concentrated under reduced pressure. The residue was diluted with ice water and the resultant solid removed by filtration. The solid was dissolved in EtOAc, filtered through a phase sep cartridge and evaporated to dryness. The residue was purified by chromatography on silica using a gradient of 0- 100% EtOAc in cyclohexane as eluent to give ethyl 5-bromo-1-[(6-methoxy-3-pyridyl)methyl]triazole-4- carboxylate (621mg, 48%) as a light brown solid. 1H NMR (400 MHz, CDCl3) δ 8.24 (d, 1H), 7.57 (dd, 1H), 6.73 (d, 1H), 5.55 (s, 2H), 4.44 (q, 2H), 3.93 (s, 3H), 1.42 (t, 3H)3.2 ethyl 5-(4-methoxyphenyl)-1-[(6-methoxy-3-pyridyl)methyl]triazole-4-carboxylate (A010)83100 FF53 To a flask charged with ethyl 5-bromo-1-[(6-methoxy-3-pyridyl)methyl]triazole-4-carboxylate (315 mg, 0.92 mmol), (4-methoxyphenyl)boronic acid (168 mg, 1.11 mmol) and Xphos Pd G3 (82 mg, 0.092 mmol) under an N2 atmosphere were added Me-THF (1.9 mL) and K3PO4 (5.0 mL of a 0.5M aq solution, 3 mmol). The mixture was degassed twice with N2 then heated at 75°C overnight. The reaction was allowed to cool to RT, diluted with water and extracted with EtOAc. The combined organic extracts were dried over MgSO4 and evaporated to dryness under reduced pressure. The crude product was purified by chromatography on silica using a gradient of 0-100% EtOAc / cyclohexane as eluent to give ethyl 5-(4-methoxyphenyl)-1-[(6-methoxy-3-pyridyl)methyl]triazole-4-carboxylate (79mg, 23%). 1H NMR (400 MHz, CDCl3) δ 7.79 (d, 1H), 7.40 (dd, 1H), 7.22 - 7.15 (m, 2H), 7.04 - 6.96 (m,2H), 6.66 (d, 1H), 5.36 (s, 2H), 4.31 (q, 2H), 3.90 (s, 3H), 3.88 (s, 3H), 1.29 (t, 3H) Example 4: Preparation of ethyl 1-[(2-hydroxypyrimidin-5-yl)methyl]-5-(4-methoxyphenyl)triazole-4- carboxylate (A047) A047 To a stirred solution of ethyl 1-[(2-tert-butoxypyrimidin-5-yl)methyl]-5-(4- methoxyphenyl)triazole-4-carboxylate (prepared using analogous procedures to those in 6.3 / 6.4 below,83100 FF54 239mg, 0.581 mmol) in CH2Cl2 (1.2 mL) under an N2 atmosphere at RT was added 2,2,2-trifluoroacetic acid (0.35 mL). The reaction was stirred at RT for 1h, then evaporated to dryness. The crude product was purified by reverse phase chromatography on C18 silica using a gradient of 10-100% CH3CN / water as eluent to give ethyl 1-[(2-hydroxypyrimidin-5-yl)methyl]-5-(4-methoxyphenyl)triazole-4-carboxylate (29mg, 14%). 1H NMR (400 MHz, DMSO-d6) 11.95 (br s, 1H), 7.90 (v br, 2H), 7.40 (d, 2H), 7.07 (d, 2H), 5.28 (s, 2H), 4.15 (q, 2H), 3.84 (s, 3H), 1.23 (t, 3H) Example 5: Synthesis of 1-[[2-(2-methoxyethoxy)pyrimidin-5-yl]methyl]-5-(4-methoxyphenyl)triazole-4- carboxylic acid (A048)5.1 ethyl 5-bromo-1-[[2-(2-methoxyethoxy)pyrimidin-5-yl]methyl]triazole-4-carboxylate To a stirred solution of 2-methoxyethanol (0.279 mL, 3.52 mmol) in THF (10 mL) at 0°C under an N2 atmosphere was added NaH (111mg of a 60% suspension, 2.77 mmol) portionwise. The reaction was stirred at 0°C for 1 hour and then a solution of ethyl 5-bromo-1-[(2-chloropyrimidin-5- yl)methyl]triazole-4-carboxylate (prepared using an analogous procedure to that disclosed in 3.1 above, 713mg, 1.95 mmol) in THF (4 mL) was added along with additional THF (10 mL). The reaction was allowed to warm to RT over 90 mins and then quenched with saturated aqueous NH4Cl solution (40 mL) and extracted with EtOAc (3 x 10 mL). The crude product was purified by reverse phase HPLC to give the desired product. 1H NMR (400 MHz, CDCl3) δ 8.58 (s, 2H), 5.56 (s, 2H), 4.56 - 4.51 (m, 2H), 4.45 (q, 2H), 3.78-3.72 (m, 2H), 3.42 (s, 3H), 1.42 (t, 3H).5.2 ethyl 1-[[2-(2-methoxyethoxy)pyrimidin-5-yl]methyl]-5-(4-methoxyphenyl)triazole-4-carboxylate83100 FF55 To a flask charged with ethyl 5-bromo-1-[[2-(2-methoxyethoxy)pyrimidin-5-yl]methyl]triazole-4- carboxylate (100 mg, 0.259 mmol), 4-methoxyphenylboronic acid (70mg, 0.438 mmol) and XPhos Pd G4 (36mg, 0.04 mmol) under an N2 atmosphere was added 2-methyltetrahydrofuran (1.5 mL) and 1M aqueous K3PO4 solution (0.65 mL). The reaction was heated at 50°C for 6 hours, allowed to cool to RT, diluted with water (20 mL) and extracted with EtOAc (3 x 5 mL). The combined organic extracts wereevaporated to dryness and purified by reverse phase HPLC to give the desired product.1H NMR (400 MHz, CDCl3) δ 8.22 (s, 2H), 7.21 (d, 2H), 7.03 (d, 2H), 5.37 (s, 2H), 4.50-4.47 (m, 2H), 4.31 (q, 2H), 3.88 (s, 3H), 3.76-3.73 (m, 2H), 3.41 (s, 3H), 1.29 (t, 3H)5.3 1-[[2-(2-methoxyethoxy)pyrimidin-5-yl]methyl]-5-(4-methoxyphenyl)triazole-4-carboxylic acid(A048) A048 To a stirred solution of ethyl 1-[[2-(2-methoxyethoxy)pyrimidin-5-yl]methyl]-5-(4- methoxyphenyl)triazole-4-carboxylate (27mg, 0.045 mmol) in 2-methyltetrahydrofuran (1 mL) at RT was added 2M aqueous NaOH solution (0.2 mL) and the reaction stirred at RT for 1 hour. The reaction was quenched with 2M HCl (20 mL) and extracted with EtOAc (7 x 5 mL). The combined organic extracts were evaporated to dryness and purified by reverse phase HPLC to give 1-[[2-(2-methoxyethoxy)pyrimidin-5-yl]methyl]-5-(4-methoxyphenyl)triazole-4-carboxylic acid (15mg, 81%).83100 FF56 1H NMR (400 MHz, CDCl3) δ 8.25 (s, 2H), 7.23 (d, 2H), 7.04 (d, 2H), 5.39 (s, 2H), 4.51-4.47 (m, 2H), 3.88 (s, 3H), 3.76-3.73 (m, 2H), 3.41 (s, 3H)Example 6: Preparation of 1-[[2-(dimethylamino)pyrimidin-5-yl]methyl]-5-(4-methoxyphenyl)triazole-4-carboxylic acid (A049)6.1 ethyl 2-(dimethylamino)pyrimidine-5-carboxylate To a stirred solution of ethyl 2-chloropyrimidine-5-carboxylate (2.00g, 10.7 mmol) in CH3CN (30 mL) under an N2 atmosphere was added K2CO3 (2.23g, 16.1 mmol) and dimethylamine (6.43 mL of a 2M solution in THF, 12.9 mmol). The reaction was stirred at RT for 22 hours, then quenched with water (50 mL) and extracted with EtOAc (2 x 30 mL). The combined organic extracts were dried over MgSO4 and evaporated to dryness. The crude product was purified by reverse phase chromatography on C18 silica using a gradient of 30-60% CH3CN in water (+0.1% formic acid) as eluent to give the desired product (1.57g, 71%) as an off-white solid. 1H NMR (400 MHz, CDCl3) δ 8.85 (s, 2H), 4.34 (q, 2H), 3.27 (s, 6H), 1.37 (t, 3H)6.2 [2-(dimethylamino)pyrimidin-5-yl]methanol To a stirred solution of ethyl 2-(dimethylamino)pyrimidine-5-carboxylate (1.52g, 7.40 mmol) in 2-methyltetrahydrofuran (19 mL) at 0°C under an atmosphere of N2 was added dropwise DIBAL-H (25.9 mL of a 1M solution in hexanes, 25.9 mmol). The reaction was stirred at 0°C for 1 hour, then quenched by addition of EtOAc (5 ml) and a saturated aqueous solution of Rochelle’s salt (50 mL). The reaction was stirred vigorously for 30 minutes, then extracted with EtOAc (2 x 30 mL). The combined organic extracts were dried over MgSO4 and evaporated to dryness to give the desired product (1.16g, 97%). 1H NMR (400 MHz, CDCl3) δ 8.31 (s, 2H), 4.51 (s, 2H), 3.19 (s, 6H), 1.84 (br s, 1H). 6.3 5-(azidomethyl)-N,N-dimethyl-pyrimidin-2-amine83100 FF57 Reaction carried out using a Uniqsis Flowsyn (as shown in the diagram above) and [2-(dimethylamino)pyrimidin-5-yl]methanol (398mg, 2.60 mmol). The system was flushed with solvent and pressurised to 7 bar. The temperature of chip and coil was set to 50 °C. The UV detector was turned on and a blank collected. The flow was set to 4.5 mL / min on each pump (9 mL / min overall flow). The sample loops (5 mL) containing solutions were switched in. Collection into a tube based on UV. The solution of 5-(azidomethyl)-N,N-dimethyl-pyrimidin-2-amine was used directly in the next step. 6.4 ethyl 1-[[2-(dimethylamino)pyrimidin-5-yl]methyl]-5-(4-methoxyphenyl)triazole-4-carboxylate To the stirred crude solution of 5-(azidomethyl)-N,N-dimethyl-pyrimidin-2-amine (2.60 mmol) in CH3CN from the previous step was added DBU (0.41 mL, 2.60 mmol) and ethyl 3-(4-methoxyphenyl)- 3-oxo-propanoate (0.996 mL, 5.20 mmol) and the reaction heated at 60°C for 18 hours. The reaction83100 FF58 was allowed to cool to RT and the K2CO3 (370mg, 2.60mmol) was added and the reaction heated to 60°C for 64 hours. The reaction was allowed to cool to RT and then filtered through solid supported PPh3 (1 equivalent wrt the DPPA). The reaction was evaporated to dryness, then diluted with saturated aqueous NH4Cl solution (5 mL) and extracted with EtOAc (3 x 5 mL). The combined organic extracts were evaporated to dryness and purified by reverse phase chromatography on C18 silica using a gradient of 20-100% CH3CN / water (+0.1% formic acid) as eluent to give ethyl 1-[[2-(dimethylamino)pyrimidin-5-yl]methyl]-5-(4-methoxyphenyl)triazole-4-carboxylate of ~30% purity (theremainder being ethyl 3-(4-methoxyphenyl)-3-oxo-propanoate).6.5 1-[[2-(dimethylamino)pyrimidin-5-yl]methyl]-5-(4-methoxyphenyl)triazole-4-carboxylic acid(A049) A049 To a stirred solution of ethyl 1-[[2-(dimethylamino)pyrimidin-5-yl]methyl]-5-(4-methoxyphenyl)triazole-4-carboxylate (724mg of 30% purity, 0.57 mmol) in 2-methyltetrahydrofuran (3.6mL) was added NaOH (1.42 mL of a 2M aqueous solution). The reaction was stirred at RT for 19 hours and then quenched by addition of 2M HCl (1.6 mL). The reaction was evaporated to dryness and purifiedby reverse phase chromatography on C18 silica using a gradient of 25-40% CH3CN / water (+0.1% formicacid) as eluent to give the desired product (42mg). 1H NMR (400 MHz, DMSO-d6) δ 12.80 (br s, 1H), 7.98 (s, 2H), 7.38 (d, 2H), 7.08 (d, 2H), 5.30 (s, 2H), 3.84 (s, 3H), 3.06 (s, 6H) Example 7: ethyl 5-(3-methoxyiminobenzofuran-6-yl)-1-[(6-methoxy-3-pyridyl)methyl]triazole-4- carboxylate (A060)7.1 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzofuran-3-one 83100 FF59 To a microwave vial was added 6-bromobenzofuran-3-one (1.0g, 4.69 mmol), B2pin2 (1.31g, 5.16 mmol), KOAc, (0.698g, 7.04 mmol), PdCl2(dppf)2.CH2Cl2 (0.196g, 0.23 mmol) and 2-Me THF (14 mL) and the reaction heated at 120°C for 1 hour. The reaction was cooled to RT, filtered through a pad of celite, washed through with EtOAc and evaporated to dryness under reduced pressure. The crude product was purified by flash chromatography on SiO2 using a gradient of 5-50% EtOAc / cyclohexane as eluent to give the desired product (514mg) of ~75% purity.1H NMR (400 MHz, CDCl3) 7.65 (d, 1H), 7.58 (s, 1H), 7.50 (d, 1H), 4.62 (s, 2H), 1.39 (s, 12H).7.2: ethyl 1-[(6-methoxy-3-pyridyl)methyl]-5-(3-oxobenzofuran-6-yl)triazole-4-carboxylate To a stirred suspension of XPhos Pd G3 (0.076g, 0.088 mmol), 6-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)benzofuran-3-one (0.914g of 75% purity, 2.64 mmol) and K3PO4 (4 mL of a 0.5M aqueous solution, 2.0 mmol) at RT was added ethyl 5-bromo-1-[(6-methoxy-3-pyridyl)methyl]triazole-4- carboxylate (0.30g, 0.88 mmol) and 2-Me THF (4 mL) and the reaction heated at 70°C for 2 hours. Thereaction was cooled to RT, diluted with water (20 mL) and extracted with EtOAc (3 x 15 mL). Thecombined organic extracts were evaporated to dryness under reduced pressure and purified by reverse phase chromatography on C18 silica gel using a gradient of 40-100% CH3CN in water as eluent to give the desired product (0.12g, 35%) as a white solid.1H NMR (400 MHz, CDCl3) 7.80-7.74 (m, 2H), 7.39 (dd, 1H), 7.04 (s, 1H), 6.92 (d, 1H), 6.67 (d, 1H), 5.40 (s, 2H), 4.73 (s, 2H), 4.32 (q, 2H), 3.89 (s, 3H), 1.28 (t, 3H)7.3: ethyl 5-(3-methoxyiminobenzofuran-6-yl)-1-[(6-methoxy-3-pyridyl)methyl]triazole-4-carboxylate(A060)83100 FF60 To a stirred suspension of ethyl 1-[(6-methoxy-3-pyridyl)methyl]-5-(3-oxobenzofuran-6-yl)triazole-4- carboxylate (0.12g, 0.304 mmol) in MeOH (1.5 mL) at RT was added pyridine (0.054 mL, 0.67 mmol) and O-methylhydroxylamine hydrochloride (0.038g, 0.46 mmol) and the reaction stirred at RT for 4 hours. The reaction was diluted with water (15 mL) and extracted with EtOAc (3 x 10 mL). The combined organic extracts were evaporated to dryness under reduced pressure to give the desired product (0.123g, 96%, 4:1 mixture of isomers) as an orange gum.1H NMR (400 MHz, CDCl3) Major 7.78 (d, 1H), 7.70 (d, 1H), 7.39 (dd, 1H), 6.86-6.81 (m, 2H), 6.68 (d, 1H), 5.38 (s, 2H), 5.17 (s, 2H), 4.32 (q, 2H), 4.06 (s, 2H), 3.89 (s, 3H), 1.28 (t, 3H). Minor 8.15 (d, 1H), 7.80 (d, 1H), 7.40 (dd, 1H), 6.80-6.77 (m, 2H), 6.69 (d, 1H), 5.38 (s, 2H), 5.13 (s, 2H), 4.32 (q, 2H), 4.07 (s, 2H), 3.90 (s, 3H), 1.28 (t, 3H).Example 8: 5-[4-[1,1-dimethyl-2-(methylamino)-2-oxo-ethoxy]phenyl]-1-[(6-methoxy-3-pyridyl)methyl]triazole-4-carboxylic acid (A066) 8.1: 2-(4-bromophenoxy)-2-methyl-propanoyl chloride To a stirred solution of 2-(4-bromophenoxy)-2-methylpropanoic acid (1.50g, 5.50 mmol) in CH2Cl2 (15 mL) at RT was added two drops of DMF (cat) and oxalyl chloride (1.45 mL, 16.5 mmol). The reaction was stirred at RT for 2 hours and then evaporated to dryness under reduced pressure to give the desired product (1.53g, quant) as a brown oil.8.2: 2-(4-bromophenoxy)-N,2-dimethyl-propanamide83100 FF61 To a stirred solution of 2-(4-bromophenoxy)-2-methyl-propanoyl chloride (1.53g, 5.50 mmol) in THF (7.5 mL) at RT under an atmosphere of N2 was added methylamine (8.3 mL of a 2M solution in THF, 16.5 mmol) and the reaction heated at 40°C for 1.5h. The reaction was allowed to cool to RT, diluted with EtOAc (20 mL) and washed with 0.5M HCl (10 mL), saturated aqueous NaHCO3 (10 mL) and brine. The organic phase was dried over MgSO4 and evaporated to dryness under reduced pressure to give the desired product.1H NMR (400 MHz, CDCl3) 7.38 (d, 2H), 6.79 (d, 2H), 6.66 (br s, 1H), 2.87 (d, 3H), 1.49 (s, 6H). 8.3: N,2-dimethyl-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]propenamide To a stirred solution of 2-(4-bromophenoxy)-N,2-dimethyl-propanamide (1.50g, 5.50 mmol) in degassed 1,4-dioxane (27 mL) at RT under an atmosphere of N2 was added KOAc (1.37g, 13.8 mmol), B2pin2 (1.70g, 6.61 mmol) and PdCl2(dppf)2.CH2Cl2 (0.227g, 0.276 mmol) and the reaction heated at 80°C for 24 hours. The reaction was allowed to cool to RT, evaporated to dryness under reduced pressure and the residue purified by reverse phase chromatography on C18 silica gel using a gradient of 50-70% CH3CN / water as eluent to give the desired product (1.60g, 91%) as a brown gum.1H NMR (400 MHz, CDCl3) 7.73 (d, 2H), 6.88 (d, 2H), 6.65 (br s, 1H), 2.85 (d, 3H), 1.53 (s, 6H), 1.33 (s, 12H)8.4: ethyl 5-[4-[1,1-dimethyl-2-(methylamino)-2-oxo-ethoxy]phenyl]-1-[(6-methoxy-3-pyridyl)methyl]triazole-4-carboxylate83100 FF62 To a stirred solution of ethyl 5-bromo-1-[(6-methoxy-3-pyridyl)methyl]triazole-4-carboxylate (0.40 g, 1.17 mmol), N,2-dimethyl-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]propanamide (0.449g, 1.41 mmol), K3PO4 (0.754g, 3.52 mmol) at RT under an atmosphere of N2 in degassed 2-Me THF (8 mL) and water (0.8 mL) was added XPhos Pd G3 (0.101g, 0.117 mmol) and the reaction heated at 75°C for 18 hours. The reaction was allowed to cool to RT, evaporated to dryness under reduced pressureand the residue purified by reverse phase chromatography on C18 silica using a gradient of 40-70%CH3CN / water as eluent to give the desired product (0.193g, 36%) as a colourless gum.1H NMR (400 MHz, CDCl3) 7.69 (d, 1H), 7.35 (dd, 1H), 7.14 (d, 2H), 6.98 (d, 2H), 6.64 (d, 1H), 6.61 (br s, 1H), 5.36 (s, 2H), 4.30 (q, 2H), 3.88 (s, 3H), 2.89 (d, 3H), 1.59 (s, 6H), 1.28 (t, 3H).8.5: 5-[4-[1,1-dimethyl-2-(methylamino)-2-oxo-ethoxy]phenyl]-1-[(6-methoxy-3-pyridyl)methyl]triazole-4-carboxylic acid (A066) To a stirred solution of ethyl 5-[4-[1,1-dimethyl-2-(methylamino)-2-oxo-ethoxy]phenyl]-1-[(6-methoxy-3- pyridyl)methyl]triazole-4-carboxylate (0.19g, 0.42 mmol) in 2-Me THF (4 mL) and MeOH (2 mL) at RT was added NaOH (0.42 mL of a 2M aqueous solution, 0.84 mmol). The reaction was stirred at RT for 17 hours, made acidic with 2M HCl and extracted with EtOAc (2 x 10 mL). The combined organics were83100 FF63 washed with brine, dried over MgSO4 and evaporated to dryness under reduced pressure to give the desired product (0.110g, 62%) as a white solid.1H NMR (400 MHz, DMSO-d6) 8.15-8.07 (m, 1H), 7.69 (d, 1H), 7.32-7.23 (m, 3H), 6.93 (d, 2H), 6.69 (d, 1H), 5.44 (s, 2H), 3.77 (s, 3H), 2.65 (d, 3H), 1.47 (s, 6H).Example 9: 2,2-difluoroethyl 5-(4-methoxyphenyl)-1-[(6-methoxy-3-pyridyl)methyl]triazole-4-carboxylate (A098) 9.1: 2,2-difluoroethyl 5-(4-methoxyphenyl)-1-[(6-methoxy-3-pyridyl)methyl]triazole-4-carboxylate (A098) To a stirred solution of 5-(4-methoxyphenyl)-1-[(6-methoxy-3-pyridyl)methyl]triazole-4-carboxylic acid (0.200g, 0.59 mmol) in CH2Cl2 (3 mL) at RT was added DMF (two drops, cat) and oxalyl chloride (0.076 mL, 0.89 mmol) and the reaction was stirred for 30 minutes.2,2-difluoroethanol (0.097g, 1.18 mmol), pyridine (0.096 ml, 0.089 mmol) and DMF (2 mL) were added and the reaction heated at 100°C for 15 minutes under microwave irradiation. The reaction was cooled to RT, evaporated to dryness under reduced pressure and the residue purified by mass-directed reverse phase prep HPLC to give the desired product (0.141g).1H NMR (500 MHz, DMSO-d6) 7.81 (s, 1H), 7.42-7.35 (m, 3H), 7.06 (d, 2H), 6.73 (d, 1H), 6.23 (tt, 1H), 5.50 (s, 2H), 4.47 (td, 2H), 3.85 (s, 3H), 3.80 (s, 3H).Example 10: ethyl 1-[(6-methoxy-3-pyridyl)methyl]-5-quinazolin-5-yl-triazole-4-carboxylate (A124)10.1: ethyl 1-[(6-methoxy-3-pyridyl)methyl]triazole-4-carboxylate83100 FF64 To a stirred solution of 5-(azidomethyl)-2-methoxy-pyridine (10.0 g, 59.7 mmol) intBuOH (150 mL) and H2O (35 mL) at RT under an atmosphere of N2 were added ethyl prop-2-ynoate (7.03 g, 71.6 mmol) and sodium ascorbate (5.91 g, 29.8 mmol) followed by CuSO4 (3.81 g, 23.9 mmol). The reaction was stirred at RT for 16h, diluted with water (50 mL), filtered through celite and washed through with EtOAc. The phases were separated and the aqueous phase extracted with EtOAc (2 x 50 mL). The combinedorganic extracts were washed with brine (50 mL), dried over Na2SO4 and evaporated to dryness underreduced pressure. The crude product was purified by flash chromatography on SiO2 using a gradient of 10-80% EtOAc / hexane as eluent to give the desired product.1H NMR (400 MHz, DMSO-d6) 8.86 (s, 1H), 8.28 (d, 1H), 7.73 (dd, 1H), 6.83 (dd, 1H), 5.61 (s, 2H), 4.29 (q, 2H), 3.84 (s, 3H), 1.28 (t, 3H).10.2: ethyl 1-[(6-methoxy-3-pyridyl)methyl]-5-quinazolin-5-yl-triazole-4-carboxylate (A124) To a stirred solution of 5-bromoquinazoline (0.478g, 2.29 mmol) and ethyl 1-[(6-methoxy-3- pyridyl)methyl]triazole-4-carboxylate (0.50g, 1.91 mmol) in o-xylene (6 mL) at RT under an atmosphere of N2 was added K2CO3 (0.67g, 4.77 mmol), pivalic acid (0.058g, 0.57 mmol) and CataCXium A Pd G3 (0.073, 0.095 mmol) and the reaction was heated at 135°C for 18 hours. The reaction was allowed to cool to RT, diluted with water (150 mL) and extracted with EtOAc (3 x 100 mL). The combined organic extracts were evaporated to dryness under reduced pressure and the crude product purified by reverse phase chromatography on C18 silica using a gradient of 20-100% CH3CN / water as eluent to give the desired product (0.39g, 50%) as a white solid.83100 FF651H NMR (400 MHz, CDCl3) 9.32 (s, 1H), 8.62 (s, 1H), 8.24 (d, 1H), 8.01 (dd, 1H), 7.48 (d, 1H), 7.36 (s, 3H), 7.22 (dd, 1H), 6.53 (d, 1H), 5.33 (dd, 2H), 4.22-4.14 (m, 1H), 3.39 (s, 3H), 1.05 (t, 3H) Where necessary, enantiomerically pure final compounds may be obtained from racemic materials as appropriate via standard physical separation techniques, such as reverse phase chiral chromatography, or through stereoselective synthetic techniques, (e.g., by using chiral starting materials).Table A- NMR data for compounds according to formula (I):1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) ethyl 1-[(6- (DMSO-d6) 8.05 chloro-3- (d, 1H), 7.50-7.43 pyridyl)methyl]-(m, 2H), 7.35 (d,A001 5-(4-2H), 7.05 (d, 2H),methoxyphenyl)t 5.48 (s, 2H), 4.15 riazole-4- (q, 2H), 3.82 (s, carboxylate 3H), 1.13 (t, 3H) O 5-(4- 7.82 (d, 1H), 7.41 N OH methoxyphenyl)- (dd, 1H), 7.19 (d, N 1-[(6-methoxy-3- 2H), 6.99 (d, 2H), A002 N pyridyl)methyl]tri 6.67 (d, 1H), 5.35 N azole-4- (s, 2H), 3.89 (s, O O carboxylic acid 3H), 3.86 (s, 3H) N (DMSO-d6) Cl 1-[(6-chloro-3- 12.89 (s, 1H), O pyridyl)methyl]- 8.04 (d, 1H), N 5-(4- 7.49-7.43 (m, A003 N methoxyphenyl)t2H), 7.33 (d, 2H),H O N riazole-4-7.03 (d, 2H), 5.54carboxylic acid (s, 2H), 3.81 (s, O 3H)83100 FF66 1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) 1-[(5,6-dichloro- 3- 7.94 (s, 1H), 7.57 pyridyl)methyl]- (s, 1H), 7.19 (d, A004 5-(4-2H), 7.00 (d, 2H),methoxyphenyl)t 5.43 (s, 2H), 3.87 riazole-4- (s, 3H) carboxylic acid 5-(4- 9.12 (s, 1H), 8.48 methoxyphenyl)- (s, 2H), 7.22 (d, 1-(pyrimidin-5- A005 2H), 7.00 (d, 2H), ylmethyl)triazole 5.50 (s, 2H), 3.88 -4-carboxylic (s, 3H) acid O 5-(4- methoxyphenyl)- 8.27 (s, 2H), 7.23 N 1-[(2- (d, 2H), 7.04 (d,O methoxypyrimidi A006 2H), 5.39 (s, 2H), N N n-5- O 3.99 (s, 3H), 3.89 N yl)methyl]triazol (s, 3H) N e-4-carboxylic H O acid 8.05 (d, 1H), 7.49 1-[(6-chloro-3- (dd, 1H), 7.28 (d,pyridyl)methyl]- 1H), 7.03 - 6.965-(4-ethoxy-3- (m, 2H), 6.86 (d,A007 methyl- 1H), 5.42 (s, 2H), phenyl)triazole- 4.09 (q, 2H), 2.224-carboxylic (s, 3H), 1.47 (t, acid 3H)83100 FF67 1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) (CD3OD) 8.00 (d, 1-[(6-chloro-3- 1H), 7.51 (dd, pyridyl)methyl]- 1H), 7.38 (d, 1H), 5-(4-7.28 - 7.21 (m,A008 isopropoxyphen2H), 7.05 - 6.98yl)triazole-4- (m, 2H), 5.60 (s, carboxylic acid 2H), 4.70 (spt, 1H), 1.37 (d, 6H) 5-(4- 8.21 (d, 1H), 7.45 methoxyphenyl)-(dd, 1H), 7.19 (d,1-[(6-methyl-3- 2H), 7.13 (d, 1H), A009 pyridyl)methyl]tri6.97 (d, 2H), 5.42azole-4- (s, 2H), 3.83 (s, carboxylic acid 3H), 2.55 (s, 3H) 7.79 (d, 1H), 7.40 (dd, 1H), 7.22 - ethyl 5-(4- 7.15 (m, 2H), methoxyphenyl)- 7.04 - 6.96 (m,1-[(6-methoxy-3- A010 2H), 6.66 (d, 1H), pyridyl)methyl]tri 5.36 (s, 2H), 4.31 azole-4- (q, 2H), 3.90 (s, carboxylate 3H), 3.88 (s, 3H), 1.29 (t, 3H)83100 FF68 1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) 1-[(6-chloro-3- 8.03 (d, 1H), 7.50 pyridyl)methyl]-- 7.46 (m, 3H),5-[4-7.30 - 7.28 (m,A011 (methoxymethyl)1H), 7.26 - 7.22phenyl]triazole- (m, 2H), 5.43 (s, 4-carboxylic 2H), 4.55 (s, 2H), acid 3.48 (s, 3H) (DMSO-d6) 8.18 (d, 1H), 7.77 (d, 5-(4- 1H), 7.38-7.30 methoxyphenyl)- (m, 2H), 7.08- 1-[(5-methoxy-3- A012 7.00 (m, 2H), pyridyl)methyl]tri 6.95-6.90 (m, azole-4- 1H), 5.52 (s, 2H), carboxylic acid 3.81 (s, 3H), 3.73 (s, 3H) (DMSO-d6) 12.86 (s, 1H), 1-[(5-chloro-3- 8.54 (d, 1H), 8.15 pyridyl)methyl]- (d, 1H), 7.53 (t, 5-(4- A0131H), 7.36 - 7.32methoxyphenyl)t (m, 2H), 7.06 - riazole-4- 7.02 (m, 2H), carboxylic acid 5.56 (s, 2H), 3.82 (s, 3H)83100 FF69 1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) (DMSO-d6) 7.91 1-[[6- (d, 1H), 7.66 (t, (difluoromethoxy 1H), 7.56 (dd, )-3- 1H), 7.38 - 7.33pyridyl]methyl]- A014 (m, 2H), 7.08 - 5-(4- 7.04 (m, 2H), methoxyphenyl)t 7.02 (d, 1H), 5.51 riazole-4- (s, 2H), 3.83 (s, carboxylic acid 3H) 1-[(5-fluoro-6- 7.61 (s, 1H), 7.24 methoxy-3- (d, 2H), 7.18 (d, pyridyl)methyl]- 1H), 7.03 (d, 2H),A015 5-(4- 5.38 (s, 2H), 4.00 methoxyphenyl)t (s, 3H), 3.90 (s, riazole-4- 3H) carboxylic acid (DMSO-d6) 5-(2-fluoro-4- 12.83 (br s, 1H), methoxy- 7.79 (d, 1H), 7.40 phenyl)-1-[(6- (t, 1H), 7.35 (dd, A016 methoxy-3-1H), 7.01 - 6.91pyridyl)methyl]tri (m, 2H), 6.74 (d, azole-4- 1H), 5.43 (s, 2H), carboxylic acid 3.85 (s, 3H), 3.80 (s, 3H)83100 FF70 1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) 5-(4-(DMSO-d6) 8.45methoxyphenyl)-- 8.43 (m, 1H),1-[[6- 7.84 (d, 1H), 7.69 (trifluoromethyl)- (dd, 1H), 7.38 - A017 3- 7.33 (m, 2H), pyridyl]methyl]tri7.05 - 7.01 (m,azole-4- 2H), 5.67 (s, 2H), carboxylic acid 3.81 (s, 3H) 8.58 (br 1H), 8.31 5-(4- (br 1H), 7.53 (d, methoxyphenyl)- 1H), 7.32-7.26 (m 1-(3- A018 1H), 7.18 (d, 2H), pyridylmethyl)tri 6.96 (d, 2H), 5.45 azole-4- (s, 2H), 3.73 (s, carboxylic acid 3H) 8.02 (d, 1H), 7.49 1-[(6-chloro-3- (dd, 1H), 7.33 - pyridyl)methyl]- 7.27 (m, 3H), A019 5-(p- H O7.13 (d, 2H), 5.43tolyl)triazole-4- N (s, 2H), 2.45 (s, carboxylic acid ON N3H) NCl83100 FF71 1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) (DMSO-d6) 7.92 ethyl 1-[[6- O (d, 1H), 7.65 (t, (difluoromethoxy 1H), 7.57 (dd, )-3- F 1H), 7.38 (d, 2H), N pyridyl]methyl]- A020 F 7.06 (d, 2H), 7.02 O N O 5-(4- (d, 1H), 5.54 (s, N methoxyphenyl)t N 2H), 4.17 (q, 2H), O riazole-4- 3.83 (s, 3H), 1.14 carboxylate (t, 3H) O (DMSO-d6) 8.54 ethyl 1-[(5- Cl (d, 1H), 8.17 (s, chloro-3- 1H), 7.55 (s, 1H), pyridyl)methyl]- 7.37 (d, 2H), 7.05 A021 N 5-(4- N (d, 2H), 5.60 (s, O N methoxyphenyl)t 2H), 4.17 (q, 2H), N riazole-4- O 3.83 (s, 3H), 1.14 carboxylate (t, 3H) 7.77 (d, 1H), 7.35 ethyl 5-(2-fluoro- (dd, 1H), 7.06 (t, 4-methoxy-1H), 6.81 - 6.73phenyl)-1-[(6- (m, 2H), 6.64 (d, A022 methoxy-3- 1H), 5.36 (br s, pyridyl)methyl]tri 2H), 4.31 (q, 2H), azole-4- 3.88 (s, 3H), 3.87 carboxylate (s, 3H), 1.28 (t, 3H) 8.24 (s, 2H), ethyl 5-(4- 7.23-7.18 (m, methoxyphenyl)- 2H), 7.06-7.02 1-[(2- (m, 2H), 5.38 (s, A023 methoxypyrimidi 2H), 4.31 (q, 2H), n-5- 3.99 (s, 3H), 3.89 yl)methyl]triazol (s, 3H), 1.29 (t, e-4-carboxylate 3H)83100 FF72 1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) 9.15 (s, 1H), 8.48 ethyl 5-(4- (s, 2H), 7.20 (d, methoxyphenyl)- 2H), 7.03 (d, 2H), A024 1-(pyrimidin-5- 5.48 (s, 2H), 4.34ylmethyl)triazole (q, 2H), 3.90 (s, -4-carboxylate 3H), 1.30 (t, 3H) ethyl 1-[(5,6- 7.94 (s, 1H), 7.57 dichloro-3- (s, 1H), 7.16 (d, pyridyl)methyl]- 2H), 7.02 (d, 2H), A025 5-(4- 5.42 (s, 2H), 4.33 methoxyphenyl)t (q, 2H), 3.89 (s, riazole-4- 3H), 1.30 (t, 3H) carboxylate 5-(4- 8.34 (br, 2H), methoxyphenyl)- 6.96 (d, 2H), 1-(4- A026 6.77-6.70 (m, pyridylmethyl)tri 4H), 5.25 (s, 2H), azole-4- 3.64 (s, 3H) carboxylic acid (DMSO-d6) 12.83 (br s, 1H), 5(4- 7.78 (d, 1H), 7.39methoxyphenyl)- -7.29 (m, 3H),1-[(2-methoxy-4- A0277.10 - 7.01 (m,pyridyl)methyl]tri 2H), 6.73 (d, 1H), azole-4- 5.42 (s, 2H), 3.83 carboxylic acid (s, 3H), 3.79 (s, 3H).83100 FF73 1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) F 1-[(6-chloro-3- pyridyl)methyl]- 8.05 (s, 1H), 7.50 5-(3-fluoro-4- (d, 1H), 7.35-7.28 A028 methyl- (m, 2H), 6.91 (dd, H O phenyl)triazole- 2H), 5.44 (s, 2H), N N 4-carboxylic 2.33 (s, 3H) ON NCl acid 1-[(6-chloro-3- 8.03 (s, 1H), 7.49 pyridyl)methyl]- (d, 1H), 7.27 (d, 5-(4-methoxy-3- 1H), 7.03 (d, 1H), A029 methyl- 6.97 (s, 1H), 6.85 phenyl)triazole- (d, 1H), 5.40 (s, 4-carboxylic2H), 3.90 (s, 3H),acid 2.30 (s, 3H) (DMSO-d6) 1-[(6-chloro-3- 12.90 (br s, 1H), pyridyl)methyl]- 8.04 (s, 1H), 5-(3-methyl-2- 7.50-7.47 (m, A030 oxo-1,3- 2H), 7.42 (d, 1H), benzoxazol-6- 7.35 (d, 1H), 7.24 yl)triazole-4- (d, 1H), 5.53 (s, carboxylic acid 2H), 3.40 (s, 3H) 1-[(6-chloro-3- 8.02 (s, 1H), 7.48 pyridyl)methyl]- (d, 1H), 7.27 (d, 5-(4- 1H), 7.17 (d, 2H), A031 ethoxyphenyl)tri 6.95 (d, 2H), 5.40 azole-4- (s, 2H), 4.08 (q, carboxylic acid 2H), 1.45 (t, 3H)83100 FF74 1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) (DMSO-d6) 1-[(6-chloro-3- 12.90 (br s, 1H), pyridyl)methyl]- 8.08 (s, 1H), 7.50 5-(3-fluoro-4- (dd, 1H), 7.45 (d, A032 methoxy- 1H), 7.35 (d, 1H), phenyl)triazole- 7.25 (t, 1H), 7.18 4-carboxylic (d, 1H), 5.55 (s, acid 2H), 3.90 (s, 3H) 1-[(6-chloro-3- 8.07 (s, 1H), 7.46 pyridyl)methyl]- (d, 1H), 7.28 (d, 5-(2,3-dihydro- 1H), 6.95 (d, 1H), A033 1,4-benzodioxin- 6.78 (s, 1H), 6.70 6-yl)triazole-4- (d, 1H), 5.48 (s, carboxylic acid 2H), 4.30 (d, 4H) 1-[(6-chloro-3- 8.03 (s, 1H), 7.48 pyridyl)methyl]- (dd, 1H), 7.28 (d, 5-(2,3- 1H), 7.03 (s, 1H), A034 dihydrobenzofur 6.97 (d, 1H), 6.81 an-5-yl)triazole- (d, 1H), 5.40 (s, 4-carboxylic 2H), 4.63 (t, 2H), acid 3.21 (t, 2H) 1-[(6-chloro-3- 8.00 (s, 1H), 7.45 pyridyl)methyl]- (d, 1H), 7.28-7.20 5-(2,3- (m, 2H), 6.68- A035 dihydrobenzofur 6.60 (m, 2H), an-6-yl)triazole- 5.41 (s, 2H), 4.63 4-carboxylic (t, 2H), 3.28 (t, acid 2H)83100 FF75 1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) 5-(1,3- 8.05 (s, 1H), 7.49 benzodioxol-5- (d, 1H), 7.27 (d, yl)-1-[(6-chloro- 1H), 6.88 (d, 1H), A036 3- 6.70-6.62 (m, pyridyl)methyl]tri 2H), 6.03 (s, 2H), azole-4- 5.42 (2H) carboxylic acid 8.01 (s, 1H), 7.45 1-[(6-chloro-3- (dd, 1H), 7.30- pyridyl)methyl]- 7.21 (m, 3H), 5-(4- 7.12 (d, 2H), 5.41 A037 propylphenyl)tria (s, 2H), 2.62 (t, zole-4- 2H), 1.70-1.62 carboxylic acid (m, 2H), 0.95 (3H) O 1-[(6-chloro-3- 8.02 (s, 1H), 7.44 pyridyl)methyl]- (d, 1H), 7.27 (d, 5-(2-fluoro-4- 1H), 7.08 (t, 1H), A038 F methoxy- 6.78 (d, 1H), 6.73 H O phenyl)triazole- N N (d, 1H), 5.40 (s, 4-carboxylic O 2H), 3.86 (s, 3H) NNacid Cl 5-(2,1,3- benzothiadiazol- 8.10 (d, 1H), 7.97 5-yl)-1-[(6- (d, 2H), 7.45 (d, A039 chloro-3- 1H), 7.40 (d, 1H), pyridyl)methyl]tri 7.27 (d, 1H), 5.50 azole-4- (s, 2H) carboxylic acid83100 FF76 1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) N (DMSO-d6) S 5-(1,3- 12.90 (br s, 1H), benzothiazol-6- 9.51 (s, 1H), 8.26 yl)-1-[(6-chloro- (s, 1H), 8.18 (d, A040 3- 1H), 8.00 (d, 1H), H O pyridyl)methyl]tri N 7.54-7.50 (m, azole-4- O 2H), 7.40 (d NN, 1H), NClcarboxylic acid 5.60 (s, 2H) O 12.80 (br s, 1H), N 5-(1,3- 7.81 (d, 1H), 7.36 benzodioxol-5- (dd, 1H), 7.03 (d, yl)-1-[(6- 1H), 7.00 (d, 1H), A041NNmethoxy-3- 6.87 (dd, 1H), N pyridyl)methyl]tri 6.74 (d, 1H), 6.12 azole-4- (s, 2H), 5.42 (s, carboxylic acid O 2H), 3.80 (s, 3H) OH O O 8.54 (s, 1H), 7.98 ethyl 5-(4- (d, 2H), 7.78 (s, isoxazol-3- 1H), 7.40-7.35 ylphenyl)-1-[(6- (m, 3H), 6.73 (s, A042 methoxy-3- 1H), 6.54 (d, 1H), pyridyl)methyl]tri 5.38 (s, 2H), 4.30 azole-4- (q, 2H), 3.86 (s, carboxylate 3H), 1.24 (t, 3H)83100 FF77 1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) (CD3OD) 8.77 (d, 5-(4-isoxazol-3- 1H), 8.00 (d, 2H), ylphenyl)-1-[(6- 7.72 (s, 1H), 7.48 methoxy-3- (d, 2H), 7.38 (d, A043 pyridyl)methyl]tri 1H), 6.99 (d, 1H), azole-4- 6.69 (d, 1H), 5.52 carboxylic acid (s, 2H), 3.83 (s, 3H) 5-(4- (DMSO-d6) methoxyphenyl)- 12.80 (br s, 1H), 1-[(2- 8.34 (s, 2H), 7.37 methylpyrimidin- A044(d, 2H), 7.05 (d,5- 2H), 5.50 (s, 2H), yl)methyl]triazol 3.82 (s, 3H), 2.56 e-4-carboxylic (s, 3H) acid 1-[(2- (CD3OD) 8.23 (s, cyclopropylpyri 2H), 7.37 (d, 2H), midin-5- 7.04 (d, 2H), 5.52 A045 yl)methyl]-5-(4- (s, 2H), 3.88 (s, methoxyphenyl)t 3H), 2.20-2.10 riazole-4- (m, 1H), 1.09- carboxylic acid 1.00 (m, 4H)83100 FF78 1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) 1-[(2-chloro-6- (DMSO-d6) 7.32methoxy-4- (d, 2H), 7.02 (d,pyridyl)methyl]- 2H), 6.68 (s, 1H), A046 5-(4- 6.34 (s, 1H), 5.50 methoxyphenyl)t (s, 2H), 3.80 (s, riazole-4- 6H) carboxylic acid (DMSO-d6) ethyl 5-(4- 11.95 (br s, 1H), methoxyphenyl)- 7.90 (v br, 2H), 1-[(2-oxo-1H- 7.40 (d, 2H), 7.07 A047 pyrimidin-5- (d, 2H), 5.28 (s, yl)methyl]triazol 2H), 4.15 (q, 2H), e-4-carboxylate 3.84 (s, 3H), 1.23 (t, 3H) 1-[[2-(2- 8.25 (s, 2H), 7.23 methoxyethoxy) (d, 2H), 7.04 (d, pyrimidin-5- 2H), 5.39 (s, 2H), A048 yl]methyl]-5-(4- 4.51-4.47 (m, methoxyphenyl)t 2H), 3.88 (s, 3H), riazole-4- 3.76-3.73 (m, carboxylic acid 2H), 3.41 (s, 3H)83100 FF79 1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) 1-[[2- (DMSO-d6) (dimethylamino) 12.80 (br s, 1H), pyrimidin-5- 7.98 (s, 2H), 7.38 A049 yl]methyl]-5-(4-(d, 2H), 7.08 (d,methoxyphenyl)t 2H), 5.30 (s, 2H), riazole-4- 3.84 (s, 3H), 3.06 carboxylic acid (s, 6H) (CD3OD) 9.00 (dd, 1H), 8.44 (d, 1-[(6-methoxy-3- 1H), 8.15 (d, 1H),pyridyl)methyl]- 8.00 (d, 1H), 5-(6- A050 7.73-7.64 (m, quinolyl)triazole- 3H), 7.39 (dd, 4-carboxylic 1H), 6.69 (d, 1H), acid 5.59 (s, 2H), 3.83 (s, 3H) (CD3OD) 8.29 (s, 5-(4- 1H), 7.94 (s, 1H), methoxyphenyl)- 7.31 (s, 1H), 7.24 1-[(5-methyl-3- A051 (d, 2H), 7.03 (d, pyridyl)methyl]tri 2H), 5.58 (s, 2H), azole-4- 3.87 (s, 3H), 2.27 carboxylic acid (s, 3H). ethyl 1-[(2- 8.35 (s, 2H), 7.19 chloropyrimidin- (d, 2H), 7.04 (d, 5-yl)methyl]-5- 2H), 5.45 (s, 2H), A052 (4- 4.32 (q, 2H), 3.88 methoxyphenyl)t (s, 3H), 1.29 (t, riazole-4- 3H) carboxylate83100 FF80 1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) 8.33 (s, 1H), 7.59 (d, 1H), 7.34 (d, 1-[(6-chloro-3- 1H), 5.80 (br 1H), pyridyl)methyl]- 5.48 (s, 2H), A053 5-(cyclohexen- 2.24-2.18 (br m), 1-yl)triazole-4- 2H), 2.07-1.99 carboxylic acid (br m, 2H), 1.70- 1.64 (br m, 4H) (DMSO-d6) 8.385-(5-methoxy-2-(d, 1H), 8.09 (d,pyridyl)-1-[(6- 1H), 7.64 (d, 1H), methoxy-3- 7.47 (dd, 1H), A054 pyridyl)methyl]tri 7.27 (dd, 1H), azole-4- 7.01 (d, 1H), 5.73 carboxylic acid (s, 2H), 3.88 (s, 3H), 3.76 (s, 3H) 1-[(6-chloro-5- fluoro-3- 7.90 (d, 1H), 7.33 pyridyl)methyl]-(dd, 1H), 7.22 (d,A055 5-(4-2H), 7.03 (d, 2H),methoxyphenyl)t 5.46 (s, 2H), 3.88 riazole-4- (s, 3H) carboxylic acid83100 FF81 1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) 1-[(6-bromo-3- 8.04 (d, 1H), 7.45 pyridyl)methyl]-(d, 1H), 7.38 (dd,5-(4-1H), 7.19 (d, 2H),A056 methoxyphenyl)t7.02 (d, 2H), 5.42riazole-4- (s, 2H), 3.88 (s, carboxylic acid 3H) 1-[(6-fluoro-3- 7.88 (s, 1H), 7.62 pyridyl)methyl]- (t, 1H), 7.19 (d, 5-(4- 2H), 7.00 (d, 2H), A057 methoxyphenyl)t 6.89 (d, 1H), 5.43 riazole-4- (s, 2H), 3.86 (s, carboxylic acid 3H) (DMSO-d6) 5-(4- 12.89 (br s, 1H), methoxyphenyl)- 8.32 (d, 1H), 7.30 1-[(2-methyl-4- (d, 2H), 7.00 (d, A058 pyridyl)methyl]tri 2H), 6.79 (s, 1H), azole-4- 6.73 (d, 1H), 5.49 carboxylic acid (s, 2H), 3.79 (s, 3H), 2.38 (s, 3H)83100 FF82 1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) O N 7.81 (d, 1H), 7.70 5-[(3Z)-3- (d, 1H), 7.40 (dd, methoxyiminobe O O 1H), 6.86-6.81 OHnzofuran-6-yl]-1- (m, 2h), 6.68 (d, A059 [(6-methoxy-3- 1H), 5.38 (s, 2H), N N pyridyl)methyl]tri N 5.17 (s, 2H), 4.04 azole-4- (s, 3H), 3.89 (s, N carboxylic acid 3H). O As a 4:1 mixture of isomers. Major 7.78 (d, 1H), 7.70 (d, 1H), 7.39 (dd, 1H), 6.86-6.81 (m, 2H), 6.68 (d, 1H), 5.38 (s, 2H), ethyl 5-(3- 5.17 (s, 2H), 4.32 methoxyiminobe (q, 2H), 4.06 (s, nzofuran-6-yl)-1- 2H), 3.89 (s, 3H), A060 [(6-methoxy-3- 1.28 (t, 3H). pyridyl)methyl]tri Minor 8.15 (d, azole-4- 1H), 7.80 (d, 1H), carboxylate7.40 (dd, 1H),6.80-6.77 (m,2H), 6.69 (d, 1H),5.38 (s, 2H), 5.13 (s, 2H), 4.32 (q, 2H), 4.07 (s, 2H),3.90 (s, 3H), 1.28(t, 3H)83100 FF83 1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) ethyl 1-[(6- 8.48 (s, 1H), cyano-3- 7.76-7.59 (m, pyridyl)methyl]- 2H), 7.15 (d, 2H), A061 5-(4- 7.01 (d, 2H), 5.55 methoxyphenyl)t (s, 2H), 4.32 (q, riazole-4- 2H), 3.88 (s, 3H), carboxylate 1.30 (t, 3H) ethyl 1-[(6- chloro-5-fluoro- 7.87 (d, 1H), 7.31 3-(dd, 1H), 7.16 (d,pyridyl)methyl]-2H), 7.02 (d, 2H),A062 5-(4- 5.45 (s, 2H), 4.32 methoxyphenyl)t (q, 2H), 3.88 (s, riazole-4- 3H), 1.29 (t, 3H) carboxylate 5-(1,3- benzodioxol-5- 8.09 (s, 2H), 6.93 yl)-1-[[2- (d, 1H), 6.75-6.72 (dimethylamino) A063 (m, 2H), 6.08 (s, pyrimidin-5- 2H), 5.25 (s, 2H), yl]methyl]triazol 3.14 (s, 6H) e-4-carboxylic acid83100 FF84 1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) 5-(4- methoxyphenyl)-(DMSO-d6) 8.041-[(2-(s, 2H), 7.40 (d,morpholinopyrim 2H), 7.08 (d, 2H), A064 idin-5- 5.32 (s, 2H), 3.83 yl)methyl]triazol (s, 3H), 3.67 - e-4-carboxylic 3.58 (m, 8H) acid ethyl 5-(4- methoxyphenyl)- 1-[(5-methyl-3- Came from A065 pyridyl)methyl]tri Ricardo azole-4- carboxylate 5-[4-[1,1-(DMSO-d6) 8.15-dimethyl-2- 8.07 (m, 1H), (methylamino)- 7.69 (d, 1H), 2-oxo- 7.32-7.23 (m, A066 ethoxy]phenyl]-3H), 6.93 (d, 2H),1-[(6-methoxy-3- 6.69 (d, 1H), 5.44 pyridyl)methyl]tri (s, 2H), 3.77 (s, azole-4- 3H), 2.65 (d, 3H), carboxylic acid 1.47 (s, 6H).83100 FF85 1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) ethyl 5-(4- 8.06 (s, 2H), 7.26 methoxyphenyl)- (d, 2H), 7.04 (d, 1-[(2- 2H), 5.26 (s, 2H), A067 morpholinopyrim 4.31 (q, 2H), 3.89 idin-5- (s, 3H), 3.82 - yl)methyl]triazol 3.69 (m, 8H), e-4-carboxylate 1.29 (t, 3H) 5-[4-[1,1- 8.11 (br q, 1H), dimethyl-2- 7.99 (d, 1H), 7.29 (methylamino)- (d, 2H), 7.23 dd, 2-oxo- 1H), 7.14 (d, 1H), A068 ethoxy]phenyl]- 6.93 (d, 2H), 5.49 1-[(6-methyl-3- (s, 2H), 2.65 (d, pyridyl)methyl]tri3H), 2.55 - 2.47azole-4- (m, 6H), 2.39 (s, carboxylic acid 3H) (CD3OD) 7.86 (d, 5-(4- 1H), 7.42 (dd, isopropoxyphen 1H), 7.19 (d, 2H), yl)-1-[(6- 6.96 (d, 2H), 6.68 A069 methoxy-3- (d, 1H), 5.37 (s, pyridyl)methyl]tri 2H), 4.62 (sept, azole-4- 1H), 3.89 (s, 3H), carboxylic acid 1.39 (d, 6H).83100 FF86 1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) 5-[4-[(E)-N- methoxy-C- 7.83 (d, 1H), 7.79 methyl- (d, 2H), 7.42 (dd, carbonimidoyl]p 1H), 7.28 (d, 2H), A070 henyl]-1-[(6- 6.68 (d, 1H), 5.86 methoxy-3- (s, 2H), 4.03 (s, pyridyl)methyl]tri 3H), 3.89 (s, 3H), azole-4- 2.27 (s, 3H) carboxylic acid ethyl 5-[4-[(E)- 7.83-7.78 (m, N-methoxy-C- 3H), 7.39 (dd, methyl-1H), 7.27 (d, 2H),carbonimidoyl]p 6.66 (d, 1H), 5.35 A071 henyl]-1-[(6- (s, 2H), 4.30 (q, methoxy-3- 2H), 4.04 (s, 3H), pyridyl)methyl]tri 3.89 (s, 3H), 2.26 azole-4- (s, 3H), 1.27 (t, carboxylate 3H) (CD3OD) 8.10 (d, 5-(4- 2H), 7.78 (d, 1H), acetylphenyl)-1- 6.98 (d, 2H), 7.37 [(6-methoxy-3- A072 (dd, 1H), 6.70 (d, pyridyl)methyl]tri 1H), 5.52 (s, 2H), azole-4- 3.84 (s, 3H), 2.67 carboxylic acid (s, 3H)83100 FF87 1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) O 8.08 (d, 2H), 7.72 O ethyl 5-(4- (d, 1H), 7.41 - O acetylphenyl)-1- 7.35 (m, 3H), [(6-methoxy-3- 6.67 (d, 1H), 5.38 A073 N N N pyridyl)methyl]tri (s, 2H), 4.31 (q, azole-4- 2H), 3.89 (s, 3H), N carboxylate 2.68 (s, 3H), 1.27 (t, 3H). O 8.10-8.02 (m, 2H), 7.03 (dd, ethyl 5-[(1E)-1- 1H), 6.96 (s, 1H), methoxyiminotet 6.54 (d, 1H), 6.31 ralin-6-yl]-1-[(2- (s, 1H), 5.35 (s, A074 methoxy-4- 2H), 4.32 (q, 2H), pyridyl)methyl]tri 4.01 (s, 3H), 3.90 azole-4- (s, 3H), 2.77 (t, carboxylate 2H), 2.70 (t, 2H), 1.90-1.81 (m, 2H), 1.28 (t, 3H) 8.10-8.05 (m, 2H), 7.15 (dd, 1H), 7.08 (s, 1H), ethyl 1-[(2- 6.53 (dd, 1H), methoxy-4- 6.38 (s, 1H), 5.35 pyridyl)methyl]- A075 (s, 2H), 4.33 (q, 5-(1-oxotetralin- 2H), 3.90 (s, 3H), 6-yl)triazole-4- 2.93 (t, 2H), 2.70 carboxylate (t, 2H), 2.20-2.12 (m, 2H), 1.30 (t, 3H)83100 FF88 1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) OO8.52 (s, 1H), 8.15 ethyl 5-(1,3- (s, 1H), 7.47 (d, O benzodioxol-5- 1H), 6.90 (d, 1H), O yl)-1-[(5-chloro- 6.67-6.63 (m, A076 3- N N 2H), 6.08 (s, 2H), N pyridyl)methyl]tri 5.45 (s, 2H), 4.32 azole-4- N (q, 2H), 1.30 (t, carboxylate 3H) Cl O 8.10 (d, 1H), 8.05 N (d, 1H), 7.05 (d, 5-[(1E)-1- 1H), 6.98 (d, 1H), O methoxyiminotet 6.54 (d, 1H), 6.31 OHralin-6-yl]-1-[(2- (s, 1H), 5.35 (s, A077 methoxy-4- N N 2H), 4.02 (s, 3H), pyridyl)methyl]tri N 3.90 (s, 3H), 2.74 azole-4- (t, 2H), 2.70 (t, O carboxylic acid N 2H), 1.90-1.80 (m, 2H) 8.12-8.07 (m, O 2H), 7.17 (d, 1H), O 1-[(2-methoxy-4- 7.10 (s, 1H), 6.54 OH pyridyl)methyl]- (d, 1H), 6.30 (s, A078 5-(1-oxotetralin- 1H), 5.35 (s, 2H), N N N 6-yl)triazole-4- 3.39 (s, 3H), 2.93 carboxylic acid (t, 2H), 2.70 (t, O 2H), 2.20-2.12 N (m, 2H)83100 FF89 1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) 5-(1,3- 8.50 (s, 1H), 8.14 benzodioxol-5- (s, 1H), 7.45 (s, yl)-1-[(5-chloro- 1H), 6.89 (d, 1H), A079 3- 6.68-6.64 (m, pyridyl)methyl]tri 2H), 6.04 (s, 2H), azole-4- 5.45 (s, 2H) carboxylic acid O 5-(2-fluoro-4- (CD3OD) 8.03 (s, O methoxy- 1H), 7.19 (t, 1H), OH phenyl)-1-[(2- 6.88-6.81 (m, F A080 methoxy-4- 2H), 6.56 (d, 1H), N N N pyridyl)methyl]tri 6.33 (s, 1H), 5.56 azole-4- (s, 2H), 3.84 (s, O carboxylic acid 6H) N (CD3OD) 8.02 (s, 5-(2-fluoro-4- 1H), 7.43 (dd, methoxy- 1H), 7.26-7.21 phenyl)-1-[(6- (m, 2H), 6.88 (dd, A081 methyl-3- 1H), 6.82 (dd, pyridyl)methyl]tri 1H), 5.55 (s, 2H), azole-4- 3.87 (s, 3H).2.48 carboxylic acid (s, 3H)

[0007] 83100 FF90 1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) 5-(1,3- benzodioxol-5- (CD3OD) 8.28 (s, yl)-1-[(2- 2H), 6.99 (d, 1H), methoxypyrimidi 6.89-6.82 (m, A082 n-5- 2H), 6.08 (s, 2H), yl)methyl]triazol 5.55 (s, 2H), 3.99 e-4-carboxylic (s, 3H) acid (DMSO-d6) 1-[(6-chloro-3- 12.90 (br 1H), pyridyl)methyl]- 8.03 (d, 1H), 5-(2,2-dimethyl- 7.48-7.41 (m, A083 1,3-benzodioxol- 2H), 6.91 (d, 1H), 5-yl)triazole-4-6.86 - 6.80 (m,carboxylic acid 2H), 5.55 (s, 2H), 1.68 (s, 6H) (DMSO-d6) 5-(2,2-dimethyl- 12.83 (br, 1H), 1,3-benzodioxol- 7.77 (d, 1H), 7.34 5-yl)-1-[(6- (dd, 1H), 6.94 (d, A084 methoxy-3-1H), 6.87 - 6.81pyridyl)methyl]tri (m, 2H), 6.72 (d, azole-4- 1H), 5.43 (s, 2H), carboxylic acid 3.79 (s, 3H), 1.68 (s, 6H)83100 FF91 1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) O ethyl 5-(2,2- 7.82 (d, 1H), 7.40 OOdimethyl-1,3- (dd, 1H), 6.82 (d, O benzodioxol-5-1H), 6.68 - 6.64Nyl)-1-[(6- (m, 2H), 6.60 (d, A085N N methoxy-3- 1H), 5.38 (s, 2H), pyridyl)methyl]tri 4.33 (q, 2H), 3.90 N azole-4- (s, 3H), 1.73 (s, O carboxylate 6H), 1.31 (t, 3H) (CD3OD) 8.04 (s, 5-(1,3- 1H), 7.43 (dd, benzodioxol-5- 1H), 7.24 (d, 1H), yl)-1-[(6-methyl- 6.93 (d, 1H), A086 3- 6.81-6.76 (m, pyridyl)methyl]tri 2H), 6.05 (s, 2H), azole-4- 5.57 (s, 2H), 2.48 carboxylic acid (s, 3H) 5-(1,3- 8.12 (s, 1H), 6.87 benzodioxol-5- (d, 1H), 6.75-6.67 yl)-1-[(2- (m, 2H), 6.56 (d, A087 methoxy-4- 1H), 6.37 (s, 1H), pyridyl)methyl]tri 6.06 (s, 2H), 5.41 azole-4- (s, 2H), 3.91 (s, carboxylic acid 3H).83100 FF92 1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) 1-[(5,6-dimethyl- 8.11 (s, 1H), 7.63 3- (s, 1H0, 7.14 (d, pyridyl)methyl]- 2H), 6.95 (d, 2H), A088 5-(4- 5.44 (s, 2H), 3.82 methoxyphenyl)t (s, 3H), 2.65 (s, riazole-4- 3H), 2.31 (s, 3H) carboxylic acid 1-[(6-methoxy-5- 7.62 (s, 1H), 7.24 methyl-3- (s, 1H), 7.20 (d, pyridyl)methyl]- 2H), 6.98 (d, 2H), A089 5-(4- 5.31 (s, 2H), 3.93 methoxyphenyl)t (s, 3H), 3.86 (s, riazole-4- 3H) carboxylic acid 1-[(6-chloro-5- 7.59 (s, 1H), 7.21 methoxy-3- (d, 2H), 7.06 (s, pyridyl)methyl]- 1H), 6.98 (d, 2H), A090 5-(4- 5.42 (s, 2H), 3.85 methoxyphenyl)t (s, 3H), 3.82 (s, riazole-4- 3H) carboxylic acid83100 FF93 1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) 1-[(2,6-dimethyl- 4- 7.16 (d, 2H), 7.00 pyridyl)methyl]- (d, 2H), 6.98 (s, A091 5-(4- 2H), 5.52 (s, 2H), methoxyphenyl)t 3.85 (s, 3H), 2.73 riazole-4- (s, 6H) carboxylic acid 1-[(2,6- dimethoxy-4- 7.21 (d, 2H), 6.95 pyridyl)methyl]- (d, 2H), 5.95 (s, A092 5-(4- 2H), 5.32 (s, 2H), methoxyphenyl)t 3.87 (s, 6H, 3.84 riazole-4- (s, 3H) carboxylic acid 1-[(5-chloro-6- methoxy-3- 7.72 (s, 1H), 7.43 pyridyl)methyl]- (s, 1H), 7.20 (d, A093 5-(4- 2H), 7.01 (d, 2H), methoxyphenyl)t 5.33 (s, 2H), 3.98 riazole-4- (3H), 3.86 (s, 3H) carboxylic acid 1-[(5-fluoro-3- (DMSO-d6) 8.49 pyridyl)methyl]- (d, 1H), 8.07 (s, 5-(4- 1H), 7.37-7.32 A094 methoxyphenyl)t (m, 3H), 7.02 (d, riazole-4- 2H), 5.58 (s, 2H), carboxylic acid 3.80 (s, 3H)83100 FF94 1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) 1-[(5-fluoro-6- 8.02 (s, 1H), 7.28 methyl-3- (d, 1H), 7.17 (d, pyridyl)methyl]- 2H), 6.98 (d, 2H), A095 5-(4- 5.45 (s, 2H), 3.82 methoxyphenyl)t (s, 3H), 2.51 (s, riazole-4- 3H) carboxylic acid 1-[(5,6- 7.35 (s, 1H), 7.21 dimethoxy-3- (d, 2H), 6.99 (d, pyridyl)methyl]- 2H), 6.92 (s, 1H), A096 5-(4- 5.35 (s, 2H), 3.98 methoxyphenyl)t (s, 3H), 3.83 (s, riazole-4- 3H), 3.79 (s, 3H) carboxylic acid O 1-[(2-chloro-6- O 7.14 (d, 2H), 6.95 methyl-4- OH(d, 2H), 6.74 (s, pyridyl)methyl]- 1H), 6.72 (s, 1H), A097 N 5-(4- N 5.38 (s, 2H), 3.83 N methoxyphenyl)t (s, 3H)2.45 (s, riazole-4- 3H) Cl carboxylic acid N (500 MHz, 2,2-difluoroethyl DMSO-d6) 7.81 5-(4- (s, 1H), 7.42-7.35 methoxyphenyl)- (m, 3H), 7.06 (d, A098 1-[(6-methoxy-3- 2H), 6.73 (d, 1H), pyridyl)methyl]tri 6.23 (tt, 1H), 5.50 azole-4- (s, 2H), 4.47 (td, carboxylate 2H), 3.85 (s, 3H), 3.80 (s, 3H)83100 FF95 1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) (500 MHz, 2,2- O DMSO-d6) 7.80 dimethylpropyl (s, 1H), 7.40-7.34 5-(4- (m, 3H), 7.08 (d, N methoxyphenyl)- A099 2H), 6.73 (d, 1H), O N 1-[(6-methoxy-3- O N 5.40 (s, 2H), 3.83 ONpyridyl)methyl]tri (s, 3H), 3.81 (s, azole-4- 3H), 3.79 (s, 2H), carboxylate 0.70 (s, 9H) (500 MHz, DMSO-d6) 7.81 isopropyl 5-(4- (s, 1H), 7.38-7.34 methoxyphenyl)- (m, 3H), 7.08 (d, 1-[(6-methoxy-3- 2H), 6.72 (d, 1H), A100 pyridyl)methyl]tri 5.47 (s, 2H), azole-4- 5.02-4.95 (m, carboxylate 1H), 3.84 (s, 3H), 3.80 (s, 3H), 1.12 (d, 6H) (500 MHz, DMSO-d6) 7.80 (s, 1H), 7.38-7.32 1-methylhexyl 5- (m, 3H), 7.06 (d, (4- 2H), 6.72 (d, 1H), methoxyphenyl)- 5.45 (s, 2H), A101 1-[(6-methoxy-3- 4.92-4.85 (m, pyridyl)methyl]tri 1H), 3.85 (s, 3H), azole-4- 3.80 (s, 3H), carboxylate 1.40-1.42 (m, 2H), 1.20-0.95 (m, 6H), 1.12 (d, 3H), 0.80 (t, 3H)83100 FF96 1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) (500 MHz, DMSO-d6) 7.81 prop-2-ynyl 5-(4- (s, 1H), 7.40-7.35 methoxyphenyl)- (m, 3H), 7.09 (d, 1-[(6-methoxy-3- A102 2H), 6.73 (d, 1H), pyridyl)methyl]tri 5.48 (s, 2H), 4.82 azole-4- (s, 2H), 3.85 (s, carboxylate 3H), 3.81 (s, 3H), 3.52 (t, 1H) (500 MHz, cyanomethyl 5- DMSO-d6) 7.81 (4- (s, 1H), 7.42 (d, methoxyphenyl)- 2H), 7.36 (dd, A103 1-[(6-methoxy-3- 1H), 7.08 (d, 2H), pyridyl)methyl]tri 6.72 (d, 1H), 5.48 azole-4- (s, 2H), 5.10 (s, carboxylate 2H), 3.85 (s, 3H), 3.80 (s, 3H) (500 MHz, DMSO-d6) 7.81 O (4- (s, 1H), 7.38-7.32 fluorophenyl)me (m, 3H), 7.26- thyl 5-(4- 7.22 (m, 2H), O methoxyphenyl)- A104 7.14 (t, 2H), 7.03 N O 1-[(6-methoxy-3- (d, 2H), 6.72 (d, NNNpyridyl)methyl]tri 1H), 5.47 (s, 2H), F azole-4- O 5.16 (s, 2H), 3.85 carboxylate (s, 3H), 3.80 (s, 3H) 1,1- (500 MHz, dimethylpropyl DMSO-d6) 7.79 5-(4- (s, 1H), 7.47-7.40 methoxyphenyl)- (m, 3H), 7.05 (d, A105 1-[(6-methoxy-3- 2H), 6.72 (d, 1H), pyridyl)methyl]tri 5.41 (s, 2H), 3.84 azole-4- (s, 3H), 3.80 (s, carboxylate 3H), 1.60 (q, 2H),83100 FF97 1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) 1.38 (s, 6H), 0.61 (t, 3H) (500 MHz, DMSO-d6) 7.81 2-methylallyl 5- (s, 1H), 7.38-7.34 (4- (m, 3H), 7.08 (d, methoxyphenyl)- 2H), 6.73 (d, 1H), A106 1-[(6-methoxy-3- 5.43 (s, 2H), 4.80 pyridyl)methyl]tri (d, 2H), 4.56 (s, azole-4- 2H), 3.84 (s, 3H), carboxylate 3.80 (s, 3H), 1.57 (s, 3H) (500 MHz, DMSO-d6) 7.81 (s, 1H), 7.38-7.34 butyl 5-(4- (m, 3H), 7.07 (d, methoxyphenyl)- 2H), 6.73 (d, 1H), 1-[(6-methoxy-3- 5.45 (s, 2H), 4.10 A107 pyridyl)methyl]tri (t, 2H), 3.84 (s, azole-4- 3H), 3.80 (s, 3H), carboxylate 1.48-1.44 (m, 2H), 1.13-1.06 (m, 2H), 0.77 (t, 3H) (500 MHz, DMSO-d6) 7.81 (s, 1H), 7.38-7.34 benzyl 5-(4- (m, 3H), 7.32- methoxyphenyl)- 7.28 (m, 3H), 1-[(6-methoxy-3- A108 7.18-7.14 (m, pyridyl)methyl]tri 2H), 7.03 (d, 2H), azole-4- 6.72 (d, 1H), 5.45 carboxylate (s, 2H), 5.20 (s, 2H), 3.85 (s, 3H), 3.80 (s, 3H)83100 FF98 1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) (500 MHz, DMSO-d6) 7.80 (s, 1H), 7.37-7.32 cyclopropyl 5-(4- (m, 3H), 7.06 (d, methoxyphenyl)- 2H), 6.72 (d, 1H), 1-[(6-methoxy-3- 5.45 (s, 2H), A109 pyridyl)methyl]tri 4.17-4.12 (m, azole-4- 1H), 3.85 (s, 3H), carboxylate 3.80 (s, 3H), 0.68-0.64 (m, 2H), 0.54-0.48 (m, 2H) (500 MHz, DMSO-d6) 7.82 (s, 1H), 7.38-7.34 (m, 3H), 7.06 (d, 2-methylbutyl 5- 2H), 6.74 (d, 1H), (4- 5.42 (s, 2H), methoxyphenyl)- 3.98-3.92 (m, A110 1-[(6-methoxy-3- 2H), 3.84 (s, 3H), pyridyl)methyl]tri 3.80 (s, 3H), azole-4- 1.53-1.47 (m, carboxylate 1H), 1.17-1.10 (m, 1H), 0.98- 0.90 (m, 1H), 0.74 (t, 3H), 0.70 (d, 3H) (500 MHz, 2,2- DMSO-d6) 7.70 dimethylbutyl 5- (s, 1H), 7.37 (dd, (4- 1H), 7.34 (d, 2H), methoxyphenyl)- 7.08 (d, 2H), 6.74 A111 1-[(6-methoxy-3- (d, 1H), 5.40 (s, pyridyl)methyl]tri 2H), 3.84-3.80 azole-4- (m, 8H), 0.96 (q, carboxylate 2H), 0.66-0.60 (m, 9H)83100 FF99 1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) (500 MHz, DMSO-d6) 7.80 3-methylbut-2- (s, 1H), 7.38-7.34 enyl 5-(4- (m, 3H), 7.06 (d, methoxyphenyl)- 2H), 6.73 (d, 1H), A112 1-[(6-methoxy-3- 5.45 (s, 2H), 5.24 pyridyl)methyl]tri (t, 1H), 4.63 (d, azole-4- 2H), 3.85 (s, 3H), carboxylate 3.80 (s, 3H), 1.70 (s, 3H), 1.62 (s, 3H) (500 MHz, DMSO-d6) 7.80 (s, 1H), 7.38-7.33 (m, 3H), 7.08 (d, tetrahydrofuran- 2H), 6.72 (d, 1H), 2-ylmethyl 5-(4- 5.45 (s, 1H), methoxyphenyl)- 4.14-4.08 (m, A113 1-[(6-methoxy-3- 2H), 3.96-3.90 pyridyl)methyl]tri (m, 1H), 3.84 (s, azole-4- 3H), 3.80 (s, 3H), carboxylate 3.65-3.55 (m, 2H), 1.82-1.70 (m, 3H), 1.42- 1.38 (m, 1H) (500 MHz, DMSO-d6) 7.82 (s, 1H), 7.38-7.32 1-ethylhexyl 5- (m, 3H), 7.05 (d, (4- 2H), 6.72 (d, 1H), methoxyphenyl)- 5.44 (s, 2H), A114 1-[(6-methoxy-3- 4.83-4.77 (m, pyridyl)methyl]tri 1H), 3.85 (s, 3H), azole-4- 3.80 (s, 3H), carboxylate 1.55-1.00 (m, 10H), 0.84 (t, 3H), 0.70 (t, 3H)1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) (500 MHz, DMSO-d6) 7.72 (s, 1H), 7.37-7.32 (m, 3H), 7.06 (d, pentyl 5-(4- 2H), 6.72 (d, 1H), methoxyphenyl)- 5.45 (s, 2H), 4.10 1-[(6-methoxy-3- A115 (t, 2H), 3.85 (s, pyridyl)methyl]tri 3H), 3.80 (s, 3H), azole-4- 1.48-1.44 (m, carboxylate 2H), 1.22-1.16 (m, 2H), 1.05- 1.00 (m, 2H), 0.78 (t, 3H) (500 MHz, DMSO-d6) 7.72 O propyl 5-(4- (s, 1H), 7.38-7.34 methoxyphenyl)- (m, 3H), 7.08 (d, 1-[(6-methoxy-3- 2H), 6.73 (d, 1H), A116 O pyridyl)methyl]tri 5.45 (s, 2H), 4.08 N N azole-4- (t, 2H), 3.85 (s, ON NO carboxylate 3H), 3.80 (s, 3H), 1.54-1.46 (m, 2H), 0.74 (t, 3H) (500 MHz, DMSO-d6) 7.80 (s, 1H), 7.38-7.34 O cyclopentyl 5-(4- (m, 3H), 7.07 (d, methoxyphenyl)- 2H), 6.73 (d, 1H), 1-[(6-methoxy-3- 5.44 (s, 2H), A117 N pyridyl)methyl]tri 5.20-5.16 (m, O N O azole-4- 1H), 3.85 (s, 3H), ONN carboxylate 3.80 (s, 3H), 1.75-1.66 (m, 2H), 1.52-1.38 (m, 6H) 101 1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) (500 MHz, O DMSO-d6) 7.82 isobutyl 5-(4- (s, 1H), 7.40-7.35 methoxyphenyl)- (m, 3H), 7.07 (d, O 1-[(6-methoxy-3- 2H), 6.74 (d, 1H), A118 pyridyl)methyl]tri 5.44 (s, 2H), 3.92 N O NNazole-4- (d, 2H), 3.85 (s, N carboxylate 3H), 3.80 (s, 3H), O 1.78-1.70 (m, 1H), 0.73 (d, 6H) (500 MHz, (2,4,6- DMSO-d6) 7.87 trimethylphenyl) (s, 1H), 7.48-7.42 5-(4- (m, 3H), 7.08 (d, methoxyphenyl)- 2H), 6.86 (s, 2H), A119 1-[(6-methoxy-3- 6.75 (d, 1H), 5.50 pyridyl)methyl]tri (s, 2H), 3.82 (s, azole-4- 3H), 3.80 (s, 3H), carboxylate 2.20 (s, 3H), 1.95 (s, 6H) (500 MHz, DMSO-d6) 7.80 3-methoxypropyl (s, 1H), 7.39-7.35 5-(4- (m, 3H), 7.08 (d, methoxyphenyl)- 2H), 6.73 (d, 1H), A120 1-[(6-methoxy-3- 5.45 (s, 2H), 4.14 pyridyl)methyl]tri (t, 2H), 3.85 (s, azole-4- 3H), 3.80 (s, 3H), carboxylate 3.15 (s, 3H), 3.12 (t, 2H), 1.72-1.65 (m, 2H)83100 FF102 1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) (500 MHz, DMSO-d6) 7.81 isopentyl 5-(4- (s, 1H), 7.38-7.34 methoxyphenyl)- (m, 3H), 7.08 (d, 1-[(6-methoxy-3- 2H), 6.73 (d, 1H), A121 pyridyl)methyl]tri 5.44 (s, 2H), 4.13 azole-4- (t, 2H), 3.85 (s, carboxylate 3H), 3.80 (s, 3H), 1.38-1.30 (m, 3H), 0.76 (d, 6H) 8.12 (d, 1H), 7.46 ethyl 5-[4- (d, 2H), 7.38 (dd, (methoxymethyl) 1H), 7.22 (d, 2H), phenyl]-1-[(6- 7.08 (d, 1H), 5.40 A122 methyl-3- (s, 2H), 4.30 (q, pyridyl)methyl]tri 2H), 3.46 (s, 3H), azole-4- 2.52 (s, 3H), 1.27 carboxylate (t, 3H) 8.82 (d, 1H), 8.38 (d, 1H), 8.01 (s, ethyl 5-(4- 1H), 7.97 (s, 1H), methoxy-7- 7.33 (d, 1H), 7.28 quinolyl)-1-[(6- (d, 1H), 7.04 (d, A123 methyl-3- 1H), 6.82 (d, 1H), pyridyl)methyl]tri 5.48 (s, 2H), 4.30 azole-4- (q, 2H), 4.10 (s, carboxylate 3H), 2.48 (s, 3H), 1.22 (t, 3H)

[0008] 83100 FF103 1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) 9.32 (s, 1H), 8.62 (s, 1H), 8.24 (d, O O ethyl 1-[(6- 1H), 8.01 (dd, methoxy-3- 1H), 7.48 (d, 1H), N pyridyl)methyl]- 7.36 (s, 3H), 7.22 A124N N5-quinazolin-5- (dd, 1H), 6.53 (d, N yl-triazole-4- 1H), 5.33 (dd, N carboxylate 2H), 4.22-4.14 (m, 1H), 3.39 (s, N O 3H), 1.05 (t, 3H) 9.28 (s, 1H), 8.63 (s, 1H), 8.22 (d, 1-[(6-methoxy-3- 1H), 7.99 (dd, pyridyl)methyl]- 1H), 7.50 (d, 1H), A125 5-quinazolin-5- 7.34 (s, 1H), 7.22 yl-triazole-4- (dd, 1H), 6.51 (d, carboxylic acid 1H), 5.32 (dd, 2H), 3.75 (s, 3H) (500 MHz, O 5-(4- DMSO-d6) 8.48 methoxyphenyl)- (s, 1H), 7.90 (d, 1-[1-(6-methyl- 1H), 7.48 (d, 1H), A126 3- 7.29 (d, 2H), 7.04 O pyridyl)ethyl]tria (d, 2H), 5.65 (q, N zole-4- 1H), 3.83 (s, 3H), NNN O Hcarboxylic acid 2.58 (s, 3H), 1.92 (d, 3H) (500 MHz, DMSO-d6) 8.58 5-(1,3- (d, 1H), 7.33 (s, N O benzodioxol-5- 1H), 7.25 (d, 1H), yl)-1-[(2-ethyl-4- 7.02 (s, 1H), 6.98 A127 ONpyridyl)methyl]tri (d, 1H), 6.86 (d, N azole-4- 1H), 6.09 (s, 2H), HO Ncarboxylic acid 5.73 (s, 2H), 2.86 O (q, 2H), 1.21 (t, 3H)83100 FF104 1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) (500 MHz, F N 5-(1,3- DMSO-d6) 12.80 O benzodioxol-5- (br, 1H), 7.51 O yl)-1-[(2-fluoro- (dd, 1H), 7.04- A128 O N 6-methoxy-3- 7.00 (m, 2H), N pyridyl)methyl]tri 6.89 (d, 1H), 6.69 HONazole-4- (d, 1H), 6.12 (s, O carboxylic acid 2H), 5.41 (s, 2H), 3.80 (s, 3H) (500 MHz, DMSO-d6) 8.57 1-[(2-ethyl-4- (d, 1H), 7.33 (d, pyridyl)methyl]- 2H), 7.24 (s, 1H), 5-(4- A129 7.18 (d, 1H), 6.98 methoxyphenyl)t (d, 2H), 5.70 (s, riazole-4- 3H), 3.80 (s, 3H), carboxylic acid 2.83 (q, 2H), 1.19 (t, 3H) O (500 MHz, O DMSO-d6) 8.32 1-[(6-ethyl-3- OH(s, 1H)7.68 (d, pyridyl)methyl]- 1H), 7.50 (d, 1H), 5-(4- A130 N N 7.35 (d, 2H), 7.04 N methoxyphenyl)t (d, 2H), 5.59 (s, riazole-4- 2H), 3.83 (s, 3H), N carboxylic acid 2.82 (q, 2H), 1.22 (t, 3H)

[0009] 83100 FF105 1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) O (500 MHz, 5-(4- DMSO-d6) 12.80 methoxyphenyl)- (br, 1H), 8.98 (s, 1-[(5- O 1H), 8.52 (s, 1H), methylsulfonyl- A131 7.91 (s, 1H), 7.33 N NO H3- (d, 2H), 7.01 (d, N N pyridyl)methyl]tri 2H), 5.70 (s, 2H), azole-4- SO3.81 (s, 3H), 3.26 carboxylic acid (s, 3H) O (500 MHz, 1-[(2-fluoro-6- DMSO-d6) 12.90 methoxy-3- (br, 1H), 7.51 pyridyl)methyl]- (dd, 1H), 7.35 (d, A132 5-(4- 2H), 7.04 (d, 2H), methoxyphenyl)t 6.68 (d, 1H), 5.41 riazole-4- (s, 2H), 3.85 (s, carboxylic acid 3H), 3.80 (s, 3H) (500 MHz, DMSO-d6) 8.14 1-[(6- (s, 1H), 7.48 (d, cyclopropyl-3- 1H), 7.35 (d, 2H), pyridyl)methyl]- 7.31 (d, 1H), 7.04 A133 5-(4- (d, 2H), 5.50 (s, methoxyphenyl)t 2H), 3.82 (s, 3H), riazole-4- 2.14-2.10 (m, carboxylic acid 1H), 1.07-1.02 (m, 2H), 0.96- 0.90 (m, 2H) 8.23 (s, 1H), 8.05 ethyl 5-[4- (s, 1H), 7.70 (s, (imidazol-1- 1H), 7.35 (d, 1H), ylmethyl)phenyl] 7.25 (d, 2H), 7.14 A134 -1-[(6-methyl-3- (s, 1H), 7.08 (d, pyridyl)methyl]tri 2H), 6.98 (s, 1H), azole-4- 5.40 (s, 2H), 5.23 carboxylate (s, 2H), 4.30 (q,83100 FF106 1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) 2H), 2.51 (s, 3H), 1.27 (t, 3H) (CD3OD) 8.04 (br 5-(2-fluoro-4- s, 1H), 7.65 (br s, methoxy- 1H), 7.14 (dd, phenyl)-1-[(5- 1H), 6.93 (s, 1H), A135 methoxy-3- 6.77 (dd, 1H), pyridyl)methyl]tri 6.71 (dd, 1H), azole-4- 5.49 (s, 3H), 3.75 carboxylic acid (s, 3H), 3.70 (s, 3H) 5-[4- 8.17 (s, 1H), (methoxymethyl) 7.45-7.39 (m, phenyl]-1-[(6- 3H), 7.24 (d, 2H), A136 methyl-3- 7.11 (d, 1H), 5.41 pyridyl)methyl]tri (s, 2H), 4.51 (s, azole-4- 2H), 3.43 (s, 3H), carboxylic acid 2.53 (s, 3H) (CD3OD) 8.11 (s, 5-(1,4- 1H), 7.58-7.50 dimethylindazol- (m, 2H), 7.33 (dd, 5-yl)-1-[(6- 1H), 7.15 )d, 1H), A137 methoxy-3- 6.64 (d, 1H), 5.37 pyridyl)methyl]tri (dd, 2H), 4.13 (s, azole-4- 3H), 3.32 (s, 3H), carboxylic acid 2.05 (s, 3H)83100 FF107 1H NMR (400 Compound Structure NameMHz, CDCl3 Number unless stated) (CD3OD) 8.30 (br 5-[4-(imidazol-1- s, 1H), 7.92 (s, ylmethyl)phenyl] 1H), 7.40-7.25 -1-[(6-methyl-3- A138 (m, 6H), 7.14 (d, pyridyl)methyl]tri 2H), 5.52 (s, 2H), azole-4- 5.40 (s, 2H), 2.45 carboxylic acid (s, 3H) (DMSO-d6) 9.25 (d, 1H), 8.51 (s, 5-(4-methoxy-7- 1H), 8.44 (d, 1H), quinolyl)-1-[(6- 8.40 (s, 1H), 8.13 methyl-3- A139 (d, 1H), 7.87 (d, pyridyl)methyl]tri 1H), 7.77 (d, 1H), azole-4- 7.52 (d, 1H), 5.70 carboxylic acid (s, 2H), 4.32 (s, 3H), 2.71 (s, 3H) 5-[4- 7.80 (s, 1H), 7.45 (methoxymethyl) (d, 2H), 7.38 (dd, phenyl]-1-[(6- 1H), 7.25 (d, 2H), A140 methoxy-3- 6.65 (d, 1H), 5.34 pyridyl)methyl]tri (s, 2H), 4.53 (s, azole-4- 3H), 3.97 (s, 3H), carboxylic acid 3.45 (s, 3H) BIOLOGICAL EXAMPLESB1: Pre-emergence efficacy – Test 1Seeds of a variety of test species are sown in standard soil in pots :- Amaranthus retroflexus(AMARE), Amaranthus palmeri (AMAPA), Setaria faberi (SETFA), Echinochloa crus-galli (ECHCG),Ipomoea hederacea (IPOHE). After cultivation for one day (pre-emergence) or after 8 days cultivation(post-emergence) under controlled conditions in a glasshouse (24°C / 19°C, day / night; 16 hours light,83100 FF108 50% humidity), the plants are sprayed with an aqueous spray solution derived from the dissolution ofthe technical active ingredient in a small amount of acetone and a special solvent and emulsifiermixture referred to as IF50 (11.12% Emulsogen EL360 TM + 44.44% N-methylpyrrolidone + 44.44%Dowanol DPM glycol ether, which was then diluted to required concentration using 0.2% GenapolXO80 (CAS No.9043-30-5) in water as the diluent. Compounds are applied at the rates stated. Thetest plants are then grown in a glasshouse under controlled conditions in a glasshouse (at 24°C / 18°C,day / night; 15 hours light, 40% humidity) and watered twice daily. After 13 days for pre and post-emergence, the test is evaluated for the percentage damage caused to the plant. The biological activities are assessed on a five point scale (5 = 80-100%; 4 = 60-79%; 3=40-59%; 2=20-39%; 1=0- 19%).The results are shown in Table B1 (below). A value of n / a indicates that this combination of weed andtest compound was not tested / assessed.Table B1 - Control of weed species by compounds of formula (I) after pre-emergence applicationCompound Rate AMARE AMAPA SETFA ECHCG IPOHE(g / ha) A001 1000 5 5 1 1 1A002 1000 5 5 2 2 3A003 1000 3 4 1 1 1A004 1000 4 2 1 1 1A005 1000 4 1 1 1 1A006 1000 5 2 2 3 1A007 1000 4 1 n / a 1 1A008 1000 5 5 n / a 1 1A009 1000 5 4 2 2 1A010 1000 5 4 1 1 1A011 1000 5 1 1 1 1A012 1000 5 2 2 4 3A013 1000 4 2 1 2 1A014 1000 4 1 1 1 1A015 1000 4 1 1 1 1A016 1000 4 3 1 1 1A017 1000 5 2 2 1 1A018 1000 5 1 1 1 1A019 1000 5 5 2 2 1A020 1000 5 1 1 1 1A021 1000 5 4 1 4 1A022 1000 5 5 1 2 183100 FF109 Compound Rate AMARE AMAPA SETFA ECHCG IPOHE(g / ha) A023 1000 3 3 1 3 1A024 1000 1 1 1 1 1A025 1000 4 1 1 1 1A026 1000 5 3 1 1 1A027 1000 5 3 1 3 1A040 1000 5 1 1 1 1B2: Pre-emergence efficacy – Test 2Seeds of a variety of test species are sown in standard soil in pots :- Amaranthus retroflexus(AMARE), Amaranthus palmeri (AMAPA), Amaranthus rudis (AMATA), Ipomoea hederacea (IPOHE).After cultivation for one day (pre-emergence) or after 8 days cultivation (post-emergence) under controlled conditions in a glasshouse (24°C / 19°C, day / night; 16 hours light, 50% humidity), the plants are sprayed with an aqueous spray solution derived from the dissolution of the technical activeingredient in a small amount of acetone and a special solvent and emulsifier mixture referred to as IF50(11.12% Emulsogen EL360 TM + 44.44% N-methylpyrrolidone + 44.44% Dowanol DPM glycol ether,which was then diluted to required concentration using 0.2% Genapol XO80 (CAS No.9043-30-5) inwater as the diluent. Compounds are applied at the rates stated. The test plants are then grown in a glasshouse under controlled conditions in a glasshouse (at 24°C / 18°C, day / night; 15 hours light, 40%humidity) and watered twice daily. After 13 days for pre and post-emergence, the test is evaluated forthe percentage damage caused to the plant. The biological activities are assessed on a five point scale (5 = 80-100%; 4 = 60-79%; 3=40-59%; 2=20-39%; 1=0-19%).The results are shown in Table B2 (below). A value of n / a indicates that this combination of weed andtest compound was not tested / assessed.Table B2 - Control of weed species by compounds of formula (I) after pre-emergence applicationCompound Rate (g / ha) AMARE AMAPA AMATA IPOHEA029 1000 1 1 1 1A031 250 3 2 2 1A032 1000 n / a 1 n / a 1A033 1000 n / a n / a n / a 1A034 1000 n / a n / a n / a 1A035 1000 n / a n / a n / a 1A036 1000 n / a n / a n / a 1A037 1000 n / a 1 1 1A038 250 5 4 3 183100 FF110Compound Rate (g / ha) AMARE AMAPA AMATA IPOHEA039 1000 n / a 1 1 1A041 1000 5 5 5 1A042 1000 4 4 4 1A043 1000 n / a n / a n / a 1A044 1000 n / a 1 1 1A045 1000 n / a 1 1 1A046 1000 n / a 1 n / a 1A047 1000 n / a 1 n / a 1A048 1000 1 1 1 1A049 1000 5 5 4 1A050 250 n / a 1 n / a 1A051 250 3 1 3 1A052 250 3 3 2 1A053 1000 1 n / a 1 1A054 1000 n / a n / a 1 1A055 1000 5 5 4 1A056 1000 5 5 5 1A057 1000 4 3 3 1A058 1000 5 4 4 1A059 1000 5 5 5 1A060 1000 5 5 5 1A061 250 1 1 1 1A062 1000 5 5 5 1A063 1000 5 5 5 1A064 1000 1 1 1 1A065 1000 1 1 1 1A066 1000 1 1 1 1A067 1000 1 1 1 1A068 1000 1 1 1 1A069 1000 2 3 3 1A070 1000 5 5 5 1A071 1000 5 5 5 1A072 1000 1 1 2 1A074 1000 1 1 1 1A075 1000 1 1 1 1A076 1000 5 4 4 1A077 1000 3 3 4 n / aA078 1000 5 5 4 n / aA079 1000 5 3 4 n / a83100 FF111Compound Rate (g / ha) AMARE AMAPA AMATA IPOHEA080 1000 5 3 3 n / aA081 1000 5 5 5 n / aA082 1000 4 4 4 n / aA083 1000 5 3 4 n / aA084 1000 5 5 4 n / aA085 1000 5 5 5 n / aA086 1000 5 5 5 n / aA087 1000 5 5 5 n / aA088 1000 1 1 1 1A089 1000 1 1 1 1A090 1000 4 2 2 1A091 1000 2 2 2 1A092 1000 3 3 2 3A093 1000 4 1 3 1A094 1000 4 3 3 1A095 1000 5 5 4 1A096 1000 4 4 3 1A097 1000 4 3 4 1A098 1000 5 5 5 1A099 1000 1 1 1 1A100 1000 5 3 5 1A101 1000 1 1 1 1A102 1000 5 5 5 1A103 1000 5 5 5 1A104 1000 2 1 3 1A105 1000 1 1 1 1A106 1000 5 5 5 1A107 1000 3 1 3 1A108 1000 5 5 4 1A109 1000 5 5 5 1A110 1000 4 2 3 1A111 1000 1 1 1 1A112 1000 3 3 4 1A113 1000 5 2 4 1A114 1000 1 1 1 1A115 1000 3 1 3 1A116 1000 5 2 5 1A117 1000 1 1 1 n / aA118 1000 5 1 3 183100 FF112 Compound Rate (g / ha) AMARE AMAPA AMATA IPOHEA119 1000 1 1 1 1A120 1000 5 3 5 1A121 1000 2 3 4 1A124 1000 1 1 1 1A125 1000 1 n / a 3 1A126 1000 2 1 2 1A127 1000 2 2 2 1A128 1000 1 n / a 1 1A129 1000 1 1 1 1A130 1000 1 1 1 1A131 1000 1 1 1 1A132 1000 1 1 1 1A133 1000 1 1 1 1A134 1000 1 1 1 1A135 1000 2 2 2 1A136 1000 4 3 3 1A137 1000 1 1 1 1A138 1000 1 1 1 1A139 1000 1 1 1 1A140 1000 5 4 4 1B3: Post-emergence efficacy – Test 3Seeds of a variety of test species are sown in standard soil in pots :- Amaranthus retroflexus(AMARE), Amaranthus palmeri (AMAPA), Setaria faberi (SETFA), Echinochloa crus-galli (ECHCG),Ipomoea hederacea (IPOHE). After cultivation for one day (pre-emergence) or after 8 days cultivation(post-emergence) under controlled conditions in a glasshouse (24°C / 19°C, day / night; 16 hours light, 50% humidity), the plants are sprayed with an aqueous spray solution derived from the dissolution ofthe technical active ingredient in a small amount of acetone and a special solvent and emulsifiermixture referred to as IF50 (11.12% Emulsogen EL360 TM + 44.44% N-methylpyrrolidone + 44.44% Dowanol DPM glycol ether, which was then diluted to required concentration using 0.2% GenapolXO80 (CAS No.9043-30-5) in water as the diluent. Compounds are applied at the rates stated. Thetest plants are then grown in a glasshouse under controlled conditions in a glasshouse (at 24°C / 18°C,day / night; 15 hours light, 40% humidity) and watered twice daily. After 13 days for pre and post-emergence, the test is evaluated for the percentage damage caused to the plant. The biological activities are assessed on a five point scale (5 = 80-100%; 4 = 60-79%; 3=40-59%; 2=20-39%; 1=0- 19%).The results are shown in Table B3 (below). A value of n / a indicates that this combination of weed andtest compound was not tested / assessed.83100 FF113Table B3 - Control of weed species by compounds of formula (I) after post-emergence applicationCompound Rate AMARE AMAPA SETFA ECHCG IPOHE(g / ha) A001 1000 5 5 1 3 2A002 1000 5 5 4 4 1A003 1000 5 5 3 3 2A004 1000 5 4 1 1 1A005 1000 5 5 2 3 1A006 1000 5 5 3 3 1A007 1000 5 5 n / a 4 1A008 1000 5 5 n / a 3 1A009 1000 5 5 3 3 1A010 1000 5 5 1 2 1A011 1000 5 5 2 2 1A012 1000 5 5 4 4 1A013 1000 5 5 2 3 1A014 1000 5 4 1 1 1A015 1000 5 5 1 1 1A016 1000 5 5 2 2 1A017 1000 5 5 1 1 1A018 1000 5 4 1 2 1A019 1000 5 5 2 2 1A020 1000 5 5 1 1 1A021 1000 5 5 1 2 1A022 1000 5 5 1 4 1A023 1000 5 5 1 1 1A024 1000 5 4 1 1 1A025 1000 5 4 1 1 1A026 1000 5 5 2 1 1A027 1000 5 5 3 4 1A040 1000 5 3 1 1 1B4: Post-emergence efficacy – Test 4Seeds of a variety of test species are sown in standard soil in pots :- Amaranthus retroflexus(AMARE), Amaranthus palmeri (AMAPA), Amaranthus rudis (AMATA), Ipomoea hederacea (IPOHE).After cultivation for one day (pre-emergence) or after 8 days cultivation (post-emergence) under controlled conditions in a glasshouse (24°C / 19°C, day / night; 16 hours light, 50% humidity), the plants are sprayed with an aqueous spray solution derived from the dissolution of the technical active83100 FF114ingredient in a small amount of acetone and a special solvent and emulsifier mixture referred to as IF50(11.12% Emulsogen EL360 TM + 44.44% N-methylpyrrolidone + 44.44% Dowanol DPM glycol ether,which was then diluted to required concentration using 0.2% Genapol XO80 (CAS No.9043-30-5) inwater as the diluent. Compounds are applied at the rates stated. The test plants are then grown in a glasshouse under controlled conditions in a glasshouse (at 24°C / 18°C, day / night; 15 hours light, 40%humidity) and watered twice daily. After 13 days for pre and post-emergence, the test is evaluated forthe percentage damage caused to the plant. The biological activities are assessed on a five point scale (5 = 80-100%; 4 = 60-79%; 3=40-59%; 2=20-39%; 1=0-19%).The results are shown in Table B4 (below). A value of n / a indicates that this combination of weed andtest compound was not tested / assessed.Table B4 - Control of weed species by compounds of formula (I) after post-emergence applicationCompound Rate (g / ha) AMARE AMAPA AMATA IPOHEA029 1000 5 5 5 1A031 250 5 5 5 2A032 1000 5 5 5 1A033 1000 5 5 5 1A034 1000 5 5 5 1A035 1000 5 5 5 1A036 1000 5 5 5 1A037 1000 5 5 5 1A038 250 5 5 5 1A039 1000 5 5 5 1A041 1000 5 5 5 2A042 1000 5 4 4 1A043 1000 5 5 5 1A044 1000 5 5 5 1A045 1000 5 5 5 1A046 1000 5 5 5 1A047 1000 1 1 1 1A048 1000 5 5 5 1A049 1000 5 5 5 2A050 250 5 4 4 1A051 250 5 5 5 1A052 250 4 4 1 1A053 1000 5 5 5 1A054 1000 1 1 1 1A055 1000 5 5 5 183100 FF115Compound Rate (g / ha) AMARE AMAPA AMATA IPOHEA056 1000 5 5 5 1A057 1000 5 5 5 1A058 1000 5 5 5 1A059 1000 5 5 5 2A060 1000 5 5 5 1A061 250 1 1 1 1A062 1000 5 5 5 1A063 1000 5 5 5 1A064 1000 5 5 3 1A065 1000 4 4 2 1A066 1000 4 4 3 1A067 1000 4 3 1 1A068 1000 1 1 1 1A069 1000 5 5 5 1A070 1000 5 5 5 1A071 1000 5 5 5 1A072 1000 5 5 4 1A074 1000 5 5 5 1A075 1000 5 4 4 1A076 1000 5 5 4 1A077 1000 5 5 5 n / aA078 1000 5 5 5 n / aA079 1000 5 4 5 n / aA080 1000 5 5 5 n / aA081 1000 5 5 5 n / aA082 1000 5 5 5 n / aA083 1000 5 5 5 n / aA084 1000 5 5 5 n / aA085 1000 5 5 5 n / aA086 1000 5 5 5 n / aA087 1000 5 5 5 n / aA088 1000 5 5 5 1A089 1000 5 5 3 1A090 1000 3 5 4 1A091 1000 5 5 5 1A092 1000 4 4 3 1A093 1000 5 5 4 1A094 1000 5 5 5 1A095 1000 5 5 5 183100 FF116Compound Rate (g / ha) AMARE AMAPA AMATA IPOHEA096 1000 4 5 5 1A097 1000 5 5 5 1A098 1000 5 5 5 1A099 1000 5 5 3 1A100 1000 5 5 4 2A101 1000 5 4 1 1A102 1000 5 5 5 2A103 1000 5 5 5 1A104 1000 5 5 5 1A105 1000 2 5 3 1A106 1000 5 5 5 1A107 1000 5 5 5 1A108 1000 5 5 5 1A109 1000 5 5 5 1A110 1000 5 5 3 1A111 1000 4 2 1 1A112 1000 5 5 5 1A113 1000 5 5 5 1A114 1000 2 2 2 1A115 1000 5 5 5 1A116 1000 5 5 5 1A117 1000 5 4 2 1A118 1000 5 5 3 1A119 1000 4 3 3 1A120 1000 5 5 5 1A121 1000 5 5 4 1A124 1000 1 1 1 1A125 1000 1 1 1 1A126 1000 1 1 1 1A127 1000 4 5 5 1A128 1000 1 4 2 1A129 1000 5 4 4 1A130 1000 2 4 4 1A131 1000 1 1 1 1A132 1000 1 4 1 1A133 1000 4 3 3 1A134 1000 1 1 1 1A135 1000 5 5 5 1A136 1000 5 5 5 183100 FF117Compound Rate (g / ha) AMARE AMAPA AMATA IPOHEA137 1000 4 4 3 1A138 1000 1 1 1 1A139 1000 1 1 2 1A140 1000 5 5 5 1

Claims

83100 FF118 CLAIMS:

1. Use of a compound of formula (I) or an agronomically acceptable salt or an N-oxide thereof, as aherbicide:wherein R1 is selected from the group consisting of hydrogen, C1-C10alkyl, C3-C6cycloalkyl, C3-C6cycloalkyl-C1-C3alkyl-, C1-C6haloalkyl, C1-C3alkoxy-C1-C3alkyl-, C2-C6alkenyl, C5-C6cycloalkenyl, C5-C6cycloalkenyl-C1-C3alkyl-, C2-C6haloalkenyl, C2-C6alkynyl, C2-C6haloalkynyl, C1-C6alkoxycarbonyl-C1-C3alkyl-, cyanoC1-C6alkyl, -N=(C1-C6alkyl)C1-C6alkyl,phenyl, benzyl, heterocyclyl, heterocyclylC1-C3alkyl-, and heteroaryl, wherein said phenyl,benzyl, heterocyclyl or heteroaryl are optionally substituted by 1, 2 or 3 R10 substituents, whichmay be the same or different, and wherein said heterocyclyl is a 3- to 6- membered ring, whichmay be partially saturated or saturated, comprising 1 or 2 heteroatoms individually selected fromN and O, and said heteroaryl is a 5- or 6- membered monocyclic aromatic ring, which comprises1, 2, 3 or 4 heteroatoms individually selected from N, O and S;A is selected from the group consisting of carbocyclyl, wherein the carbocyclyl is a 5- to 10-membered mono- or fused bicyclic ring system, which may be aromatic and / or partiallysaturated or saturated, and heterocyclyl, wherein the heterocyclyl is a 5- to 10- memberedmono- or fused bicyclic ring system, which may be aromatic and / or partially saturated orsaturated, comprising 1, 2, 3 or 4 heteroatoms individually selected from N, O and S, andwherein said carbocyclyl or heterocyclyl are optionally substituted where feasible by 1, 2, 3, 4or 5 R2substituents, which may be the same or different; each R2 is independently selected from the group consisting of oxo, hydroxy, halogen, cyano,nitro, C1-C6alkyl, C3-C6cycloalkyl, C1-C6haloalkyl, C1-C6haloalkylcarbonyl, C1-C6haloalkoxy, C1-C3haloalkoxy-C1-C3alkyl-, C1-C6haloalkoxycarbonyl, C1-C6alkoxy, C1-C3alkoxy-C1-C3alkyl-, C1-83100 FF119C3alkoxy-C1-C3alkoxy-, C2-C6alkenyl, C5-C6cycloalkenyl, C2-C6haloalkenyl, C2-C6alkynyl, C2-C6haloalkynyl, C1-C6hydroxyalkyl-, C1-C6alkoxycarbonyl-, C1-C6alkylcarbonyl-, C3-C6cycloalkylcarbonyl-, C3-C6cycloalkyloxycarbonyl-, C1-C6alkylcarbonyloxy-, -C(O)OH, C1-C6alkyl-S(O)m-, C1-C3alkyl-S(O)m-C1-C3alkyl-, C1-C6haloalkyl-S(O)m-, C3-C6cycloalkyl-S(O)m-,amino, C1-C6alkylamino, diC1-C6alkylamino, C1-C6alkylaminocarbonyl, diC1-C6alkylaminocarbonyl, C1-C6alkylcarbonylamino-, diC1-C6alkylcarbonylamino-, C1-C6alkylaminocarbonyl-C1-C3alkoxy-, diC1-C6alkylaminocarbonyl-C1-C3alkoxy-, -C(R14)=NOR11,=NOR11, phenyl, heterocyclyl, heteroaryl and heteroarylC1-C3alkyl-, wherein said phenyl,heterocyclyl, heteroaryl or heteroarylC1-C3alkyl- are optionally substituted by 1, 2 or 3 R12substituents, which may be the same or different, and wherein said heterocyclyl is a 3- to 6-membered ring, which may be partially saturated or saturated, comprising 1 or 2 heteroatomsindividually selected from N and O, and said heteroaryl is a 5- or 6- membered monocyclicaromatic ring, which comprises 1, 2, 3 or 4 heteroatoms individually selected from N, O and S;m is an integer of 0, 1, or 2;R3 and R4 are each independently selected from the group consisting of hydrogen, halogen,and C1-C6alkyl; orR3 and R4 together with the carbon atom to which they are attached form a ring selected fromthe group consisting of C3-C6cycloalkyl, C5-C6cycloalkenyl and heterocyclyl, wherein saidheterocyclyl is a 3- to 6- membered ring, which may be partially saturated or saturated,comprising 1 or 2 heteroatoms individually selected from N and O; andX1is C-R5or N; X2is C-R6or N; X3is C-R7or N;each R5, R6 and R7 are independently selected from the group consisting of hydrogen, cyano,halogen, hydroxy, nitro, C1-C6alkyl, C3-C6cycloalkyl, C2-C6alkenyl, C5-C6cycloalkenyl, C2-C6alkynyl, C1-C6haloalkyl, C1-C6haloalkoxy, C1-C6alkoxy, C1-C3alkoxyC1-C3alkyl-, hydroxyC1-C6alkyl-, C1-C3alkoxyC1-C3alkoxy-, C1-C6alkyl-S(O)m-, amino, C1-C6alkylamino, diC1-C6alkylamino, phenyl, heterocyclyl, and heteroaryl, wherein said phenyl, heterocyclyl orheteroaryl are optionally substituted by 1, 2 or 3 R13 substituents, which may be the same ordifferent, and wherein said heterocyclyl is a 3- to 6- membered ring, which may be partiallysaturated or saturated, comprising 1 or 2 heteroatoms individually selected from N and O, and83100 FF120 said heteroaryl is a 5- or 6- membered monocyclic aromatic ring, which comprises 1, 2, 3 or 4heteroatoms individually selected from N, O and S;R8and R9are each independently selected from the group consisting of hydrogen, halogen and C1-C2alkyl; each R10 is independently selected from the group consisting of halogen, cyano, hydroxy, C1-C4alkyl, C1-C4alkoxy, C1-C4haloalkyl, C1-C4haloalkoxy, amino, C1-C4alkylamino and diC1-C4alkylamino; R11 is selected from the group consisting of hydrogen and C1-C6alkyl;each R12 is independently selected from the group consisting of halogen, cyano, hydroxy, C1-C4alkyl, C1-C4alkoxy, C1-C4haloalkyl, C1-C4haloalkoxy, amino, C1-C4alkylamino and diC1-C4alkylamino; each R13 is independently selected from the group consisting of halogen, cyano, hydroxy, C1-C4alkyl, C1-C4alkoxy, C1-C4haloalkyl, C1-C4haloalkoxy, amino, C1-C4alkylamino and diC1-C4alkylamino; andR14 is selected from the group consisting of hydrogen and C1-C6alkyl;with the proviso that one or two of X1, X2 and X3 are N.

2. A compound of formula (I) or an agronomically acceptable salt or an N-oxide thereof, as definedin claim 1, with the proviso that the compound of formula (I) is not selected from the groupconsisting of5-(2-pyridyl)-1-(4-pyridylmethyl)triazole-4-carboxylic acid,83100 FF1215-(1-methylpyrazol-4-yl)-1-(3-pyridylmethyl)triazole-4-carboxylic acid,5-(2-pyridyl)-1-(3-pyridylmethyl)triazole-4-carboxylic acid,5-(3-methylimidazol-4-yl)-1-(4-pyridylmethyl)triazole-4-carboxylic acid,1-[(5-bromo-3-pyridyl)methyl]-5-(2-thienyl)triazole-4-carboxylic acid,83100 FF1225-(1-methylpyrazol-4-yl)-1-(4-pyridylmethyl)triazole-4-carboxylic acid,1-[(5-methyl-3-pyridyl)methyl]-5-(2-thienyl)triazole-4-carboxylic acid,5-(1-methylimidazol-2-yl)-1-(3-pyridylmethyl)triazole-4-carboxylic acid,5-(3-pyridyl)-1-(4-pyridylmethyl)triazole-4-carboxylic acid,83100 FF1235-(3-methylimidazol-4-yl)-1-(3-pyridylmethyl)triazole-4-carboxylic acid,1-(3-pyridylmethyl)-5-(2-thienyl)triazole-4-carboxylic acid,5-(4-piperidyl)-1-(3-pyridylmethyl)triazole-4-carboxylic acid,83100 FF124 1-(4-pyridylmethyl)-5-(2-thienyl)triazole-4-carboxylic acid,5-(3-pyridyl)-1-(3-pyridylmethyl)triazole-4-carboxylic acid,methyl 1-(4-pyridylmethyl)-5-pyrrolidin-2-yl-triazole-4-carboxylate,5-(4-pyridyl)-1-(3-pyridylmethyl)triazole-4-carboxylic acid,83100 FF1251-[(5-fluoro-3-pyridyl)methyl]-5-(2-thienyl)triazole-4-carboxylic acid,5-(1-methylimidazol-2-yl)-1-(4-pyridylmethyl)triazole-4-carboxylic acid,5-(4-pyridyl)-1-(4-pyridylmethyl)triazole-4-carboxylic acid,methyl 1-(3-pyridylmethyl)-5-pyrrolidin-2-yl-triazole-4-carboxylate,83100 FF1265-phenyl-1-(3-pyridylmethyl)triazole-4-carboxylic acid,1-[(3-chloro-4-pyridyl)methyl]-5-(2-thienyl)triazole-4-carboxylic acid,5-(4-piperidyl)-1-(4-pyridylmethyl)triazole-4-carboxylic acid and5-phenyl-1-(4-pyridylmethyl)triazole-4-carboxylic acid.83100 FF1273. The compound according to claim 2, wherein R1 is selected from the group consisting ofhydrogen, methyl and ethyl.

4. The compound according to claim 2 or claim 3, wherein R1 is hydrogen.

5. The compound according to any one of claims 2 to 4, wherein each R2 is independently selectedfrom the group consisting of oxo, hydroxy, halogen, C1-C6alkyl, C3-C6cycloalkyl, C1-C6haloalkyl,C1-C6haloalkoxy, C1-C3haloalkoxy-C1-C3alkyl-, C1-C6alkoxy, C1-C3alkoxy-C1-C3alkyl-, C1-C3alkoxy-C1-C3alkoxy-, C1-C6alkylaminocarbonyl-C1-C3alkoxy-, -C(R14)=NOR11, =NOR11,isoxazolyl and imidazolylmethyl.

6. The compound according to any one of claims 2 to 5, wherein A is selected from the groupconsisting of C5-C6cycloalkenyl, tetralinyl, phenyl, heteroaryl and the group A-I, wherein saidtetralinyl, phenyl or heteroaryl are optionally substituted by 1, 2, 3, 4 or 5 R2 substituents,which may be the same or different, and wherein said heteroaryl is a 5-or 6-membered monocyclic aromatic ring which comprises 1, 2, 3 or 4 heteroatoms individually selected fromN, O and S,and wherein the group A-I is a fused bicyclic structure of general formula;A-I in which: (i) ring A1 and ring A2 each have 5 or 6 members;(ii) A-I includes at least one heteroatom selected from N, O and S, with the remainderbeing carbon atoms; (iii) at least one of ring A1 and ring A2 is aromatic, or A-I as a whole is aromatic;(iv) A-I can be attached to the remainder of the compound of formula (I) at any availableposition provided it is a carbon atom; (v) one of the carbon atoms is optionally a carbonyl;(vi) one of the carbon atoms is optionally an oxime of formula =NOR11, wherein R11 is asdefined in claim 1; (vii) A-I is optionally substituted in any available position in either or both of ring A1 or ringA2 by p substituents R2, which may be the same or different; and(viii) p is an integer of from 0 to 5.83100 FF1287. The compound according to any one of claims 2 to 6, wherein A is selected from the groupconsisting of formula A-II to A-XVII below,wherein the jagged line defines the point of attachment to the remaining part of a compound of formula (I);each R2aand R2bare independently selected from hydrogen or C1-C6alkyl;83100 FF129 R2cis hydrogen or C1-C6alkyl; pis an integer of from 0 to 5;R2is as defined in claim 1 or claim 5; and R11is as defined in claim 1.

8. The compound according to any one of claims 2 to 7, wherein R3 and R4 are hydrogen.

9. The compound according to any one of claims 2 to 8, wherein each R5, R6 and R7 areindependently selected from the group consisting of hydrogen, halogen, hydroxy, C1-C6alkyl,C3-C6cycloalkyl, C1-C6haloalkyl, C1-C6haloalkoxy, C1-C6alkoxy, C1-C3alkoxyC1-C3alkoxy-, C1- C6alkylamino, diC1-C6alkylamino, a 3- to 6- membered heterocyclyl, which may be partiallysaturated or saturated, comprising 1 or 2 heteroatoms individually selected from N and O, anda 5- or 6- membered heteroaryl, which comprises 1, 2, 3 or 4 heteroatoms individually selectedfrom N, O and S, and wherein said heterocyclyl or heteroaryl are optionally substituted by 1, 2or 3 R13substituents, which may be the same or different.

10. The compound according to any one of claims 2 to 9, wherein each R5, R6 and R7 areindependently selected from the group consisting of hydrogen, chloro, fluoro, hydroxy, methyl,ethyl, cyclopropyl, trifluoromethyl, difluoromethoxy, methoxy, methoxyethoxy, methylamino,dimethylamino, N-morpholinyl and pyrazolyl.

11. The compound according to any one of claims 2 to 10, wherein R8 and R9 are hydrogen.

12. The use of a compound of formula (I) as defined in any one of claims 2 to 11, or an agronomicallyacceptable salt or N-oxide thereof, as a herbicide.

13. An agrochemical composition comprising a herbicidally effective amount of a compound of formula (I) as defined in any one of claims 1 to 11 and an agrochemically-acceptable diluent orcarrier.

14. The composition according to claim 13, further comprising at least one additional activeingredient.

15. A method of controlling unwanted plant growth, comprising applying a compound of formula (I)as defined in any one of claims 1 to 11, or an agrochemical composition according to claim 13 orclaim 14, to the unwanted plants or to the locus thereof.

16. A compound of formula (II),83100 FF130wherein Y is selected from the group consisting of bromo, chloro, iodo, methylsulfonyloxy,trifluoromethylsulfonyloxy and p-tolylsulfonyloxy and X1, X2, X3, R1, R3, R4, R8 and R9 are asdefined in any one of claims 1, 3, 4, 8, 9, 10 or 11.

Images